徳島大学 / 教育研究者総覧 --- 岡久稔也

個人のホームページ

https://researchmap.jp/read0088044 (researchmap)

専門分野

○	医学 (Medicine)

研究テーマ

○

著書・論文

著書:

1.	榎本崇宏, 岡久稔也, 芥川正武, 木内陽介 : 腸音図, 文光堂, 2015年.
2.	曽我部正弘, 岡久稔也, 山ノ井昭 : メタボリック症候群のNAFLDに対する生活習慣および生活習慣病の影響, 科学評論社, 東京, 2013年1月.
3.	武田英二, 岡久稔也, 高橋保子, 国清紀子, 松村晃子, 中屋豊, 西正晴, 竹谷豊, 吉本勝彦, 寺尾純二, 美馬福恵, 吉岡昌美, 山田静恵, 石澤啓介, 鈴木麗子, 藤田知代, 新井英一, 桑波田雅士, 岡田和子 : 栄養管理のチーム医療, 文光堂, 東京, 2006年4月.
4.	伊東進, 岡久稔也 : 薬剤性腸炎, 株式会社中山書店, 2005年4月.
5.	Masahiro Sogabe, Toshiya Okahisa, Koji Tsujigami, Yoshio Okita, Hiroshige Hayashi, Toshikatsu Taniki, Hiroshi Hukuno, Masahiko Nakasono, Naoki Muguruma, Seisuke Okamura and Susumu Ito : Ultrasonographic assesment of gastric motility in diabetic gastroparesis befor and after attaining glycemic control., Springer-Verlag, New York, Feb. 2005.
6.	清水一郎, 玉木克佳, 柴田啓志, 浦田真里, 板垣達三, 大塩敦郎, 井本佳孝, 岡本耕一, 佐藤康紀, 青木利佳, 福野天, 居和城宏, 村田昌彦, 筒井朱美, 六車直樹, 岡久稔也, 岡村誠介, 本田浩仁, 伊東進 : 当科におけるラジオ波焼灼療法を用いた肝腫瘍治療, --- ―preliminary report― ---, 徳島医学会, 徳島, 2003年. (徳島大学機関リポジトリ) ● Metadata: 36161 (徳島大学機関リポジトリ: 36161)
7.	岡久稔也, 曽我部正弘, 大喜田義雄, 六車直樹, 岡村誠介, 柴田啓志, 伊東進 : 消化器ポケットマニュアル, 株式会社嵯峨野, 京都, 2002年.
8.	森博愛, 清水一郎, 長瀬教夫, 野村昌弘, 西角彰良, 井内新, 伊東進, 本田浩仁, 岡村誠介, 近森一正, 齋藤憲, 白神皞, 中屋豊, 岡久稔也, 橋本俊顕 : コメディカルのための内科学(第2版), 医学出版社, 東京, 2001年4月.
9.	清水一郎, 柴田啓志, 筒井朱美, 四宮寛彦, 稲山久美, 中園雅彦, 六車直樹, 岡久稔也, 岡村誠介, 伊東進 : 肝細胞癌に対する経皮的ラジオ波熱焼灼療法(RFA)の検討, 大道学館, 福岡, 2001年.
10.	加藤寛正, 野村昌弘, 越智由恵, 齋藤憲, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 : 慢性消化性潰瘍におけるHelivobactor pylori除菌前後の自律神経活動の検討, 四国消化性潰瘍研究会, 2001年.
11.	伊東進, 岡久稔也 : 薬剤性腸炎, 株式会社中山書店, 東京, 2001年.
12.	伊東進, 岡久稔也 : 過敏性腸症候群, 文光堂, 東京, 2000年10月.
13.	清水一郎, 野田佳子, 筒井朱美, 多田津昌也, 六車直樹, 堀江貴浩, 岡久稔也, 柴田啓志, 岡村誠介, 西條哲也, 佐野暢哉, 伊東進 : 良性反復性肝内胆汁うっ滞に胆石を伴わない慢性膵炎を合併した1例, 財団法人日本消化器病学会, 東京, 1999年.
14.	野村昌弘, 名田智美, 近藤幸, 由岐中道子, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 齋藤憲, 伊東進, 中屋豊 : 慢性消化性潰瘍形成において自律神経機能異常は必要条件か?心拍変動1/fゆらぎおよびHelicobactor pyloriとの関連性, 四国消化性潰瘍研究会, 松山, 1999年.
15.	清水一郎, 福田直子, 相良安信, 北田浩三, 斎賀美恵子, 宮上盛史, 石井敏博, 佐々木春夫, 安田貢, 堀江貴浩, 岡久稔也, 岡村誠介, 本田浩仁, 伊東進 : 胃集検における追加撮影の意義, 1997年.
16.	岡久稔也, 清水一郎, 伊東進 : 胃潰瘍·十二指腸潰瘍の診断と治療, --- -当科における胃·十二支潰瘍の診断と治療- ---, 真興交易医書出版, 東京, 1997年.
17.	西條哲也, 岡久稔也, 岡村誠介, 柴田啓志, 本田浩仁, 清水一郎, 折野俊介, 野村昌弘, 齋藤憲, 伊東進 : 高血圧合併消化性潰瘍の自律神経機能の検討, ホワイトPR, 1995年.
18.	伊東進, 岡久稔也 : 過敏性腸症候群, 文光堂, 東京, 1995年.
19.	清水一郎, 西條哲也, 藤川晴信, 新居千昌, 日比野真吾, 岡久稔也, 岡村誠介, 柴田啓志, 本田浩仁, 矢野充保, 伊東進 : 実験的逆流性食道炎におよぼす防御因子製剤の効果, ホワイトPR, 東京, 1993年.
20.	清水一郎, 藤川晴信, 西條哲也, 堀北実, 日比野真吾, 岡久稔也, 岡村誠介, 林広茂, 本田浩仁, 矢野充保, 和田哲, 伊東進 : 下部十二指腸および前胃・腺胃境界部結紮による実験的逆流性食道炎作成法の検討, ホワイトPR, 東京, 1992年.
21.	清水一郎, 矢野充保, 春藤譲治, 藤川晴信, 堀北実, 日比野真吾, 岡久稔也, 岡村誠介, 林広茂, 本田浩仁, 西條哲也, 和田哲, 谷木利勝, 伊東進, 広瀬隆則 : 下血を機に発見された空腸迷入膵の1例, 広島, 1991年.

学術論文(審査論文):

1.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Takanori Kashihara, Shota Fujimoto, Tomoyuki Kawaguchi, Reiko Yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Metabolic dysfunction-associated steatotic liver disease and gallbladder polyp development: an observational study., Scientific Reports, Vol.14, No.1, 22446, 2024. (要約) The influence of metabolic dysfunction-associated steatotic liver disease (MASLD) on gallbladder polyp development in both sexes remains elusive. Therefore, to clarify the role of MASLD in gallbladder polyp development, we investigated the longitudinal association between MASLD and gallbladder polyps. In this observational study, we included 5,527 gallbladder polyp-free patients who underwent > 2 health check-ups over > 2 years. Generalized estimation equations were used to analyze associations between MASLD and gallbladder polyp development according to repeated measures at baseline and the most recent stage. Gallbladder polyp development rates in men and women were 7.5% and 5.6% (p < 0.01), respectively. MASLD was not significantly correlated with gallbladder polyp development. Regarding the association between gallbladder polyp development (men: ≥6 mm and women: ≥5 mm) and the number of MASLD components following lifestyle habits, men and women with ≥ 4 MASLD components had odds ratios of 3.397 (95% confidence interval: 1.096-10.53) and 5.338 (1.054-27.04), respectively. Higher nonalcoholic fatty liver disease fibrosis scores were associated with significant risk of gallbladder polyp development in women (1.991, 1.047-3.785). Although MASLD influence on gallbladder polyp development differs by sex, close monitoring of patients with an increasing number of MASLD components is essential to prevent gallbladder polyp development. Specifically, men with ≥ 4 MASLD components should be monitored for gallbladder polyps measuring ≥ 6 mm. (キーワード) Humans / Male / Female / Middle Aged / Polyps / Gallbladder Diseases / Adult / Risk Factors / Gallbladder / Non-alcoholic Fatty Liver Disease / Fatty Liver / Aged (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41598-024-73429-1 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39341964 ● Search Scopus @ Elsevier (PMID): 39341964 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-024-73429-1 (DOI: 10.1038/s41598-024-73429-1, PubMed: 39341964)
2.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Takanori Kashihara, Ryo Shinomiya, Takanori Miyake, Tomoyuki Kawaguchi, Reiko Yokoyama, Kaizo Kagemoto, Yoshifumi Kida, Yasuyuki Okada, Tetsu Tomonari, Yutaka Kawano, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease., Alimentary Pharmacology & Therapeutics, Vol.60, No.11-12, 1587-1598, 2024. (要約) The relationships between alcohol consumption, cardiometabolic factors, and liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease and those with metabolic dysfunction and alcohol-associated liver disease remain unclear. To investigate the longitudinal associations among alcohol consumption, cardiometabolic factors, and liver fibrosis in patients with these two liver diseases. This observational cohort study included 1866 patients with metabolic dysfunction-associated steatotic liver disease and 521 patients with metabolic dysfunction and alcohol-associated liver disease who underwent > two health checkups over >2 years. The associations of both liver diseases with worsening non-invasive liver fibrosis scores were assessed using the Cox regression analysis. Both liver diseases independently worsened liver fibrosis in both sexes. However, the hazard ratio for worsening liver fibrosis in females was significantly higher with metabolic dysfunction and alcohol-associated liver disease than with metabolic dysfunction-associated steatotic liver disease. Worsening liver fibrosis was not associated with alcohol consumption. Among males with metabolic dysfunction-associated steatotic liver disease, the hazard ratio for worsening liver fibrosis was significantly higher in those with multiple cardiometabolic factors compared to those with a single cardiometabolic factor. Although both metabolic steatotic liver disease and metabolic alcohol-associated liver disease were correlated with liver fibrosis progression in both sexes, the impact of alcohol consumption and cardiometabolic factors on fibrosis progression differed by sex. Cardiometabolic factors may have a stronger impact on liver fibrosis than alcohol consumption in males with metabolic dysfunction-associated steatotic liver disease. (キーワード) Humans / Male / Female / Middle Aged / Alcohol Drinking / Liver Cirrhosis / Adult / Cohort Studies / Aged / Liver Diseases, Alcoholic / Fatty Liver / Risk Factors / Sex Factors (出版サイトへのリンク) ● Publication site (DOI): 10.1111/apt.18280 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39310953 ● Search Scopus @ Elsevier (PMID): 39310953 ● Search Scopus @ Elsevier (DOI): 10.1111/apt.18280 (DOI: 10.1111/apt.18280, PubMed: 39310953)
3.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study., Journal of Gastroenterology and Hepatology, Vol.39, No.6, 1107-1114, 2024. (要約) Although erosive esophagitis (EE) is associated with fatty liver and metabolic dysregulation, the association between EE and metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Thus, this study aimed to investigate the longitudinal association between MASLD and EE. We included 1578 patients without EE at baseline who underwent more than two health checkups over 2 years. Generalized estimation equations were used to analyze associations between MASLD and EE according to repeated measures at baseline and most recent stages. EE development rates in men and women were 14.5% and 7.2%, respectively. After adjusting for lifestyle habits, the odds ratios of MASLD for EE development in men and women were 1.907 (95% confidence interval [CI]: 1.289-2.832, P < 0.005) and 1.483 (95% CI: 0.783-2.811, P = 0.227), respectively. In the subgroup analysis, after adjusting for lifestyle habits, among men and women aged 50 years with more than three MASLD components, the odds ratios for EE development were 2.408 (95% CI: 1.505-3.855, P < 0.001) and 2.148 (95% CI: 1.093-4.221, P < 0.05), respectively. After adjusting for various factors, the significant risk factors for EE development were different between men and women. The influence of MASLD and other factors on EE development differed by sex and age. Particularly, patients aged 50 years with MASLD and with an increased number of MASLD components should be considered at increased risk for EE. (出版サイトへのリンク) ● Publication site (DOI): 10.1111/jgh.16530 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38419514 ● Search Scopus @ Elsevier (PMID): 38419514 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16530 (DOI: 10.1111/jgh.16530, PubMed: 38419514)
4.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Association of variabilities in body mass index and waist circumference with newly achieved remission of metabolic dysfunction-associated fatty liver disease., Diabetes & Metabolic Syndrome, Vol.18, No.5, 103036, 2024. (要約) Although body weight reduction is recommended to ameliorate nonalcoholic fatty liver disease, the effects of body mass index (BMI) and waist circumference (WC) variability on newly achieved remission of metabolic dysfunction-associated fatty liver disease (MAFLD) remain unclear. We aimed to investigate the longitudinal association between BMI and WC variabilities and newly achieved MAFLD remission in both sexes. Among 26,952 patients, 1823 with MAFLD diagnosed by ultrasonography and with >2 health checkups over >2 years from April 2014 to March 2021 were included in this observational cohort study. A generalized estimation equation model analyzed the association between BMI and WC and newly achieved MAFLD remission according to repeated measures at baseline and the most recent stage. Rates of MAFLD remission in male and female patients were 7.4 % and 6.0 %, respectively. Regarding decreased BMI variability, newly achieved MAFLD remission prevalence among the subgroups differed significantly between sexes (p < 0.001). In male patients, a decrease in BMI variability of ≥1.5 kg/m and WC variability of ≥4.2 cm had adjusted odds ratios (ORs) of 5.215 and 2.820, respectively, for newly achieved MAFLD remission. Among female patients, regular exercise and breakfast consumption were accelerating factors for newly achieved MAFLD remission. Non-invasive liver fibrosis scores significantly differed between MAFLD and newly achieved MAFLD remission, including in the subgroups (p < 0.01 and p < 0.001, respectively). Reducing BMI and WC variabilities in male patients and improving lifestyle habits in female patients may accelerate MAFLD remission. (キーワード) Humans / Male / Female / Body Mass Index / Middle Aged / Non-alcoholic Fatty Liver Disease / Waist Circumference / Adult / Remission Induction / Follow-Up Studies / Prognosis / Metabolic Diseases (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.dsx.2024.103036 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38754333 ● Search Scopus @ Elsevier (PMID): 38754333 ● Search Scopus @ Elsevier (DOI): 10.1016/j.dsx.2024.103036 (DOI: 10.1016/j.dsx.2024.103036, PubMed: 38754333)
5.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Takanori Kashihara, shota Fujimoto, Tomoyuki Kawaguchi, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Yutaka Kawano, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Impact of alcohol consumption on metabolic dysfunction-associated fatty liver disease development and remission: A longitudinal cohort study., European Journal of Clinical Investigation, Vol.Online ahead of print., e14221, 2024. (要約) The influence of alcohol intake on metabolic dysfunction-associated fatty liver disease (MAFLD) development and remission remains unclear; thus, we aimed to investigate their longitudinal associations. This observational cohort study included 6349 patients who underwent more than two health check-ups over >2 years between April 2013 and March 2021. Generalized estimation equations were used to analyse the longitudinal associations between changes in alcohol intake and MAFLD according to repeated measures at baseline and the most recent stage. The MAFLD development and remission rates were 20.4 and 5.1 and 9.1 and 4.7% in men and women, respectively. Although alcohol consumption was not a significant factor for MAFLD development, consuming 0.1-69.9 g/week (odds ratio [OR]: 0.672, 95% confidence interval [CI]: 0.469-0.964, p < .05) and ≥280 g/week were significant factors for MAFLD development in males (OR: 1.796, 95% CI: 1.009-3.196, p < .05) and females (OR: 16.74, 95% CI: 3.877-72.24, p < .001). Regardless of quantity and frequency, alcohol consumption was not a significant factor for MAFLD remission. Several noninvasive liver fibrosis scores were significantly associated with alcohol intake quantity and frequency in males with MAFLD development and remission (p < .05). The nonalcoholic fatty liver disease fibrosis score differed significantly between males with and without reduced alcohol intake (p < .05) who showed MAFLD remission. Although the influence of alcohol intake on MAFLD development and remission differed, alcohol consumption was not beneficial for MAFLD remission in either sex. Alcohol intake reduction or cessation is recommended to prevent liver fibrosis, even in those who achieve MAFLD remission. (出版サイトへのリンク) ● Publication site (DOI): 10.1111/eci.14221 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38634705 ● Search Scopus @ Elsevier (PMID): 38634705 ● Search Scopus @ Elsevier (DOI): 10.1111/eci.14221 (DOI: 10.1111/eci.14221, PubMed: 38634705)
6.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study., Journal of Gastroenterology and Hepatology, Vol.39, No.4, 754-761, 2024. (要約) The influence of metabolic dysfunction-associated fatty liver disease on gallstone development remains unclear. We aimed to investigate the longitudinal association between metabolic dysfunction-associated fatty liver disease and gallstone development in both men and women. This observational cohort study included 5398 patients without gallstones who underwent > 2 health check-ups between April 1, 2014, and March 31, 2020. A generalized estimation equation model was used to analyze the association between metabolic dysfunction-associated fatty liver disease and gallstone development according to repeated measures at baseline and most recent stage. After adjustment, the odds ratios of metabolic dysfunction-associated fatty liver disease for gallstone development in men and women were 3.019 (95% confidence interval [CI]: 1.901-4.794) and 2.201 (95% CI: 1.321-3.667), respectively. Among patients aged 50 years, the odds ratio for gallstone development was significantly enhanced with increasing metabolic dysfunction-associated fatty liver disease component numbers in both sexes; however, no significance was observed in those aged < 50 years. Other significant risk factors for gallstone development were age (odds ratio: 1.093, 95% CI: 1.060-1.126) and waist circumference (odds ratio: 1.048, 95% CI: 1.018-1.079) in men and age (odds ratio: 1.035, 95% CI: 1.003-1.067) and current smoking (odd ratio: 5.465, 95% CI: 1.881-15.88) in women. Although the risk factors for gallstone development differed between sexes, metabolic dysfunction-associated fatty liver disease was common. Paying attention to an increase in the number of metabolic dysfunction-associated fatty liver disease components in patients aged 50 years is important for gallstone prevention. (出版サイトへのリンク) ● Publication site (DOI): 10.1111/jgh.16483 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38212880 ● Search Scopus @ Elsevier (PMID): 38212880 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16483 (DOI: 10.1111/jgh.16483, PubMed: 38212880)
7.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Hiroyuki Ueda, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Influence of alcohol on newly developed metabolic dysfunction-associated fatty liver disease in both sexes: A longitudinal study., Clinical Nutrition, Vol.42, No.5, 810-816, 2023. (要約) The influence of changes in alcohol consumption on newly developed metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. We investigated the influence of alcohol consumption on newly developed MAFLD in both sexes. This observational cohort study included 4071 patients who underwent more than two health check-ups between 2015 and 2020 over an interval of more than a year. Generalised estimating equations were used for analyses. At baseline, the rates of drinking and MAFLD between men and women were 72.5% versus 41.7% and 42.2% versus 22.1%, respectively. At the most recent stage, the rates of an increase in alcohol consumption for men and women were 13.3% and 8.7%, respectively, and 311/1192 (26.1%) men and 155/1566 (9.9%) women had newly developed MAFLD. The odds ratio (OR) for drinking in patients with newly developed MAFLD was 0.863 (men) (95% confidence interval [CI], 0.676-1.102, p = 0.237) and 1.041 (women) (95% CI, 0.753-1.439, p = 0.808); the OR for women who drank 140-279.9 g/week was 2.135 (95% CI, 1.158-3.939, p < 0.05) and that for all drinking categories among women was >1. Several non-invasive fibrosis scores were significantly associated with the quantity of alcohol consumption in patients with newly developed MAFLD (p < 0.005). Alcohol consumption had no significant protective effect against newly developed MAFLD in both sexes, regardless of quantity. Conversely, alcohol consumption ≥140 g/week was a risk factor for newly developed MAFLD in women. The development of liver fibrosis with increased alcohol intake should be considered in patients with MAFLD. (徳島大学機関リポジトリ) ● Metadata: 118599 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.clnu.2023.03.020 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37043935 ● Search Scopus @ Elsevier (PMID): 37043935 ● Search Scopus @ Elsevier (DOI): 10.1016/j.clnu.2023.03.020 (徳島大学機関リポジトリ: 118599, DOI: 10.1016/j.clnu.2023.03.020, PubMed: 37043935)
8.	Yoshifumi Kida, Toshiya Okahisa, Yasushi Sato, Masahiro Bando, Shota Fujimoto, ma beibei, Tadahiko Nakagawa, Tomoyuki Kawaguchi, Fumika Nakamura, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Koichi Tsuneyama and Tetsuji Takayama : Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice., Scientific Reports, Vol.13, No.1, 2899, 2023. (要約) Although several angiogenesis-related factors are reportedly involved in the pathogenesis of ulcerative colitis (UC), the mechanisms by which they contribute to disease are unclear. We first examined the expression of angiogenesis-related factors in inflamed colorectal tissue of UC patients using antibody array, and identified the 5 factors with highest expression, which included matrix metalloproteinase-8, urokinase-type plasminogen activator (uPA), angiostatin/plasminogen, hepatocyte growth factor and endoglin. Subsequent real-time PCR experiments using additional colorectal tissues revealed that uPA mRNA levels were significantly higher in inflamed tissues than in non-inflamed tissues, and significantly correlated with the severity of UC. Mirror section immunohistochemistry revealed that uPA was expressed in the neutrophils of inflamed colorectal tissues. We administered dextran sulfate sodium (DSS) in drinking water to uPA knockout (uPA) mice, and found that the disease activity index in uPA mice was marginally lower and the histological score in uPA mice was significantly lower than those in wild-type mice, suggesting the importance of uPA in colitis. When an uPA-selective inhibitor, UK122, was administered to DSS-treated C57BL6J mice, the disease activity index and histological score in those mice were significantly lower compared with control mice. Multiple cytokine/chemokine assay using colorectal tissues from uPA and UK122-treated mice revealed significantly lowered level of RANTES. In conclusion, uPA was highly expressed in neutrophils of the inflamed mucosa of UC patients, and the expression level correlated with the severity of UC. Genetic uPA deletion or pharmacological uPA blockade significantly ameliorated colitis in mice, concomitant with downregulation of RANTES. (キーワード) Animals / Mice / Urokinase-Type Plasminogen Activator / Colitis / Colitis, Ulcerative / Serine Proteases / Colorectal Neoplasms (徳島大学機関リポジトリ) ● Metadata: 118522 (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41598-023-29824-1 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36806262 ● Search Scopus @ Elsevier (PMID): 36806262 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-29824-1 (徳島大学機関リポジトリ: 118522, DOI: 10.1038/s41598-023-29824-1, PubMed: 36806262)
9.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Hiroyuki Ueda, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Influence of Alcohol Consumption on the Development of Erosive Esophagitis in Both Sexes: A Longitudinal Study., Nutrients, Vol.14, No.22, 4760, 2022. (要約) The influence of changes in alcohol consumption on erosive esophagitis (EE) development in both sexes is unclear. This observational study investigated sex differences in the influence of alcohol consumption on EE development, and included 2582 patients without EE at baseline from 13,448 patients who underwent >2 health check-ups over >1 year. The rates of non-drinkers who started drinking, and drinkers who abstained from drinking, who increased, and who decreased their weekly alcohol consumption were 7.2%, 9.7%, 14.7%, and 24.1% and 7.3%, 17.8%, 12.8%, and 39.0% in men and women, respectively. In the final cohort, 211/1405 (15.0%) men and 79/1177 (6.7%) women newly developed EE. The odds ratio (OR) for drinking in EE development was 1.252 (95% confidence interval (CI), 0.907-1.726) among men and 1.078 (95% CI, 0.666-1.747) among women. Among men aged <50 years, the OR for drinking ≥70 g/week in EE development was 2.825 (95% CI, 1.427-5.592), whereas among women, the OR for drinking ≥140 g/week in EE development was 3.248 (95% CI, 1.646-6.410). Among participants aged <50 years, the OR for daily drinking in EE development was 2.692 (95% CI, 1.298-5.586) among men and 4.030 (95% CI, 1.404-11.57) among women. The influence of alcohol consumption on EE development differed between the sexes. We recommend no alcohol consumption for individuals aged <50 years to avoid EE development. Daily drinkers should be assessed for EE development. (キーワード) Humans / Male / Female / Longitudinal Studies / Alcohol Drinking / Esophagitis / Sexual Behavior / Cohort Studies / Peptic Ulcer (徳島大学機関リポジトリ) ● Metadata: 118071 (出版サイトへのリンク) ● Publication site (DOI): 10.3390/nu14224760 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36432447 ● Search Scopus @ Elsevier (PMID): 36432447 ● Search Scopus @ Elsevier (DOI): 10.3390/nu14224760 (徳島大学機関リポジトリ: 118071, DOI: 10.3390/nu14224760, PubMed: 36432447)
10.	Masahiro Sogabe, Toshiya Okahisa, Takeshi Kurihara, Miwako Kagawa, Hiroyuki Ueda, Tomoyuki Kawaguchi, Akira Fukuya, Kaizoh Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Comparison of the role of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD in males and females., Scientific Reports, Vol.12, No.1, 16048, 2022. (要約) The clinical difference between nonalcoholic fatty liver disease (NAFLD) and metabolic-associated fatty liver disease (MAFLD) between the two sexes is unclear. This study aimed to determine the influences of alcohol consumption and qualitative abdominal fat between male and female patients with NAFLD and MAFLD. This cross-sectional study examined 11,766 participants who underwent health check-ups comparing lifestyle habits, biochemical features, and noninvasive liver fibrosis scores, between non-MAFLD and MAFLD groups. Furthermore, differences in alcohol consumption and qualitative abdominal fat were examined between male and female patients with NAFLD and MAFLD. The prevalence of metabolic dysregulation, ratio of visceral fat area to subcutaneous fat area, and noninvasive liver fibrosis scores were significantly higher in male patients with MAFLD than in those with NAFLD (p < 0.05), but these were not significantly different in female patients. Among male patients with an alcohol consumption of > 70 g/week, several noninvasive liver fibrosis scores were significantly higher in the MAFLD group than in the NAFLD group (all p < 0.05). The influences of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD were different between sexes. The development of liver fibrosis should be considered in male patients with MAFLD who exceed mild drinking. (キーワード) Alcohol Drinking / Cross-Sectional Studies / Female / Humans / Intra-Abdominal Fat / Liver Cirrhosis / Male / Non-alcoholic Fatty Liver Disease (徳島大学機関リポジトリ) ● Metadata: 117853 (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41598-022-20124-8 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36163355 ● Search Scopus @ Elsevier (PMID): 36163355 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-022-20124-8 (徳島大学機関リポジトリ: 117853, DOI: 10.1038/s41598-022-20124-8, PubMed: 36163355)
11.	Masahiro Sogabe, Yumiko Izaki, Toshiya Okahisa and Tetsuji Takayama : Improvement of acceptability in patients undergoing esophagogastroduodenoscopy using auditory and visual stimulation., The Journal of Medical Investigation : JMI, Vol.69, No.1-2, 8-18, 2022. (要約) Esophagogastroduodenoscopy (EGD) has become an indispensable examination to discover upper gastrointestinal diseases, including cancer, and perform endoscopic treatment. However, many individuals who undergo the procedure have feelings of anxiety and fear regarding EGD. Although the use of medication for sedation during EGD is useful for reducing anxiety and the stability of hemodynamics, sedation may increase the likelihood of complications. Several noninvasive distractions have been introduced to decrease pain and anxiety during endoscopic examinations;however, most assessments of these distractions evaluated subjective items such as impression. We herein add the results of our studies using objective items and review the effectiveness of distractions for EGD. J. Med. Invest. 69 : 8-18, February, 2022. (キーワード) Anxiety / Endoscopy, Digestive System / Humans / Pain / Photic Stimulation (徳島大学機関リポジトリ) ● Metadata: 117001 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.69.8 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466150 ● Search Scopus @ Elsevier (PMID): 35466150 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.8 (徳島大学機関リポジトリ: 117001, DOI: 10.2152/jmi.69.8, PubMed: 35466150)
12.	Masahiro Sogabe, Toshiya Okahisa, Takeshi Kurihara, Miwako Kagawa, Kaizoh Kagemoto, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Differences in Several Factors in the Development of Erosive Esophagitis Among Patients at Various Stages of Metabolic Syndrome: A Cross-Sectional Study., Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, Vol.14, 1589-1600, 2021. (徳島大学機関リポジトリ) ● Metadata: 116294 (出版サイトへのリンク) ● Publication site (DOI): 10.2147/DMSO.S298326 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33883913 ● Summary page in Scopus @ Elsevier: 2-s2.0-85104815967 (徳島大学機関リポジトリ: 116294, DOI: 10.2147/DMSO.S298326, PubMed: 33883913, Elsevier: Scopus)
13.	曽我部正弘, 岡久稔也, 高山哲治 : 映像・照明を用いた視覚刺激によるdistractionの上部消化管内視鏡検査受診者への影響., 日本消化器がん検診学会雑誌, Vol.58, No.6, 983-995, 2020年. (出版サイトへのリンク) ● Publication site (DOI): 10.11404/jsgcs.58.983 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390567901494381696 ● Search Scopus @ Elsevier (DOI): 10.11404/jsgcs.58.983 (DOI: 10.11404/jsgcs.58.983, CiNii: 1390567901494381696)
14.	Masahiro Sogabe, Toshiya Okahisa, Takeshi Kurihara, Masanori Takehara, Kaizoh Kagemoto, Jun Okazaki, Yoshifumi Kida, Akihiro Hirao, Hironori Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Nakasono and Tetsuji Takayama : Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome., PLoS ONE, Vol.15, No.8, e0238388, 2020. (要約) The prevalence of nonalcoholic fatty liver disease (NAFLD) in the non-obese population has increased and NAFLD is not always recognized in individuals with metabolic syndrome (MS). The risk of cirrhosis is higher in patients having NAFLD with elevated alanine aminotransferase (ALT) levels than in those having NAFLD with normal ALT levels. To measure the differences in clinical factors associated with NAFLD having elevation of ALT among subjects with Non-MS, Pre-MS, and MS, and to measure differences in metabolites between MS subjects with and without NAFLD having elevation of ALT. Among 7,054 persons undergoing health check-ups, we included 3,025 subjects who met the selection criteria. We measured differences in clinical factors for NAFLD having elevation of ALT among subjects with Non-MS, Pre-MS, and MS, and compared metabolites between subjects with and without NAFLD having elevation of ALT in 32 subjects with MS. The prevalence of NAFLD and NAFLD having elevation of ALT was significantly progressively greater in subjects with Non-MS, Pre-MS, and MS (p <0.001, respectively). In the Non-MS group, there were significant differences between subjects with and without NAFLD having elevation of ALT with respect to body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, hemoglobin A1c, uric acid, aspartate aminotransferase (AST); In the Pre-MS group, there were significant differences in BMI, hypertension, AST, and gamma-glutamyl transpeptidase (GGT); In the MS group, there were significant differences in HDL-C, impaired glucose tolerance, AST, and GGT. There were significant differences in levels of metabolites of nicotinamide, inosine, and acetyl-L-carnitine between MS subjects with and without NAFLD having elevation of ALT (all p <0.05). Although NAFLD having elevation of ALT is important for development of NAFLD, differences in factors associated with NAFLD having elevation of ALT at various stages of MS should be considered. Additionally, several metabolites may play roles in the identification of risk for NAFLD in individuals with MS. (徳島大学機関リポジトリ) ● Metadata: 115614 (出版サイトへのリンク) ● Publication site (DOI): 10.1371/journal.pone.0238388 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32866186 ● Search Scopus @ Elsevier (PMID): 32866186 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0238388 (徳島大学機関リポジトリ: 115614, DOI: 10.1371/journal.pone.0238388, PubMed: 32866186)
15.	Toshiya Okahisa, Masahiro Sogabe, Tadahiko Nakagawa, Kumiko Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Akira Takahashi, Yohsuke Kinouchi, Junji Nishioka, Naoki Igata, Hiroaki Yanagawa, takatoshi Komatsu, Yoshiaki Ohnishi, Masashi Fukuhara, Masashi Ishikawa, Hiroshi Shibata, Hirohiko Shinomiya, Masahiko Nakasono, Fumiko Kishi, Keiko Komai, Yayoi Tatsuki, Toru Murashima, Yoshihiro Deguchi, Hiroshi Aramaki, Hideyuki Fukumitsu and Tetsuji Takayama : Development of a novel automatic ascites filtration and concentration equipment with multi-ring-type roller pump units for cell-free and concentrated ascites reinfusion therapy., Artificial Organs, Vol.44, No.8, 856-872, 2020. (要約) Cell-free and concentrated ascites reinfusion therapy (CART) is an effective therapy for refractory ascites. However, CART is difficult to perform as ascites filtration and concentration is a complicated procedure. Moreover, the procedure requires the constant assistance of a clinical engineer or/and the use of an expensive equipment for the multi-purpose blood processing. Therefore, we developed a CART specialized equipment (mobility CART [M-CART]) that could be used safely with various safety measures and automatic functions such as automatic washing of clogged filtration filter and self-regulation of the concentration ratio. Downsizing, lightning of the weight, and automatic processing in M-CART required the use of newly developed multi-ring-type roller pump units. This equipment was approved under Japanese regulations in 2018. In performing 41 sessions of CART (for malignant ascites, 22 sessions; and hepatic ascites, 19 sessions) using this equipment in 17 patients, no serious adverse event occurred. An average of 4494 g of ascites was collected and the total amount of ascites was processed in all the sessions without any trouble. The mean weight of the processed ascites was 560 g and the mean concentration ratio was 8.0. The ascites were processed at a flow rate of 50 mL/min. The mean ascites processing time was 112.5 minutes and a 106.5-minutes (95.2%) ascites processing was performed automatically. The operator responded to alarms or support information 3.2 times on average (3.1 minutes, 2.1% of ascites processing time). Human errors related to ascites processing were detected by M-CART at 0.4 times per session on average and were appropriately addressed by the operator. The frequencies of automatic washing of clogged filtration filter and self-regulation of the concentration ratio were 31.7% and 53.7%, respectively. The mean recovery rates (recovery dose) of protein, albumin, and immunoglobulin G were 72.9%, 72.9%, and 71.2% (65.9 g, 34.9 g, and 13.2 g), respectively. Steroids were administered in 92.7% of the sessions to prevent fever and the mean increase in body temperature was 0.53°C. M-CART is a compact and lightweight automatic CART specialized equipment that can safely and easily process a large quantity of ascites without the constant assistance of an operator. (徳島大学機関リポジトリ) ● Metadata: 115878 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/aor.13681 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32187379 ● Search Scopus @ Elsevier (PMID): 32187379 ● Search Scopus @ Elsevier (DOI): 10.1111/aor.13681 (徳島大学機関リポジトリ: 115878, DOI: 10.1111/aor.13681, PubMed: 32187379)
16.	Masahiro Sogabe, Toshiya Okahisa, Akira Fukuya, Kaizoh Kagemoto, Yasuyuki Okada, Yuka Adachi, Takeshi Kurihara, Toru Nii, Satoshi Teramae, Hironori Tanaka, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Masahiko Nakasono and Tetsuji Takayama : Effects of audio and visual distraction on patients' vital signs and tolerance during esophagogastroduodenoscopy: a randomized controlled trial., BMC Gastroenterology, Vol.20, No.1, 122, 2020. (要約) Esophagogastroduodenoscopy (EGD) provides an indispensable and unambiguous inspection allowing the discovery upper gastrointestinal lesions. However, many patients are anxious about undergoing EGD. Few studies have investigated the influence on patients' vital signs and tolerance during EGD using subjective and objective assessments. This study was a prospective randomized controlled study that investigated the influence of audio and visual distraction on EGD. We randomly divided 289 subjects who underwent EGD into 4 groups (control group, audio group, visual group, combination group) and examined their vital signs, heart rate variability (HRV), psychological items, and acceptance of distraction. Pulse rate (PR) at post-distraction and post-EGD in the 3 distraction groups were significantly lower than those of control group (p < 0.001 and p < 0.01, respectively). Blood pressure (BP) during and post-EGD was significantly higher than that at pre-EGD in control group (p < 0.05), but no significant elevation of BP was observed during the latter half of EGD and post-EGD in the 3 distraction groups. BP at post-distraction improved significantly compared to pre-distraction in the 3 distraction groups (p < 0.05). There was a significant difference in the low-frequency (LF) power/ high-frequency (HF) power at post-distraction and post-EGD among the 4 groups (p < 0.001 and p < 0.001, respectively). The LF power/HF power at post-distraction and post-EGD in the 3 distraction groups was significantly lower than that in control group (p < 0.05). Several items of profile of mood states (POMS) and the impression of EGD at post-distraction improved significantly compared to those at pre-distraction among the 3 distraction groups (p < 0.05). Visual analog scale (VAS) of willingness for the next use of distraction in the 3 distraction groups was excellent because VAS was more than 70. Distractions effectively improved psychological factors, vital signs and some of HRV at pre and post-EGD. Distractions may suppress BP elevation during the latter half of EGD and lead to stability of HRV on EGD. This prospective trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry as UMIN000029637. Registered on 20 October 2017. (徳島大学機関リポジトリ) ● Metadata: 114760 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12876-020-01274-3 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32316918 ● Search Scopus @ Elsevier (PMID): 32316918 ● Search Scopus @ Elsevier (DOI): 10.1186/s12876-020-01274-3 (徳島大学機関リポジトリ: 114760, DOI: 10.1186/s12876-020-01274-3, PubMed: 32316918)
17.	Takaaki Shimohata, Kazuaki Mawatari, Takashi Uebanso, Airi Honjo, Akari Tsunedomi, Sho Hatayama, Yuri Sato, Junko Kido, Risa Nishisaka, Ayumi Yoshimoto, Tomoko Yamashita, Sachie Amano, Miki Maetani-Yasui, Hitomi Iba, Yumi Harada, Mutsumi Nakahashi, Sonoko Yasui-Yamada, Yasuhiro Hamada, Tadahiko Nakagawa, Masahiro Sogabe, Takahiro Emoto, Masatake Akutagawa, Toshiya Okahisa, Yohsuke Kinouchi and Akira Takahashi : Bacterial Contamination of Hemodialysis Devices in Hospital Dialysis Wards., The Journal of Medical Investigation : JMI, Vol.66, No.1.2, 148-152, 2019. (要約) Chronic care patients undergoing hemodialysis for treatment of end-stage renal failure experience higher rates of bloodstream-associated infection due to the patients' compromised immune system and management of the bloodstream through catheters. Staphylococcus species are acommon cause of hemodialysis catheterrelated bloodstream infections. We investigated environmental bacterial contamination of dialysis wards and contamination of hemodialysis devices to determine the source of bacteria for these infections. All bacterial samples were collected by the swab method and the agarose stamp method. And which bacterium were identified by BBL CRYSTAL Kit or 16s rRNA sequences. In our data, bacterial cell number of hemodialysis device was lower than environment of patient surrounds. But Staphylococcus spp. were found predominantly on the hemodialysis device (46.8%), especially on areas frequently touched by healthcare-workers (such as Touch screen). Among Staphylococcus spp., Staphylococcus epidermidis was most frequently observed (42.1% of Staphylococcus spp.), and more surprising, 48.2% of the Staphylococcus spp. indicated high resistance for methicillin. Our finding suggests that hemodialysis device highly contaminated with bloodstream infection associated bacteria. This study can be used as a source to assess the risk of contamination-related infection and to develop the cleaning system for the better prevention for bloodstream infections in patients with hemodialysis. J. Med. Invest. 66 : 148-152, February, 2019. (徳島大学機関リポジトリ) ● Metadata: 113411 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.66.148 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31064928 ● Search Scopus @ Elsevier (PMID): 31064928 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.66.148 (徳島大学機関リポジトリ: 113411, DOI: 10.2152/jmi.66.148, PubMed: 31064928)
18.	Masahiro Sogabe, Toshiya Okahisa, Yumi Adachi, Masanori Takehara, Shinichi Hamada, Jun Okazaki, Yasuteru Fujino, akira fukuya, Akihiro Hirao, Kaizoh Kagemoto, Akihiro Hirao, Koichi Okamoto, Masahiko Nakasono and Tetsuji Takayama : The influence of various distractions prior to upper gastrointestinal endoscopy: a prospective randomized controlled study., BMC Gastroenterology, Vol.18, No.1, 132, 2018. (要約) Although many patients still have anxiety about upper gastrointestinal (GI) endoscopy, there have been few reports on the influence of distractions for a person who is going to undergo upper GI endoscopy soon. This study was a prospective randomized controlled study investigating the influence of distractions, such as auditive and visual distractions using subjective and objective assessments including autonomic nervous function prior to upper GI endoscopy. 206 subjects who underwent upper GI endoscopy as regular health check-ups were divided randomly into 4 groups prior to upper GI endoscopy; group 1 (control group), group 2 (auditive group), group 3 (visual group), and group 4 (combination group). We measured vital signs, autonomic nervous function, profile of mood state (POMS), and the impression for upper GI endoscopy pre- and post-distraction in the 4 groups. There was no significant difference in vital signs between 5 and 15 min after sitting in group 1, however, several vital signs in all distraction groups improved significantly after distraction (Pulse rate (P): p < 0.001 in group 4; blood pressure: p < 0.05 in group 2, 3, 4) and the rate of decrease in P and diastolic blood pressure was highest in group 4 (p < 0.001). Several scores of POMS and the impression for upper GI endoscopy post-distraction improved significantly compared to pre-distraction between distraction groups and the satisfaction for distraction was highest in group 4 (p < 0.01). Regarding autonomic nerve function, the low- frequency power/ high- frequency power ratio post-distraction was significantly lower than that pre-distraction in all distraction groups (p < 0.001). Although auditive distraction alone and visual distraction alone were effective, a combination distraction was more effective than any other distraction by subjective and objective assessments. These distractions, which were simple and safe, may play an assistive role in the stability of physical and psychological conditions prior to upper GI endoscopy. This trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry as UMIN000022801 . Registered on 10 July 2016. (キーワード) Adult / Affect / Anxiety / Autonomic Nervous System / Blood Pressure / Endoscopy, Gastrointestinal / Female / Heart Rate / Humans / Male / Middle Aged / Motion Pictures / Music / Oxygen / Prospective Studies / Respiration / Surveys and Questionnaires (徳島大学機関リポジトリ) ● Metadata: 114349 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12876-018-0859-y (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30157771 ● Summary page in Scopus @ Elsevier: 2-s2.0-85052523648 (徳島大学機関リポジトリ: 114349, DOI: 10.1186/s12876-018-0859-y, PubMed: 30157771, Elsevier: Scopus)
19.	Rie Harada, Masako Kimura, Yasushi Sato, Tatsuya Taniguchi, Tetsu Tomonari, Takahiro Tanaka, Hironori Tanaka, Naoki Muguruma, Hirohiko Shinomiya, Hirohito Honda, Issei Imoto, Masahiro Sogabe, Toshiya Okahisa and Tetsuji Takayama : APOB codon 4311 polymorphism is associated with hepatitis C virus infection through altered lipid metabolism., BMC Gastroenterology, Vol.18, No.1, 24, 2018. (要約) It has been reported that some single-nucleotide polymorphisms (SNPs) in lipid regulators such as apolipoproteins and cell surface molecules for hepatitis C virus (HCV) entry into hepatocytes are associated with HCV infection. However, it is unknown how HCV infection is affected by altered lipid metabolism resulting from the SNPs. We investigated the relationship between these SNPs and HCV infection status, and also analyzed the mechanism by which these SNPs mediate HCV infection via lipid metabolism alterations. Serum lipid and apolipoprotein profiles were tested in 158 HCV-positive and 220 HCV-negative subjects. We selected 22 SNPs in five lipid regulator genes which were related to HCV entry into hepatocytes and to lipid metabolism (APOA1, APOB, SR-B1, LDLR, and APOE), and their polymorphisms were analyzed using the PCR-sequence-specific oligonucleotide probe-Luminex method. An APOB N4311S (g.41553a > g) SNP, rs1042034, was significantly associated with HCV positivity; the HCV positivity rate for the minor allele AA genotype was significantly higher than for genotype AG + GG (P = 0.016). Other SNPs except for APOB P2712L SNP rs676210, which is in linkage disequilibrium with rs1042034, showed no significant difference in genotype distribution. The serum level of low density lipoprotein-cholesterol (LDL-C) in the genotype AA group was significantly lower than in the genotype non-AA group (P = 0.032), whereas the triglyceride (TG) level was significantly higher (P = 0.007). An APOB SNP, rs1042034, is closely associated with HCV infection through lipid metabolism alteration. The minor allele AA genotype might contribute to facilitating serum LDL uptake into hepatocytes via LDLR by modifying their affinity and interaction and may have an influence on HCV infection by their entry to the liver through the LDLR. (徳島大学機関リポジトリ) ● Metadata: 111808 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12876-018-0747-5 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29382324 ● Summary page in Scopus @ Elsevier: 2-s2.0-85041353404 (徳島大学機関リポジトリ: 111808, DOI: 10.1186/s12876-018-0747-5, PubMed: 29382324, Elsevier: Scopus)
20.	Yasuyuki Okada, Tetsuo Kimura, Tadahiko Nakagawa, Koichi Okamoto, Akira Fukuya, Takahiro Goji, Shota Fujimoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Yasushi Tsuji, Toshiya Okahisa and Tetsuji Takayama : EGFR Down-regulation After anti-EGFR Therapy Predicts the Anti-tumor Effect in Colorectal Cancer., Molecular Cancer Research : MCR, Vol.15, No.10, 1445-1454, 2017. (要約) Anti-EGFR mAb is reported to induce EGFR internalization in colorectal cancer cells. However, the biological relevance of EGFR internalization with anti-EGFR mAb is unknown. Therefore, the relevance of EGFR downregulation with anti-EGFR mAb to antitumor activity in colorectal cancer cells was investigated. Quantification of EGFR on the cell surface before cetuximab treatment was assessed by flow cytometry, and its growth-inhibitory effects were measured by Trypan blue exclusion, in 10 wild-type colorectal cancer cell lines, but there was no significant correlation between EGFR number and its growth-inhibitory effect. However, a significant correlation existed between the percentage decrease in the number of EGFRs after cetuximab treatment and its growth-inhibitory effect in those cell lines. Treatment with TGFα, a ligand for EGFR, induced EGFR internalization in colorectal cancer cells, but most EGFRs subsequently recycled to the cell surface, consistent with previous studies. While cetuximab treatment induced EGFR internalization, most receptors subsequently translocated into the late endosome, leading to lysosomal degradation, as revealed by immunoblotting and double immunofluorescence. Cetuximab-sensitive colorectal cancer cells showed greater EGFR internalization, stronger cell growth inhibition, and more augmented apoptotic signals than nonsensitive cells. IHC for EGFR, performed using an EGFR pharmDx Kit (mouse anti-human EGFR mAb clone 2-18C9), in clinical specimens before and after anti-EGFR mAb therapy in 13 colorectal cancer patients showed a significant correlation between the response to anti-EGFR mAb and decreased staining after therapy. This report clearly demonstrates that anti-EGFR mAb facilitates internalization and subsequent degradation of EGFRs in lysosomes, which is an important determinant of the efficacy of anti-EGFR mAb treatment for colorectal cancer. . (キーワード) Adult / Aged / Antineoplastic Agents, Immunological / Caco-2 Cells / Cell Line, Tumor / Cell Survival / Cetuximab / Colorectal Neoplasms / Down-Regulation / Endosomes / Female / HCT116 Cells / HT29 Cells / Humans / Male / Middle Aged / Proto-Oncogene Proteins B-raf / Receptor, Epidermal Growth Factor / Transforming Growth Factor alpha / ras Proteins (徳島大学機関リポジトリ) ● Metadata: 110960 (出版サイトへのリンク) ● Publication site (DOI): 10.1158/1541-7786.MCR-16-0383 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28698359 ● Search Scopus @ Elsevier (PMID): 28698359 ● Search Scopus @ Elsevier (DOI): 10.1158/1541-7786.MCR-16-0383 (徳島大学機関リポジトリ: 110960, DOI: 10.1158/1541-7786.MCR-16-0383, PubMed: 28698359)
21.	Kohei Sugihara, Masashi Masuda, Mari Nakao, Maerjianghan Abuduli, Yukiko Imi, Naoko Oda, Toshiya Okahisa, Hironori Yamamoto, Eiji Takeda and Yutaka Taketani : Dietary phosphate exacerbates intestinal inflammation in experimental colitis., Journal of Clinical Biochemistry and Nutrition, Vol.61, No.2, 91-99, 2017. (要約) study, the effects of phosphate on proinflammatory cytokine induction and reactive oxygen species production in RAW264.7 macrophage were examined. Dietary phosphate exacerbated intestinal inflammation in experimental colitis in a dose-dependent manner, as assessed by the clinical disease activity score, colon length, and histology. Furthermore, the high phosphate diet increased myeloperoxidase activity and proinflammatory cytokine mRNA expression through the activation of nuclear factor B in the inflamed colon. In addition, high phosphate loading in RAW264.7 cells directly enhanced reactive oxygen species production and proinflammatory cytokine gene expression. Our results demonstrated that the high phosphate diet exacerbated intestinal inflammation in experimental colitis. These findings have important therapeutic implications for inflammatory bowel disease patients. (徳島大学機関リポジトリ) ● Metadata: 110124 (出版サイトへのリンク) ● Publication site (DOI): 10.3164/jcbn.16-117 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28955125 ● Search Scopus @ Elsevier (PMID): 28955125 ● Search Scopus @ Elsevier (DOI): 10.3164/jcbn.16-117 (徳島大学機関リポジトリ: 110124, DOI: 10.3164/jcbn.16-117, PubMed: 28955125)
22.	大井文香, 中川忠彦, 岡本耕一, 高山哲治, 曽我部正弘, 岡久稔也, 芥川正武, 榎本崇宏, 木内陽介 : LED光を用いた対外循環照射モデルの構築., 電子情報通信学会研究技術報告(MEとバイオサイバネティックス), Vol.117, No.165, 17-20, 2017年. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1520009408978527360 (CiNii: 1520009408978527360)
23.	Masahiro Sogabe, Toshiya Okahisa, Masahiko Nakasono, Hiroshi Fukuno, Yoshihiko Miyamoto, Yasuyuki Okada, Jun Okazaki, Jinsei Miyoshi, Tetsu Tomonari, Tatsuya Taniguchi, Takahiro Goji, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : The differing influence of several factors on the development of fatty liver with elevation of liver enzymes between genders with metabolic syndrome: A cross-sectional study., PLoS ONE, Vol.12, No.6, e0177925, 2017. (要約) Nonalcoholic fatty liver disease (NAFLD) is known to be strongly associated with obesity, visceral fat, metabolic syndrome (MS), lifestyle, and lifestyle-related diseases in both males and females. However, the prevalence of NAFLD, MS, and clinical backgrounds is different between males and females. We conducted a cross-sectional study to examine the differing influence of lifestyle-related factors and visceral fat on fatty liver (FL) with elevation of liver enzymes between males and females with MS. We enrolled 42,134 persons who underwent a regular health check-up, and after excluding subjects who fulfilled excluding criteria, the remaining subjects were 2,110 persons with MS. We examined the differing influence of lifestyle-related factors and visceral fat on FL with elevation of alanine aminotransferase (ALT) (ALT elevation was defined as ALT level of ≥31 IU/l in the present study). The odds rations for FL with ALT elevation were as follows: WC, 1.83 (95% confidence interval (CI) 1.36-2.46); dyslipidemia, 1.89 (95% CI 1.34-2.68); hemoglobin A1c, 1.36 (95% CI 1.00-1.85); visceral fat type MS (V-type MS), 5.78 (95% CI 4.29-7.80); and light drinker, 0.56 (95% CI 0.41-0.78) in males with MS and BMI, 2.18 (95% CI 1.43-3.33); WC, 1.85 (95% CI 1.27-2.70); diastolic blood pressure, 1.69 (95% CI 1.16-2.45); triglyceride, 2.22 (95% CI 1.56-3.17); impaired glucose tolerance, 1.66 (95% CI 1.11-2.47); and V-type MS, 3.83 (95% CI 2.57-5.70) in females with MS. The prevalence of FL with ALT elevation and ALT was significantly higher in V-type MS than in the subcutaneous fat type MS in both males and females with MS (P < 0.001). Although V-type MS and WC is a common significant predictor of an increased prevalence of FL with ALT elevation in both males and females with MS, gender, lifestyle-related factors, and MS type in individuals with MS should be considered for the development of FL with ALT elevation. (徳島大学機関リポジトリ) ● Metadata: 112319 (出版サイトへのリンク) ● Publication site (DOI): 10.1371/journal.pone.0177925 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28574988 ● Summary page in Scopus @ Elsevier: 2-s2.0-85020298128 (徳島大学機関リポジトリ: 112319, DOI: 10.1371/journal.pone.0177925, PubMed: 28574988, Elsevier: Scopus)
24.	Tatsuya Taniguchi, Kazuhiro Kishi, Tadahiko Nakagawa, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Toshiya Okahisa, Naoki Muguruma, Mayumi Kajimoto, Ikuko Sagawa and Tetsuji Takayama : Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma., Digestion, Vol.95, No.3, 242-251, 2017. (要約) Although des-gamma-carboxy prothrombin (DCP) is a well-known tumor marker for hepatocellular carcinoma (HCC), the mechanism of DCP production is unclear. This study aimed to investigate the mechanism how DCP is produced in HCC cells. Levels of mRNA and DCP were analyzed by real-time polymerase chain reaction and electro-chemiluminescence immunoassay respectively. Secreted alkaline phosphatase (SEAP) expression vectors including deletion mutants of the prothrombin gene promoter were constructed for reporter gene assay. The transcription factors bound to DNA fragments were analyzed by mass spectrometry. An electrophoretic mobility shift assay (EMSA) was performed using a biotin end-labeled DNA. The prothrombin mRNA levels in all 5 DCP producing cell lines were appreciably high. However, those in 2 DCP non-producing cell lines were below detectable levels. A SEAP vector with -2985 to +27 showed a very high transcription activity in DCP-producing Huh-1 cells. However, transcription abruptly decreased when the vector with -2955 to +27 was transfected, and then remained at the similar levels with larger deletion mutants, indicating the existence of a cis-element at -2985 to -2955 (31-bp). Mass spectrometry analysis identified the protein that bound to the 31-bp DNA as poly-(ADP-ribose) polymerase-1 (PARP-1). Knockdown of the PARP-1 gene by small interfering RNA in Huh-1 cells induced marked inhibition of prothrombin gene transcription. The EMSA clearly showed that PARP-1 specifically binds to the 31-bp DNA fragment in the prothrombin gene promoter. Our data suggest that PARP-1 activates prothrombin gene transcription and that the excessive prothrombin gene transcription induces DCP production in DCP-producing HCC cells. (徳島大学機関リポジトリ) ● Metadata: 110173 (出版サイトへのリンク) ● Publication site (DOI): 10.1159/000470837 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28384634 ● Search Scopus @ Elsevier (PMID): 28384634 ● Search Scopus @ Elsevier (DOI): 10.1159/000470837 (徳島大学機関リポジトリ: 110173, DOI: 10.1159/000470837, PubMed: 28384634)
25.	Takahiro Emoto, Udantha R. Abeyratne, Yuki Gojima, Kazuki Nanba, Masahiro Sogabe, Toshiya Okahisa, Masatake Akutagawa, Shinsuke Konaka and Yohsuke Kinouchi : Evaluation of human bowel motility using non-contact microphones, Biomedical Physics & Engineering Express, Vol.2, No.4, 1-8, 2016. (出版サイトへのリンク) ● Publication site (DOI): 10.1088/2057-1976/2/4/045012 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1088/2057-1976/2/4/045012 (DOI: 10.1088/2057-1976/2/4/045012)
26.	Toshi Takaoka, Tetsuo Kimura, Rai Shimoyama, Shunji Kawamoto, Kazuki Sakamoto, Fuminori Goda, Hiroshi Miyamoto, Yuji Negoro, Akihito Tsuji, Koji Yoshizaki, Takahiro Goji, Shinji Kitamura, Hiromi Yano, Koichi Okamoto, Masako Kimura, Toshiya Okahisa, Naoki Muguruma, Yoshiro Niitsu and Tetsuji Takayama : Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer., Cancer Chemotherapy and Pharmacology, Vol.78, No.2, 397-403, 2016. (徳島大学機関リポジトリ) ● Metadata: 109985 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00280-016-3096-5 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27342247 ● Summary page in Scopus @ Elsevier: 2-s2.0-84976254460 (徳島大学機関リポジトリ: 109985, DOI: 10.1007/s00280-016-3096-5, PubMed: 27342247, Elsevier: Scopus)
27.	Masahiro Sogabe, Toshiya Okahisa, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Influence of metabolic syndrome on upper gastrointestinal disease., Clinical Journal of Gastroenterology, Vol.9, No.4, 191-202, 2016. (要約) A recent increase in the rate of obesity as a result of insufficient physical exercise and excess food consumption has been seen in both developed and developing countries throughout the world. Additionally, the recent increased number of obese individuals with lifestyle-related diseases associated with abnormalities in glucose metabolism, dyslipidemia, and hypertension, defined as metabolic syndrome (MS), has been problematic. Although MS has been highlighted as a risk factor for ischemic heart disease and arteriosclerotic diseases, it was also recently shown to be associated with digestive system disorders, including upper gastrointestinal diseases. Unlike high body weight and high body mass index, abdominal obesity with visceral fat accumulation is implicated in the onset of various digestive system diseases because excessive visceral fat accumulation may cause an increase in intra-abdominal pressure, inducing the release of various bioactive substances, known as adipocytokines, including tumor necrosis factor-α, interleukin-6, resistin, leptin, and adiponectin. This review article focuses on upper gastrointestinal disorders and their association with MS, including obesity, visceral fat accumulation, and the major upper gastrointestinal diseases. (キーワード) Adenocarcinoma / Barrett Esophagus / Esophageal Neoplasms / Gastritis / Gastroesophageal Reflux / Gastrointestinal Diseases / Hernia, Hiatal / Humans / Metabolic Syndrome X / Peptic Ulcer / Stomach Neoplasms (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s12328-016-0668-1 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27372302 ● Summary page in Scopus @ Elsevier: 2-s2.0-84976486171 (DOI: 10.1007/s12328-016-0668-1, PubMed: 27372302, Elsevier: Scopus)
28.	Masahiro Sogabe, Toshiya Okahisa, Tadahiko Nakagawa, Hiroshi Fukuno, Masahiko Nakasono, Tetsu Tomonari, Takahiro Tanaka, Hironori Tanaka, Tatsuya Taniguchi, Naoki Muguruma and Tetsuji Takayama : Influence of light alcohol consumption on lifestyle-related diseases: a predictor of fatty liver with liver enzyme elevation in Japanese females with metabolic syndrome., BMC Gastroenterology, Vol.16, No.1, 17, 2016. (要約) Although heavy drinking is known to lead to liver injury, some recent studies have reported that light alcohol consumption (LAC) may play a protective role against fatty liver in the general population, and may even play a protective role against non-alcoholic fatty liver disease (NAFLD) in males with metabolic syndrome (MS). However, the association between LAC and fatty liver with liver enzyme elevation in females with MS is unclear. Participants of this study were 20,853 females who underwent a regular health check-up between April 2008 and March 2012 at our hospital. Enrolled subjects were 1141 females with MS, who underwent all necessary tests and drank less than 20 g/day of alcohol. We investigated the presence of fatty liver with liver enzyme elevation, defined in this study as alanine aminotransferase (ALT) levels ≧31 IU/I, and the association between LAC and fatty liver with ALT elevation. There was no significant difference in the prevalence of fatty liver and ALT between light drinkers and non-drinkers. The prevalence of individuals receiving a treatment for dyslipidemia and impaired glucose tolerance (IGT) was significantly lower in light drinkers than in non-drinkers. Body mass index (BMI), waist circumference (WC), diastolic blood pressure (DBP), triglyceride (TG), uric acid (UA), IGT, and visceral fat type MS (V-type MS) were significant predictors of the prevalence of fatty liver with ALT elevation in logistic regression analysis. The odds ratio [OR] (95 % confidence interval [CI], p value) for fatty liver with ALT elevation were as follows: BMI, 2.181 (1.445-3.293, p <0.001); WC, 1.853 (1.280-2.684, p <0.01); DBP, 1.604 (1.120-2.298, p <0.05); TG, 2.202 (1.562-3.105, p <0.001); UA, 2.959 (1.537-5.698, p <0.01); IGT, 1.692 (1.143-2.506, p <0.01); and V-type MS, 3.708 (2.529-5.437, p <0.001). There was no significant difference in the prevalence of fatty liver with ALT elevation in females with MS between light drinkers and non-drinkers, suggesting that other factors such as BMI, WC, V-type MS, and lifestyle-related disease may be more important than LAC for the prevalence of fatty liver with ALT elevation. (徳島大学機関リポジトリ) ● Metadata: 114348 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12876-016-0431-6 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26892109 ● Search Scopus @ Elsevier (PMID): 26892109 ● Search Scopus @ Elsevier (DOI): 10.1186/s12876-016-0431-6 (徳島大学機関リポジトリ: 114348, DOI: 10.1186/s12876-016-0431-6, PubMed: 26892109)
29.	Jinsei Miyoshi, Hiroshi Miyamoto, Takahiro Goji, Tatsuya Taniguchi, Tetsu Tomonari, Masahiro Sogabe, Tetsuo Kimura, Shinji Kitamura, Koichi Okamoto, Yasuteru Fujino, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs., Journal of Gastroenterology and Hepatology, Vol.30, No.11, 1582-1590, 2015. (要約) Objective evaluation of intestinal mucosal damage due to anticancer drugs is generally difficult. Serum diamine oxidase (DAO) activity is reported to reflect the integrity and maturity of the small intestinal mucosa. Therefore, we investigated whether serum DAO activity is an indicator of gastrointestinal toxicity or nutritional status in patients receiving chemotherapy. We prospectively enrolled 20 patients with unresectable metastatic gastric cancer who received oral S-1 (80 mg/m(2) ) on days 1-14, and intravenous cisplatin (60 mg/m(2) ) and docetaxel (50 mg/m(2) ) on day 8 every 3 weeks. Serum DAO activity was measured by colorimetry. Gastrointestinal toxicity was evaluated by CTCAE v4.0. Endoscopic examination and biopsy of duodenal mucosa assessed mucosal damage. Malnutrition was evaluated by measuring serum total protein and albumin levels. Serum DAO activity decreased step-by-step significantly during anticancer drug treatment and recovered after drug holidays. In all 14 patients who experienced diarrhea, serum DAO activity significantly decreased prior to diarrhea onset. Percent decrease in DAO activity was significantly correlated with severity of diarrhea. Significant correlation was observed between percent decrease in DAO activity and percent decrease in duodenal villus height or surface area from baseline. There were also significant correlations between percent decrease in serum DAO activity at day 14 and percent decrease in serum total protein or albumin levels at day 21 from baseline. Serum DAO activity sensitively indicates gastrointestinal damage prior to symptom onset and can be a useful predictor of intestinal mucosal damage and nutritional status in patients receiving chemotherapy. (徳島大学機関リポジトリ) ● Metadata: 109519 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/jgh.13004 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25968084 ● Summary page in Scopus @ Elsevier: 2-s2.0-84943595915 (徳島大学機関リポジトリ: 109519, DOI: 10.1111/jgh.13004, PubMed: 25968084, Elsevier: Scopus)
30.	Takahiro Goji, Tetsuo Kimura, Hiroshi Miyamoto, Masanori Takehara, kaizo Kagamoto, Yasuyuki Okada, Jun Okazaki, Yoshifumi Takaoka, Yoshihiko Miyamoto, Yasuhiro Mitsui, Tatsunao Sueuchi, Kumiko Tanaka, Yasuteru Fujino, Sayo Matsumoto, Toshi Takaoka, Shinji Kitamura, Koichi Okamoto, Masako Kimura, Masahiro Sogabe, Naoki Muguruma, Toshiya Okahisa, Yasuhiro Sato, Tamotsu Sagawa, Koji Fujikawa, Yasushi Sato, Hitoshi Ikushima and Tetsuji Takayama : A Phase I/II Study of Fixed-dose-rate Gemcitabine and S-1 with Concurrent Radiotherapy for Locally Advanced Pancreatic Cancer, Cancer Chemotherapy and Pharmacology, Vol.76, No.3, 615-620, 2015. (要約) This study was conducted to identify the maximum-tolerated dose (MTD) of fixed-dose-rate gemcitabine (FDR-gem) administered concurrently with S-1 and radical radiation for locally advanced pancreatic cancer (LAPC) and to provide efficacy and safety data. Patients with unrespectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400 mg/m(2), 5 mg/m(2)/min) on days 1, 8, 22, and 29 and 60 mg/m(2) of S-1 orally on days 1-14, 22-35. A total radiation dose of 50.4 Gy (1.8 Gy/day, 28 fractions) was delivered concurrently. Twenty-five patients were enrolled; all were evaluable for toxicity assessment. In phase I, eight patients were treated in sequential cohorts of three to five patients per dose level. The MTD was reached at level 2, and dose-limiting toxicities were neutropenia and thrombocytopenia. The recommended doses were 300 mg/m(2) of gemcitabine and 60 mg/m(2) of S-1 daily. The overall response rate was 25% and disease control rate (partial response plus stable disease) was 92%. The progression-free survival was 11.0 months. The median overall survival and 1-year survival rates were 16.0 months and 73%, respectively. The combination of FDR-gem and S-1 with radiation is a feasible regimen that shows favorable antitumor activity with an acceptable safety profile in patients with LAPC. (徳島大学機関リポジトリ) ● Metadata: 110046 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00280-015-2835-3 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26220846 ● Summary page in Scopus @ Elsevier: 2-s2.0-84939568942 (徳島大学機関リポジトリ: 110046, DOI: 10.1007/s00280-015-2835-3, PubMed: 26220846, Elsevier: Scopus)
31.	Masahiro Sogabe, Toshiya Okahisa, Masahiko Nakasono, Yasuteru Fujino, Yasuhiro Mitsui, Yoshihumi Takaoka, Tetsuo Kimura, Koichi Okamoto, Naoki Muguruma and Tetsuji Takayama : Investigation of Gastroduodenal Mucosal Injury in Japanese Asymptomatic Antiplatelet Drug Users, Medicine, Vol.94, No.26, e1047, 2015. (要約) Antiplatelet drugs are widely used for the prevention of cardiovascular disease and cerebral vascular disorders. Although there have been several studies on gastroduodenal mucosal injury with gastrointestinal (GI) symptoms such as GI bleeding, in antiplatelet drug users (including low-dose aspirin (LDA)), there have been few reports on the association between antiplatelet drug use and gastroduodenal mucosal injury in asymptomatic antiplatelet drug users. This study was a cross-sectional study elucidating the association between antiplatelet drug use and gastroduodenal mucosal injury in asymptomatic antiplatelet drug users.Subjects were 186 asymptomatic Japanese antiplatelet drug users who underwent a regular health checkup. Subjects were divided into those with and without gastroduodenal mucosal injury endoscopically, and the association between gastroduodenal mucosal injury and other data in asymptomatic antiplatelet drug users was investigated.The prevalence of males and drinkers were significantly higher in subjects with gastroduodenal mucosal injury than in those without. In addition, the prevalence of proton pump inhibitor (PPI) users was significantly lower in subjects with gastroduodenal mucosal injury than in subjects without gastroduodenal mucosal injury. Logistic regression analysis showed PPI (odds ratios: 0.116; 95% confidence intervals: 0.021-0.638; P < 0.05) was a significant predictor of a decreased prevalence of gastroduodenal mucosal injury and closed-type (C-type) atrophy (3.172; 1.322-7.609; P < 0.01) was a significant predictor of an increased prevalence of severe gastroduodenal mucosal injury in asymptomatic antiplatelet drug users.Gender and lifestyle, such as drinking, may have an impact on risk of gastroduodenal mucosal injury in asymptomatic subjects taking antiplatelet drugs. Although PPI is a significant predictor of a decreased prevalence of gastroduodenal mucosal injury, including in asymptomatic antiplatelet drug users, status of gastric atrophy should also be considered against severe gastroduodenal mucosal injury. (キーワード) Adult / Aged / Aged, 80 and over / Endoscopy, Gastrointestinal / Female / Gastric Mucosa / Humans / Male / Middle Aged / Platelet Aggregation Inhibitors / Retrospective Studies / Stomach Diseases / Young Adult (徳島大学機関リポジトリ) ● Metadata: 115594 (出版サイトへのリンク) ● Publication site (DOI): 10.1097/MD.0000000000001047 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26131815 ● Summary page in Scopus @ Elsevier: 2-s2.0-84942531762 (徳島大学機関リポジトリ: 115594, DOI: 10.1097/MD.0000000000001047, PubMed: 26131815, Elsevier: Scopus)
32.	Masahiro Sogabe, Toshiya Okahisa, Tatsuya Taniguchi, Tetsu Tomonari, Takahiro Tanaka, Hironori Tanaka, Masahiko Nakasono and Tetsuji Takayama : Light alcohol consumption plays a protective role against non-alcoholic fatty liver disease in Japanese men with metabolic syndrome., Liver International, Vol.35, No.6, 1707-1714, 2015. (要約) Although excess alcohol consumption has been believed to cause liver injury, light alcohol consumption (LAC) has been reported to play a protective role against fatty liver in recent studies. However, the association between non-alcoholic fatty liver disease (NAFLD) and LAC in men with metabolic syndrome (MS) is unclear. The aim of this study was to examine the association between NAFLD and LAC in men with MS. Subjects were 1055 men with MS who underwent a regular health check-up and drank less 20 g/day of alcohol. A distinction was made between non-drinkers and light drinkers and the association between NAFLD and LAC in men with MS was elucidated. NAFLD was referred as fatty liver with alanine aminotransferase (ALT) levels 31 IU/L in this study. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and the prevalence of NAFLD were significantly lower in light drinkers than in non-drinkers. Logistic regression analysis showed body mass index (BMI), waist circumference (WC), uric acid (UA), haemoglobin A1c (HbA1c), visceral fat type MS and LAC (odds ratios: 0.654; 95% confidence intervals: 0.473-0.906; <0.05) were significant predictors of the prevalence of NAFLD. The prevalence of NAFLD in light drinkers was significantly lower than in non-drinkers, and supporting previous reports studying the general population, LAC is one of the significant predictors of a decreased prevalence of NAFLD in men with MS. (キーワード) Abdomen / Adult / Aged / Alanine Transaminase / Alcohol Drinking / Asian Continental Ancestry Group / Aspartate Aminotransferases / Body Mass Index / Hemoglobin A, Glycosylated / Humans / Intra-Abdominal Fat / Japan / Logistic Models / Male / Metabolic Syndrome X / Middle Aged / Multivariate Analysis / Non-alcoholic Fatty Liver Disease / Odds Ratio / Surveys and Questionnaires / Uric Acid / Waist Circumference (出版サイトへのリンク) ● Publication site (DOI): 10.1111/liv.12754 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25438866 ● Search Scopus @ Elsevier (PMID): 25438866 ● Search Scopus @ Elsevier (DOI): 10.1111/liv.12754 (DOI: 10.1111/liv.12754, PubMed: 25438866)
33.	Atsushi Inoue, Koichi Okamoto, Yasuteru Fujino, Tadahiko Nakagawa, Naoki Muguruma, Katsutaka Sannomiya, Yasuhiro Mitsui, Toshi Takaoka, Shinji Kitamura, Hiroshi Miyamoto, Toshiya Okahisa, Takahiro Fujimori, Issei Imoto and Tetsuji Takayama : B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF),sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P., British Journal of Cancer, Vol.112, No.2, 403-412, 2015. (要約) Sessile serrated adenomas/polyps (SSA/Ps) are a putative precursor of colon cancer with microsatellite instability (MSI). However, the developmental mechanism of SSA/P remains unknown. We performed genetic analysis and genome-wide DNA methylation analysis in aberrant crypt foci (ACF), SSA/P, and cancer in SSA/P specimens to show a close association between ACF and the SSA/P-cancer sequence. We also evaluated the prevalence and number of ACF in SSA/P patients. ACF in the right-side colon were observed in 36 patients with SSA/Ps alone, 2 with cancers in SSA/P, and 20 normal subjects and biopsied under magnifying endoscopy. B-RAF mutation and MSI were analysed by PCR-restriction fragment length polymorphism (RFLP) and PCR-SSCP, respectively, in 15 ACF, 20 SSA/P, and 2 cancer specimens. DNA methylation array analysis of seven ACF, seven SSA/P, and two cancer in SSA/P specimens was performed using the microarray-based integrated analysis of methylation by isochizomers (MIAMI) method. B-RAF mutations were frequently detected in ACF, SSA/P, and cancer in SSA/P tissues. The number of methylated genes increased significantly in the order of ACF<SSA/P<cancer. The most commonly methylated genes in SSA/P were PQLC1, HDHD3, RASL10B, FLI1, GJA3, and SLC26A2. Some of these genes were methylated in ACF, whereas all genes were methylated in cancers. Immunohistochemistry revealed their silenced expression. Microsatellite instability and MLH1 methylation were observed only in cancer. The prevalence and number of ACF were significantly higher in SSA/P patients than in normal subjects. A significant correlation was seen between the numbers of SSA/P and ACF in SSA/P patients. Our results suggest that ACF are precursor lesions of the SSA/P-cancer sequence in patients with SSA/P, where ACF arise by B-RAF mutation and methylation of some of the six identified genes and develop into SSA/Ps through accumulated methylation of these genes. (キーワード) Aberrant Crypt Foci / Adenoma / Aged / Case-Control Studies / Colonic Neoplasms / DNA Methylation / Female / Genetic Association Studies / Genetic Predisposition to Disease / Humans / Male / Middle Aged / Mutation, Missense / Proto-Oncogene Proteins B-raf (徳島大学機関リポジトリ) ● Metadata: 106441 (出版サイトへのリンク) ● Publication site (DOI): 10.1038/bjc.2014.545 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25314065 ● Summary page in Scopus @ Elsevier: 2-s2.0-84922337339 (徳島大学機関リポジトリ: 106441, DOI: 10.1038/bjc.2014.545, PubMed: 25314065, Elsevier: Scopus)
34.	Masahiro Sogabe, Toshiya Okahisa, Akira Yamanoi and Tetsuji Takayama : Subtypes of metabolic syndrome and of other risk factors in Japanese women with erosive esophagitis., Medicine, Vol.93, No.28, e276, 2014. (要約) Obesity and metabolic syndrome (MS) are strongly associated with erosive esophagitis (EE). The prevalence of MS and EE, and the distribution of adipose tissue have been known to differ markedly between men and women. Although the prevalence of EE in men with MS is known to be higher in visceral fat type MS (V-type MS) than in subcutaneous fat type MS (S-type MS), the association between EE and the types of MS in women with MS is unclear. This study was a cross-sectional study elucidating the association between EE and the types of MS in women with MS. Subjects were 454 women with MS who underwent a regular health check-up. A distinction was made between V-type MS and S-type MS and the prevalence of EE and the association between EE and other data were elucidated. Although there were some significant different factors in characteristics between V-type MS and S-type MS, there was no significant difference in the prevalence of EE between V-type MS and S-type MS. The presence of Helicobacter pylori (H. pylori) was significantly lower than in subjects with EE (13.7%) than in subjects without EE (41.9%). The frequency of hiatal hernia was significantly higher in subjects with EE (60.8%) than in subjects without EE (24.6%). Logistic regression analysis showed hiatal hernia (odds ratio: 4.673; 95% confidence interval: 2.448-8.920; P<0.001), hemoglobin A1c (HbA1c) (2.325; 1.110-4.870; P<0.05), and the presence of H. pylori (0.239; 0.101-0.567; P<0.005) were significant predictors of the prevalence of EE. V-type MS may not be such an important factor for the prevalence of EE in women with MS as in men with MS. The absence of H. pylori, hiatal hernia, and HbA1c may be more important for the prevalence of EE than the types of MS in women with MS. (キーワード) Adult / Aged / Aged, 80 and over / Cross-Sectional Studies / Esophagitis / Esophagoscopy / Female / Follow-Up Studies / Humans / Japan / Metabolic Syndrome X / Middle Aged / Obesity / Prevalence / Prognosis / Retrospective Studies / Risk Assessment / Risk Factors / Tomography, X-Ray Computed (徳島大学機関リポジトリ) ● Metadata: 115595 (出版サイトへのリンク) ● Publication site (DOI): 10.1097/MD.0000000000000276 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25526458 ● Search Scopus @ Elsevier (PMID): 25526458 ● Search Scopus @ Elsevier (DOI): 10.1097/MD.0000000000000276 (徳島大学機関リポジトリ: 115595, DOI: 10.1097/MD.0000000000000276, PubMed: 25526458)
35.	新田佳伯, 芥川正武, 榎本崇宏, 岡久稔也, 宮本弘志, 大西芳明, 木内陽介, S. Abhijit PANDYA : 体外循環療法中に腎臓で行われる水分の再吸収効率の推定, 医工学治療, Vol.26, No.1, 24-31, 2014年.
36.	Momoko Sato, Naoki Muguruma, Nakagawa Tadahiko, Koichi Okamoto, Tetsuo Kimura, Shinji Kitamura, Hiromi Yano, Sannomiya Katsutaka, Takahiro Goji, Hiroshi Miyamoto, Toshiya Okahisa, Hiroaki Mikasa, Wada Satoshi, Iwata Masao and Tetsuji Takayama : High antitumor activity of pladienolide B and its derivative in gastric cancer, Cancer Science, Vol.105, No.1, 110-116, 2014. (要約) The antitumor activity of pladienolide B, a novel splicing inhibitor, against gastric cancer is totally unknown and no predictive biomarker of pladienolide B efficacy has been reported. We investigated the antitumor activity of pladienolide B and its derivative on gastric cancer cell lines and primary cultured cancer cells from carcinomatous ascites of gastric cancer patients. The effect of pladienolide B and its derivative on six gastric cancer cell lines was investigated using a MTT assay and the mean IC50 values determined to be 1.6 ± 1.2 (range, 0.6-4.0) and 1.2 ± 1.1 (range, 0.4-3.4) nM, respectively, suggesting strong antitumor activity against gastric cancer. The mean IC50 value of pladienolide B derivative against primary cultured cells from 12 gastric cancer patients was 4.9 ± 4.7 nM, indicative of high antitumor activity. When 18 SCID mice xenografted with primary cultured cells from three patients were administered the pladienolide B derivative intraperitoneally, all tumors completely disappeared within 2 weeks after treatment. Histological examination revealed a pathological complete response for all tumors. In the xenograft tumors after treatment with pladienolide B derivative, immature mRNA were detected and apoptotic cells were observed. When the expressions of cell-cycle proteins p16 and cyclin E in biopsied gastric cancer specimens were examined using immunohisctochemistry, positivities for p16 and cyclin E were significantly and marginally higher, respectively, in the low-IC50 group compared with the high-IC50 group, suggesting the possibility that they might be useful as predictive biomarkers for pladienolide B. In conclusion, pladienolide B was very active against gastric cancer via a mechanism involving splicing impairment and apoptosis induction. (キーワード) Aged / Aged, 80 and over / Animals / Antineoplastic Agents / Apoptosis / Cell Line, Tumor / Cyclin E / Cyclin-Dependent Kinase Inhibitor p16 / Epoxy Compounds / Female / Humans / Macrolides / Male / Mice / Mice, SCID / Middle Aged / RNA Splicing / Random Allocation / Stomach Neoplasms / Xenograft Model Antitumor Assays (徳島大学機関リポジトリ) ● Metadata: 106055 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/cas.12317 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24635824 ● Summary page in Scopus @ Elsevier: 2-s2.0-84892849884 (徳島大学機関リポジトリ: 106055, DOI: 10.1111/cas.12317, PubMed: 24635824, Elsevier: Scopus)
37.	Masahiro Sogabe, Toshiya Okahisa, K Tsujigami, H Fukuno, S Hibino and A Yamanoi : Visceral fat predominance is associated with non-alcoholic fatty liver disease in Japanese women with metabolic syndrome., Hepatology Research, Vol.44, No.5, 512-522, 2014.
38.	Naoki Muguruma, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : Endoscopic Molecular Imaging: Status and Future Perspective., Clinical Endoscopy, Vol.46, No.6, 603-610, 2013. (要約) During the last decade, researchers have made great progress in the development of new image processing technologies for gastrointestinal endoscopy. However, diagnosis using conventional endoscopy with white light optical imaging is essentially limited, and ultimately, we still rely on the histopathological diagnosis from biopsy specimens. Molecular imaging represents the most novel imaging methods in medicine, and the future of endoscopic diagnosis is likely to be impacted by a combination of biomarkers and technology. Endoscopic molecular imaging can be defined as the visualization of molecular characteristics with endoscopy. These innovations will allow us not only to locate a tumor or dysplastic lesion but also to visualize its molecular characteristics and the activity of specific molecules and biological processes that affect tumor behavior and/or its response to therapy. In the near future, these promising technologies will play a central role in endoluminal oncology. (徳島大学機関リポジトリ) ● Metadata: 115065 (出版サイトへのリンク) ● Publication site (DOI): 10.5946/ce.2013.46.6.603 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24340252 ● Search Scopus @ Elsevier (PMID): 24340252 ● Search Scopus @ Elsevier (DOI): 10.5946/ce.2013.46.6.603 (徳島大学機関リポジトリ: 115065, DOI: 10.5946/ce.2013.46.6.603, PubMed: 24340252)
39.	Miho Tsuda, Koichi Okamoto, Naoki Muguruma, Katsutaka Sannomiya, Tadahiko Nakagawa, Hiroshi Miyamoto, Shinji Kitamura, Takahiro Goji, Tetsuo Kimura, Toshiya Okahisa, Keisuke Izumi and Tetsuji Takayama : Suppressive effect of RAS inhibitor manumycin A on aberrant crypt foci formation in the azoxymethane-induced rat colorectal carcinogenesis model., Journal of Gastroenterology and Hepatology, Vol.28, No.10, 1616-1623, 2013. (要約) The mean number of ACF in the 8-week manumycin A group (72.9 ± 20.1) was significantly lower than in the vehicle group (155.6 ± 56.7, P < 0.01), and it was significantly lower even in the 4-week manumycin A group than in the vehicle group (92.2 ± 13.0 vs 222.3 ± 83.3, P < 0.01). The positive rate for phosphorylated ERK in the manumycin A group (13.5 ± 19.2%) was significantly lower than in the vehicle group (50.2 ± 19.8%, P < 0.01). The positive rate for Ki-67 in the manumycin A group (2.2 ± 3.4%) was significantly lower than in the vehicle group (14.7 ± 8.2%, P < 0.01). There were significantly more terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling-positive cells in tissue samples from the manumycin A group versus the vehicle group (8.6 ± 9.7% vs 2.9 ± 2.0%, P < 0.05). (徳島大学機関リポジトリ) ● Metadata: 105897 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/jgh.12287 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23730936 ● Search Scopus @ Elsevier (PMID): 23730936 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12287 (徳島大学機関リポジトリ: 105897, DOI: 10.1111/jgh.12287, PubMed: 23730936)
40.	Koichi Okamoto, Shinji Kitamura, Naoki Muguruma, Toshi Takaoka, Yasuteru Fujino, Yoshiro Kawahara, Toshiya Okahisa and Tetsuji Takayama : Mucosectom2-short blade for safe and efficient endoscopic submucosal dissection of colorectal tumors., Endoscopy, Vol.45, No.11, 928-930, 2013. (要約) The M2-SB seems to be a safe and efficient tool for colorectal ESD. (出版サイトへのリンク) ● Publication site (DOI): 10.1055/s-0033-1344644 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24019129 ● Search Scopus @ Elsevier (PMID): 24019129 ● Search Scopus @ Elsevier (DOI): 10.1055/s-0033-1344644 (DOI: 10.1055/s-0033-1344644, PubMed: 24019129)
41.	Takahiro Tanaka, Tatsuya Taniguchi, Katsutaka Sannomiya, Hidetaka Takenaka, Tetsu Tomonari, Koichi Okamoto, Shinji Kitamura, Toshiya Okahisa, Katsuyoshi Tamaki, Hiroaki Mikasa, Sadao Suzuki and Tetsuji Takayama : Novel des-γ-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma., Journal of Gastroenterology and Hepatology, Vol.28, No.8, 1348-1355, 2013. (要約) The DCP/NX-DCP ratio is very useful for diagnosing HCC. DCP in HCC patients is distinct from that in vitamin K-deficient patients. (徳島大学機関リポジトリ) ● Metadata: 106139 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/jgh.12166 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23432345 ● Search Scopus @ Elsevier (PMID): 23432345 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12166 (徳島大学機関リポジトリ: 106139, DOI: 10.1111/jgh.12166, PubMed: 23432345)
42.	Takahiro Emoto, Koichi Shono, Udantha R. Abeyratne, Toshiya Okahisa, Hiromi Yano, Masatake Akutagawa, Shinsuke Konaka and Yohsuke Kinouchi : ARMA based spectral bandwidth for evaluation of bowel motility by the analysis of bowel sounds, Physiological Measurement, Vol.34, No.8, 925-936, 2013. (要約) ARMAスペクトルピークの3dB帯域幅を用いて自動的に腸蠕動音を検出する方法を提案する．提案法の性能評価の結果，提案法は感度:87.8±5.88%，特異度:91.7±4.33%およびAUC:0.923の高精度な自動抽出が行える事が分かった．被験者16人に対して薬剤負荷試験を行い，腸蠕動促進剤摂取前後における腸運動性を腸蠕動音の発生頻度をもとに評価できることが分かった． (出版サイトへのリンク) ● Publication site (DOI): 10.1088/0967-3334/34/8/925 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23893043 ● Search Scopus @ Elsevier (PMID): 23893043 ● Search Scopus @ Elsevier (DOI): 10.1088/0967-3334/34/8/925 (DOI: 10.1088/0967-3334/34/8/925, PubMed: 23893043)
43.	Shinji Kitamura, Mitsugi Yasuda, Naoki Muguruma, Koichi Okamoto, Hisashi Takeuchi, Yoshimi Bando, Hiroshi Miyamoto, Toshiya Okahisa, Mitsuyasu Yano, Ryusuke Torisu and Tetsuji Takayama : Prevalence and characteristics of nodular gastritis in Japanese elderly., Journal of Gastroenterology and Hepatology, Vol.28, No.7, 1154-1160, 2013. (要約) NG was found in 62 cases (0.94%) out of 6623 patients who underwent endoscopy, with a mean age of 47.3 ± 13.3 years. Female patients were present at a significantly higher rate in the elderly group (P < 0.001). The grade of neutrophil infiltration in the greater curvature of the upper gastric body was recognized at a significantly higher rate in the elderly group (P < 0.05). PG II was present at a higher rate and PG I/II at a lower rate in the elderly group (P < 0.05). The odds ratio for the risk of gastric cancer in patients with NG was 2.1 (95% confidence interval 0.3-15.3) in the elderly group. (キーワード) Age Factors / Aged / Aged, 80 and over / Asian Continental Ancestry Group / Gastritis / Gastroscopy / Humans / Japan / Prevalence / Risk Factors / Stomach Neoplasms (出版サイトへのリンク) ● Publication site (DOI): 10.1111/jgh.12180 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23432631 ● Search Scopus @ Elsevier (PMID): 23432631 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12180 (DOI: 10.1111/jgh.12180, PubMed: 23432631)
44.	Tetsuo Kimura, Naoki Muguruma, Takahiro Goji, Koichi Okamoto, Shinji Kitamura, Hiromi Yano, Hiroshi Miyamoto, Toshiya Okahisa, Naomi Sakashita and Tetsuji Takayama : Pedunculated duodenal carcinoid successfully removed by endoscopic resection with endoloop., Journal of Digestive Diseases, Vol.14, No.7, 402-404, 2013. (出版サイトへのリンク) ● Publication site (DOI): 10.1111/1751-2980.12033 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23302224 ● Summary page in Scopus @ Elsevier: 2-s2.0-84878388921 (DOI: 10.1111/1751-2980.12033, PubMed: 23302224, Elsevier: Scopus)
45.	Koichi Okamoto, Naoki Muguruma, Shinji Kitamura, Y Fujino, Takahiro Goji, Hiromi Yano, Tetsuo Kimura, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : A new large-diameter overtube for endoscopic submucosal dissection in the colon., Endoscopy, Vol.44, No.Suppl 2 UCTN, E395-6, 2012. (キーワード) Aged / Aged, 80 and over / Colonic Diseases / Colonoscopy / Equipment Design / Female / Humans / Intestinal Mucosa / Male / Middle Aged (出版サイトへのリンク) ● Publication site (DOI): 10.1055/s-0032-1310249 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23139039 ● Search Scopus @ Elsevier (PMID): 23139039 ● Search Scopus @ Elsevier (DOI): 10.1055/s-0032-1310249 (DOI: 10.1055/s-0032-1310249, PubMed: 23139039)
46.	Koichi Okamoto, Seisuke Okamura, Naoki Muguruma, Shinji Kitamura, Tetsuo Kimura, Yoshitaka Imoto, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : Endoscopic submucosal dissection for early gastric cancer using a cross-counter technique., Surgical Endoscopy, Vol.26, No.12, 3676-3681, 2012. (要約) Endoscopic submucosal dissection (ESD) in early gastric cancer has rapidly come into widespread use. However, since complications such as bleeding and perforation often occur, and the procedure time is longer for ESD than endoscopic mucosal resection (EMR), development of safer and more reliable technique is required. The subjects comprised 45 patients with lesions diagnosed histologically as early gastric cancer. They were divided into three groups: cross-counter technique group (CC, n = 15), peroral traction-assisted ESD with suture material group (PT, n = 15), and no-traction group (NT, n = 15). ESD was carried out by two endoscopists who had experienced fewer than 30 cases of ESD. To compare safety and efficacy of a new traction method (CC group) for ESD in early gastric cancer with other methods (PT group and NT group), procedure time, dissected area per unit time, complete resection rate, perforation rate, and bleeding rate were evaluated. There was no significant difference among these three groups in terms of complications, complete resection rate or procedure time. The dissection area per unit time was 22.4, 15.7, and 13.5 mm(2)/min in the CC, PT, and NT groups, respectively, and there was a significant difference between the CC and NT groups (p = 0.007). The cross-counter technique shortened the treatment time for endoscopists without abundant experience in gastric ESD, and it is considered a useful method to institute in order to introduce ESD. (キーワード) Aged / Aged, 80 and over / Early Medical Intervention / Equipment Design / Female / Gastric Mucosa / Gastroscopes / Gastroscopy / Humans / Male / Middle Aged / Stomach Neoplasms (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00464-012-2364-7 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22692462 ● Search Scopus @ Elsevier (PMID): 22692462 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-012-2364-7 (DOI: 10.1007/s00464-012-2364-7, PubMed: 22692462)
47.	Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Masako Kimura, Shinji Kitamura, Hidetaka Takenaka, Naoki Muguruma, Toshiya Okahisa, Eriko Aoyagi, Mayumi Kajimoto, Yasushi Tsuji, Takahiro Kogawa, Akihito Tsuji and Tetsuji Takayama : Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy., Oncology, Vol.82, No.5, 298-304, 2012. (要約) We compared high-sensitivity KRAS mutation testing with direct sequencing for predicting the efficacy of antiepidermal growth factor receptor antibodies in patients with metastatic colorectal cancer (mCRC). We analyzed the KRAS status in 61 tumors from cetuximab-treated mCRC patients by both direct sequencing and a high-sensitivity method: 2-step PCR restriction fragmentation length polymorphism (RFLP). Therapeutic effects in each mutational status were evaluated. The incidences of KRAS mutations determined by direct sequencing and 2-step PCR RFLP were 34.4 and 52.5%, respectively (p = 0.02). Patients were categorized into 3 groups [W/W, wild-type by both methods (n = 29); W/M, wild-type by direct sequencing, detected mutation by 2-step PCR RFLP (n = 11); M/M, mutant-type by both methods (n = 21)]. The response rate for cetuximab in the W/M group (0%) was the same as that in the M/M group, and was significantly lower than in the W/W group (41.4%) (p < 0.001). Progression-free survival in the W/M group (11.0 weeks) was similar to that in the M/M group (8.0 weeks), and was significantly shorter than in the W/W group (18.0 weeks) (p < 0.002). High-sensitivity KRAS mutation testing is useful for selecting true responders to cetuximab. (キーワード) Adult / Aged / Aged, 80 and over / Antibodies, Monoclonal / Antineoplastic Agents / Colorectal Neoplasms / Female / Humans / Male / Middle Aged / Mutation / Proto-Oncogene Proteins / Receptor, Epidermal Growth Factor / Retrospective Studies / ras Proteins (出版サイトへのリンク) ● Publication site (DOI): 10.1159/000336792 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22555244 ● Search Scopus @ Elsevier (PMID): 22555244 ● Search Scopus @ Elsevier (DOI): 10.1159/000336792 (DOI: 10.1159/000336792, PubMed: 22555244)
48.	Takeuchi Hisashi, Tetsuo Kimura, Koichi Okamoto, Aoyagi Eriko, Hiroshi Miyamoto, Masako Kaji, Hidetaka Takenaka, Seisuke Okamura, Yasushi Sato, Kato Junji, Toshiya Okahisa and Tetsuji Takayama : A mechanism for abnormal angiogenesis in human radiation proctitis: analysis of expression profile for angiogenic factors, Journal of Gastroenterology, Vol.47, No.1, 56-64, 2012. (要約) Radiation proctitis is an increasingly prevalent problem, with many patients being treated with radiotherapy for pelvic cancers. However, the mechanisms by which radiation proctitis develops in humans are not well understood. In this study, the expression profiles of angiogenic factors were analyzed to clarify their role in the etiology of radiation proctitis. Rectal biopsies were taken from 8 patients with radiation proctitis and 8 normal subjects. Protein lysates of the tissues were applied to an antibody array for angiogenesis-related factors. The mRNA level of each factor was evaluated by Taqman real-time PCR. Immunohistochemistry was performed using the labeled streptavidin biotin method. Antibody array analysis revealed 2.12- to 7.31-fold higher expression levels of angiogenin, fibroblast growth factor 1 (FGF1), endoglin, matrix metalloproteinase (MMP)-8, urokinase-type plasminogen activator (uPA) and maspin in radiation proctitis tissues compared with normal rectal mucosa. The mRNA level of each factor in radiation proctitis tissue was significantly higher than in normal rectal mucosa, suggesting their transcriptional activation. Immunohistochemical staining showed strong expression of angiogenin and maspin in rectal epithelia, MMP-8 and uPA in infiltrating lymphocytes, FGF1 in fibroblasts and endoglin in endothelial cells. The expression of VEGF was not evident. Our results suggest that in radiation proctitis, MMP-8 and uPA cooperatively degrade the extracellular matrix and basement membrane to provide space for angiogenesis. Simultaneously, angiogenin and FGF1 promote endothelial cell proliferation, and endoglin induces vessel formation, culminating in angiogenesis. Inhibitors of angiogenic factors such as angiogenin and FGF1 may be effective for treating radiation proctitis. (キーワード) Aged / Case-Control Studies / Extracellular Matrix / Female / Fibroblast Growth Factor 1 / Gene Expression Regulation / Humans / Male / Matrix Metalloproteinase 8 / Middle Aged / Neovascularization, Pathologic / Pelvic Neoplasms / Polymerase Chain Reaction / Proctitis / RNA, Messenger / Radiation Injuries / Ribonuclease, Pancreatic / Urokinase-Type Plasminogen Activator (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00535-011-0470-2 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22081051 ● CiNii @ 国立情報学研究所 (CRID): 1573387450550673408 ● Search Scopus @ Elsevier (PMID): 22081051 ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-011-0470-2 (DOI: 10.1007/s00535-011-0470-2, PubMed: 22081051, CiNii: 1573387450550673408)
49.	Naoki Muguruma, Koichi Okamoto, Tetsuo Kimura, Kazuhiro Kishi, Toshiya Okahisa, Seisuke Okamura and Tetsuji Takayama : Endoscopic ablation therapy for gastrointestinal superficial neoplasia., Digestive Endoscopy, Vol.24, No.3, 139-149, 2011. (要約) In Japan, endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have been widely accepted and standardized for the treatment of gastrointestinal superficial neoplasia. In contrast, mucosal ablation techniques are more common in Western countries and a variety of endoscopic ablation modalities, including argon plasma coagulation (APC), photodynamic therapy (PDT) and lasers, are used. Recently developed modalities such as radiofrequency ablation (RFA) and cryotherapy are also available for the treatment of superficial lesions such as dysplasia of Barrett's esophagus. Although we should understand that the completeness of destruction of neoplastic tissue can only be judged at follow up, endoscopic ablation is a viable alternative to endoscopic resection for dysplasia and early-stage malignancies, especially for poor candidates of surgery or endoscopic resection. (キーワード) Adenoma / Argon Plasma Coagulation / Carcinoma, Squamous Cell / Catheter Ablation / Cryotherapy / Endoscopy, Gastrointestinal / Forecasting / Gastrointestinal Neoplasms / Humans / Japan / Laser Therapy / Photochemotherapy / Precancerous Conditions (出版サイトへのリンク) ● Publication site (DOI): 10.1111/j.1443-1661.2011.01227.x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22507086 ● Search Scopus @ Elsevier (PMID): 22507086 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1443-1661.2011.01227.x (DOI: 10.1111/j.1443-1661.2011.01227.x, PubMed: 22507086)
50.	Tetsuji Takayama, Kouzou Yoshikawa, Toshiya Okahisa, Masako Kaji, Nobuhiro Kurita, Masanori Nishioka, Toru Ikegami, Toshiaki Sano, J Inoi and Mitsuo Shimada : Idiopathic phlebosclerosis: an atypical presentation of ischemic colitis treated by laparoscopic colectomy., Surgery, Vol.145, No.6, 682-684, 2009. (キーワード) Aged / Colectomy / Colitis, Ischemic / Colon / Colonoscopy / Female / Humans / Intestinal Mucosa / Laparoscopy / Tomography, X-Ray Computed / Treatment Outcome (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.surg.2008.04.015 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19486773 ● Search Scopus @ Elsevier (PMID): 19486773 ● Search Scopus @ Elsevier (DOI): 10.1016/j.surg.2008.04.015 (DOI: 10.1016/j.surg.2008.04.015, PubMed: 19486773)
51.	Sogabe Masahiro, Kimura Yoshitaka, Iwaki Hiroshi, Okita Yoshio, Hibino Shingo, Sawda Seizo, Toshiya Okahisa, Okamoto Koichi, Tsujigami Koji, Hayashi Hiroshige, Hukui Yasuo, Nakamura Toshio, Taniki Toshikatsu, Nakasono Masahiko, Naoki Muguruma, Seisuke Okamura and Susumu Ito : Ultrasonographic comparison of gastric motility between diabetic gastroparesis patients with and without metabolic syndrome., Journal of Gastroenterology and Hepatology, Vol.23, No.7 Pt 2, e17-22, 2007. (要約) Diabetic patients with poor glycemic control or long standing disease often have impaired gastric motility. Recently, metabolic factors such as blood glucose have been reported as influencing gastric motility independently of autonomic neuropathy. Many diabetic patients have metabolic syndrome, which is strongly associated with coronary and other diseases. We investigated whether metabolic syndrome influences diabetic gastroparesis patients. We observed gastric motility ultrasonographically in diabetic gastroparesis patients including nine with and nine without metabolic syndrome. Both groups complained of upper abdominal symptoms when hospitalized to improve blood sugar control. All patients underwent upper gastrointestinal endoscopy to rule out gastric and duodenal lesions. All had autonomic neuropathy. Gastric motility was evaluated within 3 days after admission by transabdominal ultrasonography after a test meal. Gastric emptying was 45.0 +/- 13.7% in patients with and 39.1 +/- 11.9% in patients without metabolic syndrome, which was not statistically significant. Frequency of gastric contractions was 8.33 +/- 2.78 per 3 min in patients with metabolic syndrome and 7.44 +/- 2.13 per 3 min in the others, which was not statistically significant. The motility index, which involves antral contractility, was 3.21 +/- 2.18 in patients with metabolic syndrome and 2.80 +/- 1.87 in the others, which was not statistically significant. Metabolic syndrome did not appear to contribute to delayed gastric motility in diabetic gastroparesis. (キーワード) Adult / Aged / Diabetes Complications / Female / Gastric Emptying / Gastroparesis / Humans / Male / Metabolic Syndrome X / Middle Aged (出版サイトへのリンク) ● Publication site (DOI): 10.1111/j.1440-1746.2007.05055.x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17645473 ● Summary page in Scopus @ Elsevier: 2-s2.0-47649107714 (DOI: 10.1111/j.1440-1746.2007.05055.x, PubMed: 17645473, Elsevier: Scopus)
52.	Iwaki Hiroshi, Toshiya Okahisa, Murata Masahiro, Miyamoto Hiorshi, Yasuhiro Kuroda, Yoshiaki Ohnishi, Masaji Nishimura, Masatake Akutagawa, Yohsuke Kinouchi and Susumu Ito : Influence of Lipid Emulsion for the Hematocrit Value Measured With Continuous Hematocrit Monitor., ASAIO Journal, Vol.53, No.4, 474-478, 2007. (要約) Continuous monitoring of hematocrit with a CRIT-LINE monitor (CLM) is used to prevent excess ultrafiltration during hemodialysis and continuous renal replacement therapy. The presence of substances affecting the scattering and absorption rates of multiple wavelengths of near infrared rays of CLM in the blood may affect the measured values with CLM. We examined the influences of lipid emulsion (LE) on hematocrit and relative blood volume (RBV) which were measured with CLM using an in vitro experimental model with human blood. Additions of 10% or 20% of LE increased the hematocrit measured by LCM and decreased the percent change of RBV in proportion to the dose. One percentage of 20% LE in the plasma increased the expected hematocrit measured with CLM by 2.9%. The decrease of initial hematocrit from 48.1% to 43.4% decreased the expected percent change of RBV from -3.4% to -3.7% with the addition of 1 ml of 20% LE to 100 ml blood. These findings indicate that additions of LE increase hematocrit that is measured with CLM in proportion to the dose of LE. Low levels of initial hematocrit will increase the degree of expected percent change of RBV. Attention should be paid to the influence of LE during monitoring with CLM. (キーワード) Adult / Blood Volume / Dose-Response Relationship, Drug / Emulsions / Fat Emulsions, Intravenous / Hematocrit / Humans / Monitoring, Physiologic / Osmolar Concentration / Phospholipids / Soybean Oil (出版サイトへのリンク) ● Publication site (DOI): 10.1097/MAT.0b013e31805c998e (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17667234 ● Search Scopus @ Elsevier (PMID): 17667234 ● Search Scopus @ Elsevier (DOI): 10.1097/MAT.0b013e31805c998e (DOI: 10.1097/MAT.0b013e31805c998e, PubMed: 17667234)
53.	Masaharu Suzuki, Toshiya Okahisa, Masahiro Sogabe, Hiroshi Iwaki, Yoshio Okita, Yoshiaki Ohnishi and Susumu Ito : Kinetics of group IB and IIA phospholipase A2 during low-volume continuous hemodiafiltration in severe acute pancreatitis., Artificial Organs, Vol.31, No.5, 395-401, 2007. (要約) Continuous hemodiafiltration (CHDF) has been performed for the treatment of severe acute pancreatitis. Phospholipase A2 (PLA2) is one of the important mediators which exacerbate acute pancreatitis, but whether PLA2 can be removed by CHDF is unclear. In this study, the kinetics of group IB and group IIA PLA2 was examined at the first session of low-volume CHDF in eight patients with severe acute pancreatitis. CHDF was performed using polysulfone hemofilters (surface area: 0.7 m(2)) at a blood flow rate of 100 mL/min and a filtration and dialysate flow rate of 10 mL/min each. The plasma concentrations of group IB and IIA PLA2 before the start of CHDF were 47.4 +/- 52.0 microg/L and 352 +/- 390 microg/L, respectively, and did not change significantly. The clearances of group IB and IIA PLA2 achieved by the CHDF circuit 1 h after the start of CHDF were 20.7 +/- 11.6 mL/min and 16.7 +/- 4.4 mL/min, respectively, with both clearances decreasing significantly with time. The clearance of group IB PLA2 into the waste fluid tended to increase with time; however, the concentrations of group IIA PLA2 in the waste fluid were less than the measurable sensitivity. These results indicate that group IB PLA2 is adsorbed on the hemofilter membrane in preference to being removed into the waste fluid, while group IIA PLA2 is mainly removed by adsorption. However, low-volume CHDF is not effective at eliminating the group IB and IIA PLA2 plasma concentration. (キーワード) APACHE / Adsorption / Adult / Aged / Female / Group IB Phospholipases A2 / Group II Phospholipases A2 / Hemodiafiltration / Humans / Kinetics / Male / Middle Aged / Pancreatitis / Phospholipases A / Phospholipases A2 / Prospective Studies (出版サイトへのリンク) ● Publication site (DOI): 10.1111/j.1525-1594.2007.00398.x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17470210 ● Summary page in Scopus @ Elsevier: 2-s2.0-34247603631 (DOI: 10.1111/j.1525-1594.2007.00398.x, PubMed: 17470210, Elsevier: Scopus)
54.	Yoshio Okita, Toshiya Okahisa, Masahiro Sogabe, Masao Suzuki, Yoshiaki Ohnishi and Susumu Ito : Low-volume continuous hemodiafiltration with nafamostat mesilate increases trypsin clearance without decreasing plasma trypsin concentration in severe acute pancreatitis., ASAIO Journal, Vol.53, No.2, 207-212, 2007. (要約) Continuous hemodiafiltration (CHDF) has recently been used for treatment of severe acute pancreatitis. CHDF is capable of eliminating small molecules from blood, but whether trypsin can be eliminated by CHDF is not clear. In this study, elimination of trypsin-like enzyme activity (TLE) and cationic trypsin-like immunoreactivity (TLI) using low-volume CHDF was examined at the first CHDF session in eight patients with severe acute pancreatitis. CHDF was performed with a polysulfone hemofilter (membrane area, 0.7 m2) and nafamostat mesilate, a protease inhibitor and anticoagulant, at a blood flow rate of 100 ml/min and a filtration and dialysis flow rate of 10 ml/min each. Before beginning CHDF, plasma TLE was 3.41 +/- 2.86 nmol/(ml.min), and TLI was 5,900 +/- 9,008 ng/ml. The average plasma clearances of TLE and TLI achieved by the circuit during the 12-hour therapy were 56.7 +/- 4.9 ml/min and 8.0 +/- 7.2 ml/min, respectively. The average plasma clearance of TLI into the waste fluid was 2.4 +/- 1.6 ml/min whereas TLE was below the measurable sensitivity. The plasma concentration of TLE and TLI remained unchanged. These results indicate that low-volume CHDF using nafamostat mesilate as an anticoagulant can increase trypsin plasma clearance. However, low-volume CHDF is not effective to eliminate the plasma trypsin concentration. (キーワード) APACHE / Acute Disease / Adult / Aged / Anticoagulants / Female / Guanidines / Hemodiafiltration / Humans / Kinetics / Male / Middle Aged / Pancreatitis / Retrospective Studies / Trypsin (出版サイトへのリンク) ● Publication site (DOI): 10.1097/MAT.0b013e3180310473 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17413562 ● Search Scopus @ Elsevier (PMID): 17413562 ● Search Scopus @ Elsevier (DOI): 10.1097/MAT.0b013e3180310473 (DOI: 10.1097/MAT.0b013e3180310473, PubMed: 17413562)
55.	Hiroshi Miyamoto, Toshiya Okahisa, Hiroshi Iwaki, Masahiro Murata, Susumu Ito, Yoshinori Nitta, Masatake Akutagawa, Yohsuke Kinouchi, Yoshiaki Ohnishi, Jun Oto and Masaji Nishimura : Influence of leukocytapheresis therapy for ulcerative colitis on anemia and hemodynamics., Therapeutic Apheresis and Dialysis, Vol.11, No.1, 16-21, 2007. (要約) In Japan, leukocytapheresis (LCAP) therapy has been carried out for ulcerative colitis as an effective therapy with a low incidence of side-effects. In the present study, we serially investigated the influence of LCAP therapy on anemia and hemodynamics in patients with ulcerative colitis using a non-invasive method with a Crit-Line monitor (CLM) (Hema Metrics Inc., Salt Lake City, UT and Boston, MA, USA). We carried out LCAP on 10 patients with ulcerative colitis using a CS-100 Cellsorba EX LCAP filter in 34 courses of LCAP. The mean hematocrit value, which was measured using the Crit-Line monitor, was 21.8 +/- 0.2% (21.0-22.4%), which showed no significant changes after each LCAP therapy. The actual erythrocyte count, hemoglobin and hematocrit values decreased by 244 000/mm3, 0.7 g/dL and 2.1%, respectively, however, the differences were insignificant. These values corresponded to 7.8, 8.0 and 7.6% of the values before LCAP, respectively. There were no significant changes in systolic blood pressure, diastolic blood pressure, or heart rate during LCAP. The results of this study suggest that one course of LCAP does not exacerbate anemia, and it does not influence hemodynamics. However, considering the exacerbation of anemia in patients with severe ulcerative colitis caused by massive melena, monitoring with a less invasive Crit-Line monitor and a vital information monitor might be useful. (キーワード) Adult / Aged / Anemia / Colitis, Ulcerative / Erythrocyte Count / Female / Hematocrit / Humans / Leukapheresis / Male / Melena / Middle Aged (出版サイトへのリンク) ● Publication site (DOI): 10.1111/j.1744-9987.2007.00451.x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17309570 ● Search Scopus @ Elsevier (PMID): 17309570 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1744-9987.2007.00451.x (DOI: 10.1111/j.1744-9987.2007.00451.x, PubMed: 17309570)
56.	Tadashi Motomura, Hisashi Okubo, Takeshi Oda, Daisuke Ogawa, Toshiya Okahisa, Stephan Igo, Toshiyuki Shinohara, Yoshiro Yamamoto, Chikaya Noguchi, Tsukasa Ishizuka, Eiji Okamoto and Yukihiko Nose' : Ten-year NEDO BVAD development program: moving forward to the clinical arena., ASAIO Journal, Vol.52, No.4, 378-385, 2006. (要約) Since 1995, the Baylor Group has been developing a totally implantable NEDO BVAD system. This 10-year program was completed in March 2005, and preparation for clinical trials is underway. This article summarizes the entire 10-year NEDO program and describes the strategy for clinical trials. The project aimed to achieve: (1) dual centrifugal pumps with the ability of full biventricular support, (2) a compact system implantable into small adults, (3) a totally implantable system with transcutaneous energy transmission system (TETS), (4) a durable system with a lifetime of over 5 years, and (5) a system free of thrombus and with minimal hemolysis. The final goals are to complete preclinical system evaluations and commence the clinical trials in the near future. In vitro studies have demonstrated a pump capacity of over 8.5 l/min and an Index of Hemolysis of <0.004 g/100 l. The pump-bearing life expectancy was over 5 years. To date, eight pumps endured in vivo studies of over 3 months without complications, including thromboembolic events. The in vitro endurance studies of eight pumps are longer than 1 year. There were no mechanical malfunctions or pump failure. A stepwise clinical trial is being planned: Step1, a wearable BVAD/VAD will be clinically studied; Step 2, the BVAD/VAD will be implanted intracorporeally without TETS; and, Step 3, a totally implantable system will be clinically evaluated. The NEDO BVAD system has completed preclinical testing. Clinical trial preparation is underway. (キーワード) Animals / Assisted Circulation / Biocompatible Materials / Biomedical Engineering / Cattle / Centrifugation / Equipment Design / Evaluation Studies as Topic / Heart, Artificial / Heart-Assist Devices / Hemolysis / Humans / Materials Testing / Miniaturization / Models, Cardiovascular / Prosthesis Design / Prosthesis Implantation / Surface Properties / Titanium (出版サイトへのリンク) ● Publication site (DOI): 10.1097/01.mat.0000225263.48393.93 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16883116 ● Search Scopus @ Elsevier (PMID): 16883116 ● Search Scopus @ Elsevier (DOI): 10.1097/01.mat.0000225263.48393.93 (DOI: 10.1097/01.mat.0000225263.48393.93, PubMed: 16883116)
57.	Daisuke Ogawa, Makoto Yoshizawa, Akira Tanaka, Ken-ichi Abe, Paul Olegario, Tadashi Motomura, Hisashi Okubo, Takeshi Oda, Toshiya Okahisa, SR Igo and Kenya Kusunose : Indirect flow rate estimation of the NEDO PI Gyro pump for chronic BVAD experiments., ASAIO Journal, Vol.52, No.3, 266-271, 2006. (要約) In totally implantable ventricular assist device systems, measuring flow rate of the pump is necessary to ensure proper operation of the pump in response to the recipient's condition or pump malfunction. To avoid problems associated with the use of flow probes, several methods for estimating flow rate of a rotary blood pump used as a ventricular assist device have been studied. In the present study, we have performed a chronic animal experiment with two NEDO PI gyro pumps as the biventricular assist device for 63 days to evaluate our estimation method by comparing the estimated flow rate with the measured one every 2 days. Up to 15 days after identification of the parameters, our estimations were accurate. Errors increased during postoperation days 20 to 30. Meanwhile, their correlation coefficient r was higher than 0.9 in all the acquired data, and estimated flow rate could simulate the profile of the measured one. (キーワード) Animals / Cattle / Centrifugation / Equipment Design / Evaluation Studies as Topic / Heart, Artificial / Heart-Assist Devices / Implants, Experimental / Infusion Pumps / Miniaturization / Models, Animal / Pulsatile Flow / Regional Blood Flow / Research Design (出版サイトへのリンク) ● Publication site (DOI): 10.1097/01.mat.0000219066.21197.34 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16760714 ● Search Scopus @ Elsevier (PMID): 16760714 ● Search Scopus @ Elsevier (DOI): 10.1097/01.mat.0000219066.21197.34 (DOI: 10.1097/01.mat.0000219066.21197.34, PubMed: 16760714)
58.	Toshiya Okahisa, Hisashi Okubo, Erlend Hansen, Takeshi Oda, Tadashi Motomura, Julie Glueck, Hiorshi Miyamoto, Susumu Ito, Yoshiaki Ohnishi, Masahiro Tamura, Katsuyuki Yoshikawa and Yukihiko Nose' : Development of a clipped single-bag with bicarbonate replacement fluid to ensure proper mixing., ASAIO Journal, Vol.52, No.3, 343-348, 2006. (要約) A clipped single-bag for bicarbonate replacement fluid was developed to ensure proper mixing before administering to the patient. Nonmixture can cause imbalances of electrolytes and pH, which is a key problem for the current double-bag type bicarbonate replacement fluid sets. To resolve this problem, this single bag properly mixes the solutions before use. The new bag consists of a clip that is placed in the middle to keep the two solutions separated and sealed. When the caregiver is ready to administer treatment, the bag is simply unfolded and the clip automatically detaches, releasing the fluids. Thereby, the bicarbonate fluids are effectively mixed. An optimal clip size with an outer diameter of 16 mm and thickness of 2 mm was determined using compression tests and drop tests. This bag may be a safer and more effective way to provide proper replacement fluid supply for both hemofiltration and hemodiafiltration. (キーワード) Bicarbonates / Buffers / Equipment Design / Hemodialysis Solutions / Humans / Solutions (出版サイトへのリンク) ● Publication site (DOI): 10.1097/01.mat.0000214854.79451.40 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16760726 ● Search Scopus @ Elsevier (PMID): 16760726 ● Search Scopus @ Elsevier (DOI): 10.1097/01.mat.0000214854.79451.40 (DOI: 10.1097/01.mat.0000214854.79451.40, PubMed: 16760726)
59.	Yoshio Okita, Toshiya Okahisa, Masahiro Sogabe, Masaharu Suzuki, Yoshiaki Ohnishi and Susumu Ito : Low Volume Continuous Hemodiafiltration with Nafamostat Mesilate Increases Trypsin, ASAIO Journal, 1-8, 2006.
60.	Masahiko Nakasono, Mitsuyoshi Hirokawa, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura, Susumu Ito, Hiroshi Miyamoto, Satoshi Wada, Tamotsu Fukuda and Toshiaki Sano : Colorectal xanthomas with polypoid lesion:report of 25 cases., APMIS, Vol.112, No.1, 3-10, 2004. (要約) Little attention has been paid to colorectal xanthoma. To clarify the clinical and pathological features of colorectal xanthoma, we report 28 colorectal xanthomas biopsied from 25 patients. All were composed of typical xanthoma cells and showed polypoid configuration. Median age of the patients was 64 years and there were 15 men and 10 women. Diabetes mellitus, constipation, and hyperlipidemia were found in two, one, and seven patients, respectively. Seventeen (60.7%) of the 28 polyps were located in the sigmoid colon and the remaining 11 in the rectum. Twenty-three polyps (82.1%) were sessile. Twelve (60.0%) of twenty polyps that were recorded were reddish in color. Only two polyps revealed a yellowish tone. Microscopically, foamy cells were present in the lamina propria, but the submucosa did not contain foamy cells. Immunohistochemically, the foamy cells invariably expressed extensive positivity for CD68. The colonic glands showed a deformity in the case with moderate to intense density of the foamy cells. The surface epithelium showed a hyperplastic change in 22 (78.6%) xanthomas. The colonic glands in four xanthomas were also associated with hyperplastic changes. The basement membrane of the surface epithelium was often thickened. Cell debris and proliferation of the capillaries were observed just below the surface epithelium in 19 (67.9%) and 22 (78.6%) xanthomas, respectively. Previous mucosal minute injury was suggested as the pathogenesis of colorectal xanthomas. Colorectal xanthomas were not identical to gastric and esophageal xanthoma, endoscopically or microscopically. We prefer the term "xanthomatous polyp" rather than xanthoma in the colorectal region. They may be regarded as a novel type of colorectal non-neoplastic polyp. (キーワード) Adult / Aged / Aged, 80 and over / Biopsy / Colonic Diseases / Female / Humans / Immunohistochemistry / Male / Middle Aged / Rectal Diseases / Retrospective Studies / Xanthomatosis (出版サイトへのリンク) ● Publication site (DOI): 10.1111/j.1600-0463.2004.apm1120102.x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14961968 ● Search Scopus @ Elsevier (PMID): 14961968 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1600-0463.2004.apm1120102.x (DOI: 10.1111/j.1600-0463.2004.apm1120102.x, PubMed: 14961968)
61.	岡久稔也, 宮本弘志, 居和城宏, 伊東進, 大西芳明, 黒田泰弘, 芥川正武, 新田佳伯, 木内陽介 : 高速フーリエ解析を用いた圧波形解析によるフィルタの目詰まり評価, ICUとCCU, Vol.28, No.suppl-1, S128-S130, 2004年. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1521980704997023232 (CiNii: 1521980704997023232)
62.	Hiroko Matsunaga, Hirohito Honda, Kenichiro Kubo, Katsutaka Sannomiya, Xuezhi Cui, Yoshio Toyota, Toshifumi Mori, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura, Ichiro Shimizu and Susumu Ito : Clinical value of the determination of serum guanase activity in patients with chronic hepatitis type C, The Journal of Medical Investigation : JMI, Vol.50, No.1-2, 64-71, 2003. (要約) The study examines the clinical significance of guanase (GU) measurement in patients with hepatitis C. 688 patients in whom either ALT was abnormal, or in whom HBsAg or HCVAb was detected in the serum, were enrolled into this study. The percentage of cases in which normal ALT while elevated GU was compared among the different disease groups. Then, the percentage of cases with normal ALT but elevated GU was compared between HBV and HCV groups. For the entire population, a significant correlation was observed between ALT and GU (r=0.872). The overall percentage of cases with normal ALT but elevated GU activity was 11.4%. In HCV group, 449 cases had normal ALT. Of these cases, 20.3% had elevated GU, while ALT was normal. Before 1989, no test to check donated blood for HCV antibody was available. However, screening of donated blood for high GU was associated with a reduced incidence of post-transfusion hepatitis. This is probably because following the screening, blood donated by patients with hepatitis C who had normal ALT but elevated GU was rejected. After the introduction of HCV antibody measurement, GU measurement is still useful to reveal the pathophysiological condition in-patients with chronic hepatitis type C. (キーワード) Alanine Transaminase / Biological Markers / Blood Donors / Comorbidity / Guanine Deaminase / Hepatitis B Surface Antigens / Hepatitis B, Chronic / Hepatitis C Antibodies / Hepatitis C, Chronic / Humans / Incidence / Japan / Mass Screening / Prospective Studies / Sensitivity and Specificity (徳島大学機関リポジトリ) ● Metadata: 110679 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12630570 ● CiNii @ 国立情報学研究所 (CRID): 1050865122807436032 ● Summary page in Scopus @ Elsevier: 2-s2.0-0037762732 (徳島大学機関リポジトリ: 110679, PubMed: 12630570, CiNii: 1050865122807436032, Elsevier: Scopus)
63.	野山晏志, 野村昌弘, 伊賀彰子, 上村英子, 友兼優子, 蔭山徳人, 山下潤司, 近藤憲保, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 西角彰良, 矢野充保, 清水一郎, 伊東進 : 消化器内視鏡下総胆管処置中における自律神経活動と心電図変化, 消化管の臨床, Vol.9, 57-62, 2003年.
64.	清水一郎, 野村昌弘, 青木利佳, 福野天, 居和城宏, 筒井朱美, 六車直樹, 岡久稔也, 岡村誠介, 本田浩仁, 伊東進 : 高齢者消化管癌検診時の循環動態モニタリングの重要性, 消化器科, Vol.37, 103-108, 2003年.
65.	S Ichikawa, Seisuke Okamura, K Tujigami, Y Kusaka, M Tadatsu, Y Okita, A Tsutsui, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Ichiro Shimizu, Susumu Ito and K Umino : Quantitative Analysis of Red Color Sign in the Endoscopic Evaluation of Esophageal Varices, Endoscopy, Vol.33, No.9, 747-753, 2001. (要約) Bleeding due to esophageal variceal rupture is associated with an extremely high mortality rate. Variceal bleeding is frequent in patients who have a red color sign on endoscopy. However, the red color sign is subjectively evaluated on the basis of color tone and the shape of the varices. To allow standardization and facilitate consensus, an objective method of assessing the red color sign is needed. In this study, a system was established for quantifying the red color sign during endoscopic evaluation. Between July 1995 and February 1997, 55 untreated patients with portal hypertension and esophageal varices identified on upper gastrointestinal endoscopy were enrolled in the study. Images obtained about 5 cm oral to the esophagogastric junction during endoscopy were stored on magnetic optical disks using an endoscopic image processor. The still images were transmitted to a computer and analyzed using computer software. The RGB components (R, red; G, green; B, blue) were measured at points showing flare consistent with the red color sign. The endoscopic assessment was based on the Japanese Research Society for Portal Hypertension's general rules for recording endoscopic findings in esophagogastric varices. The ratio of the red color area to the variceal area increased with increasing red color grade. There were significant positive correlations between the R and G, and G and B components. This suggests that comparing the R components alone would allow assessment of the color differences in the red color area and in the varices. The R value was significantly higher in the red color area (115 +/- 20) than in the varices (57 +/- 19). An R value of 90 was found at the boundary between the two parts (P < 0.001). The red color area can be automatically calculated and quantified using the analysis program. Improvements in data storage methods may allow real-time evaluation during endoscopy in the future. (キーワード) Aged / Color / Endoscopy, Digestive System / Esophageal and Gastric Varices / Female / Follow-Up Studies / Gastrointestinal Hemorrhage / Humans / Hypertension, Portal / Japan / Liver Cirrhosis / Male / Middle Aged (出版サイトへのリンク) ● Publication site (DOI): 10.1055/s-2001-16514 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11558027 ● Search Scopus @ Elsevier (PMID): 11558027 ● Search Scopus @ Elsevier (DOI): 10.1055/s-2001-16514 (DOI: 10.1055/s-2001-16514, PubMed: 11558027)
66.	Hitoshi Miyajima, Masahiro Nomura, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu, Masafumi Harada, Ken Saito, Yutaka Nakaya and Susumu Ito : Relationship among gastric motility,autonomic activity,and portal hemodynamics in patients with liver cirrhosis, Journal of Gastroenterology and Hepatology, Vol.16, No.6, 647-659, 2001. (要約) We examined the effects of the autonomic nervous function and the volume of portal blood flow to clarify the mechanism of the abnormal gastric motility in patients with liver cirrhosis. Heart rate variability, electrogastrogram (EGG), and volume of portal blood flow were measured before and after a meal in 27 patients with liver cirrhosis (LC group) and in 20 normal subjects (N group). Autonomic nervous function was evaluated by using spectral analysis of heart rate variability. We used the cine phase-contrast (PC) method, using magnetic resonance imaging (MRI) to measure the portal flow, while the peak frequency and spectral power of the EGG were measured at pre- and postprandial change. The ratio of low frequency power to high frequency power (LF/HF) was significantly higher, and the HF power was significantly lower in the LC group than in the N group both before and after a meal. In both groups, the electrogastrographic peak power ratio before and after a meal showed a positive correlation with the HF ratio, and an inverse correlation with the LF/HF ratio. In addition, portal blood flow volume was significantly decreased in the LC group than in the N group. However, the increased rate of portal blood flow after a meal correlated positively with the increased rate of electrogastrographic peak power. Moreover, gastric motility was positively correlated with esophageal varices and coma scale with the use of multivariate analysis. Parasympathetic hypofunction, sympathetic hyperfunction and portal hemodynamics were closely related with gastric motility in cirrhotic patients. In addition, gastric motility was decreased, at least in part, by the ingestion of food in cirrhotic patients because of abnormalities in autonomic functions and portal blood flow following a meal. (キーワード) Aged / Autonomic Nervous System / Electrophysiology / Female / Gastrointestinal Motility / Heart Rate / Hemodynamics / Humans / Liver Cirrhosis / Magnetic Resonance Imaging / Male / Middle Aged / Portal System (出版サイトへのリンク) ● Publication site (DOI): 10.1046/j.1440-1746.2001.02493.x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11422618 ● Summary page in Scopus @ Elsevier: 2-s2.0-0035722279 (DOI: 10.1046/j.1440-1746.2001.02493.x, PubMed: 11422618, Elsevier: Scopus)
67.	佐野壽昭, 岡久稔也, 清川誠治, 片岡孝一, 若槻真吾, 鈴木雅晴, 安友康二, 漆原真樹, 伊東進, 高橋正倫 : 潰瘍性大腸炎に併発した小児胃癌の1例, 胃と腸, Vol.36, No.4, 580-584, 2001年.
68.	柴田啓志, 筒井朱美, 四宮寛彦, 稲山久美, 中園雅彦, 六車直樹, 岡久稔也, 岡村誠介, 清水一郎, 伊東進 : 肝細胞に対する経皮的ラジオ波熱焼灼療法(RFA)の検討, 臨床と研究, Vol.78, No.7, 93-98, 2001年.
69.	Masahiro Nomura, Michiko Yukinaka, Hitoshi Miyajima, Tomomi Nada, Yuki Kondo, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu, Ken Saito, T. Oki, Yutaka Nakaya and Susumu Ito : Is autonomic dysfunction a necessary condition for chronic peptic ulcer formation ?, Alimentary Pharmacology & Therapeutics, Vol.14suppl, No.1, 82-86, 2000. (要約) The relationship between 1/f fluctuation of the heart rate variability and Helicobacter pylori infection was evaluated, in order to clarify whether autonomic nervous dysfunction is a necessary condition for chronic peptic ulcer formation. The subjects were 11 patients with recurrent chronic peptic ulcer and 20 age-matched normal subjects. Holter ECGs were recorded over 24 h, and the 1/f(-x) fluctuation of the heart rate was computed. The 1/f(-x) fluctuation of the heart rate is a novel index of autonomic function that has been shown to reflect a patient's pleasant mood. For 1/f(-x) fluctuation, the slope of the regression line (-x) was determined and cosine fitting of the absolute slope of the regression line over a 24-h period was performed. For the normal group, the absolute slope of the regression line during daytime and night-time were 0.53 +/- 0.16 and 1.05 +/- 0.18, respectively. For the peptic ulcer group, the corresponding values during daytime and night-time were 0.94 +/- 0.15 and 1.84 +/- 0.18, respectively. The mean value of the cosine curve was 0.76 +/- 0.23 in the normal group and 1.12 +/- 0.25 in the peptic ulcer group. Thus, these values were significantly higher for the latter group than for the former group (P<0.05). No statistically significant difference in H. pylori infection between the two groups was observed. Autonomic nervous dysfunction as well as H. pylori infection appears to be a necessary condition for chronic peptic ulcer formation. (キーワード) Aged / Autonomic Nervous System Diseases / Chronic Disease / Electrocardiography / Female / Heart Rate / Helicobacter Infections / Helicobacter pylori / Humans / Male / Middle Aged / Peptic Ulcer (出版サイトへのリンク) ● Publication site (DOI): 10.1046/j.1365-2036.2000.014s1082.x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10807408 ● Summary page in Scopus @ Elsevier: 2-s2.0-0034127977 (DOI: 10.1046/j.1365-2036.2000.014s1082.x, PubMed: 10807408, Elsevier: Scopus)
70.	野村昌弘, 宮島等, 名田智美, 森下智文, 木下桂午, 多田由恵, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進, 中屋豊 : 老年者における上部消化管内視鏡検査中の自律神経活動およびQTc dispersionの変動, 老年消化器病, Vol.12, No.3, 259-264, 2000年.
71.	野村昌弘, 川口律子, 由岐中道子, 近藤幸, 宮島等, 名田智美, 多田由恵, 齋藤憲, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進, 中屋豊 : 高齢者における食後低血圧の成因, --- 自律神経活動および胃運動との関連性について ---, 日本高齢者消化器医学会議会誌, Vol.1, No.2, 36-41, 1999年.
72.	Naoki Muguruma, Seisuke Okamura, Toshiya Okahisa, Hiroshi Shibata, Susumu Ito and Keiko Yagi : Endoscopic sonography in the diagnosis of xanthogranulomatous cholecystitis, Journal of Clinical Ultrasound, Vol.27, No.6, 347-350, 1999. (要約) Xanthogranulomatous cholecystitis (XGC) is an unusual inflammatory disease of the gallbladder that may simulate gallbladder cancer. We report the findings with conventional sonography, endoscopic sonography (EUS), and CT in 3 cases of XGC. EUS could visualize hyperechoic nodules in the gallbladder wall, probably representing xanthogranulomas, but loss of the multilayered structure of the gallbladder wall and infiltration into adjacent organs make differentiating XGC from gallbladder cancer difficult with EUS alone. (キーワード) Aged / Cholecystitis / Diagnosis, Differential / Endosonography / Female / Gallbladder / Granuloma / Humans / Male / Tomography, X-Ray Computed / Ultrasonography (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10395132 ● Summary page in Scopus @ Elsevier: 2-s2.0-0033012672 (PubMed: 10395132, Elsevier: Scopus)
73.	Seisuke Okamura, Akemi Tsutsui, Naoki Muguruma, Soichi Ichkawa, Masahiro Sogabe, Yoshio Okita, Tamotsu Fukuda, Shigehito Hayashi, Toshiya Okahisa, Susumu Ito and Toshiaki Sano : The utility and limitations of an ultrasonic miniprobe in the staging of gastric cancer, The Journal of Medical Investigation : JMI, Vol.46, No.1, 49-53, 1999. (要約) To determine the utility and limitations of an ultrasonic miniprobe (UMP) in the staging of gastric cancer, we evaluated 46 patients who underwent endoscopic ultrasonography (EUS) using an UMP and who were histologically determined to have gastric cancers. In every case, UMP findings were compared with histopathological findings after treatment. The total accuracy of UMP relative to the depth of tumor invasion was 71.7% (33/46 cases). Accuracy with respect to T1-m tumor diagnosis was 75.7% (22/29 cases), and for T1-sm, 76.9% (10/13 cases), but accuracy for T2 tumor diagnosis was low, due to ultrasound attenuation. When the analysis was carried out based on the size of tumor, the accuracy for UMP was 50.0% (9/18 cases) for all tumors over 20 mm and 85.7% (24/28 cases) for all tumors smaller than 20 mm. We conclude that UMP is suitable for investigation of tumor extension when the lesion is superficial and/or small gastric cancers which do not cause ultrasonic attenuation, but not when the tumor is large or located in certain sites, although conventional EUS is useful in some of these cases. (キーワード) Aged / Endosonography / Female / Humans / Male / Neoplasm Staging / Sensitivity and Specificity / Stomach Neoplasms (徳島大学機関リポジトリ) ● Metadata: 83262 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10408157 ● Search Scopus @ Elsevier (PMID): 10408157 (徳島大学機関リポジトリ: 83262, PubMed: 10408157)
74.	Toshiya Okahisa, M Sogabe, S Hayashi, H Shibata and Susumu Ito : Contrast medium-removing effect of hemofiltration and hemodiafiltration., The Journal of Medical Investigation : JMI, Vol.45, No.1-4, 87-93, 1998. (要約) The contrast medium-removing effect of hemofiltration (HF) and hemodiafiltration (HDF) was experimentally investigated using a bovine blood tank model. HF and HDF were performed at a blood flow rate of 100 ml/min with a polysulfone hemofilter (PS filter-CF; membrane area: 0.7 m2). Two hundred milliliters of iomeprol (300 mgI/ml) was administered by a single injection into 4 liters of bovine blood. The blood half-lives of iomeprol were 1.0 hr for the high flow rate HDF group [replacement fluid flow rate (QF): 10 ml/min and dialysate flow rate (QD): 40 ml/min], 1.8 hr for the HDF group (QF: 10 ml/min and QD: 10 ml/min), and 3.8 hr for the HF group (QF: 10 ml/min). The mean clearance rates were 39.7 ml/min for the high flow rate HDF group, 21.4 ml/min for the HDF group, and 12.0 ml/min for the HF group. Iomeprol was mostly excreted in the waste fluid. It is concluded that HDF can remove contrast media more effectively than HF. (キーワード) Animals / Cattle / Contrast Media / Half-Life / Hemodiafiltration / Hemofiltration / Iopamidol (徳島大学機関リポジトリ) ● Metadata: 111620 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9864968 ● Search Scopus @ Elsevier (PMID): 9864968 (徳島大学機関リポジトリ: 111620, PubMed: 9864968)
75.	Naoki Muguruma, Seisuke Okamura, Toshiya Okahisa, M Yasuda, S Hayashi, H Shibata and Susumu Ito : Electrohydraulic lithotripsy treatment for persimmon bezoars., Digestive Endoscopy, Vol.30, No.5, S60, 1998.
76.	Susumu Ito, Naoki Muguruma, Shigehito Hayashi, Satoko Taoka, Terumi Bando, Kumi Inayama, Masahiro Sogabe, Toshiya Okahisa, Seisuke Okamura, Hiroshi Shibata, Tatsuro Irimura, Kazuhiro Takesako and Seiichi Shibamura : Development of agents for reinforcement of fluorescence on near-infrared ray excitation for immunohistological staining, Bioorganic & Medicinal Chemistry, Vol.6, No.5, 613-618, 1998.
77.	Susumu Ito, Toshiya Okahisa, Seisuke Okamura, Satoshi Wada, Mikio Yano, Tetsuya Saijo, Hirohito Honda, Hiroshige Hayashi and Ichiro Shimizu : Endoscopic therapy using monopolar and bipolar snare with a high-frequency current in patients with a pacemaker, Endoscopy, Vol.26, No.2, 270, 1994.
78.	Hirohito Honda, Shingo Hibino, Chiyo Nii, Minoru Horokita, Masako Kamamura, Tomoko Nishikado, Takahiro Horie, Toshiya Okahisa, Hiroshi Shibata, Ichiro Shimizu and Susumu Ito : Prevalence of HCV-antibodies And HCV-RNA In Donor Blood In Tokushima Prefecture, The Tokushima Journal of Experimental Medicine, Vol.41, No.1-2, 9-15, 1994.
79.	Ichiro Shimizu, Satoshi Wada, Toshiya Okahisa, Masako Kamamura, Mitsuyasu Yano, Tsukasa Kodaira, Katsushi Nishino, Kenji Shima and Susumu Ito : Radioimmunoreactive plasma bradykinin levels and histological changes during the course of cerulein-induced pancreatitis in rats., Pancreas, Vol.8, No.2, 220-225, 1993. (要約) The plasma bradykinin (BK) and serum amylase levels and histological changes in rats during the course of acute pancreatitis induced by a large dose of cerulein were examined. Animals were given four intraperitoneal injections of 20 micrograms/kg body wt of cerulein at hourly intervals. The plasma concentration of BK-like immunoreactivity (BK-LI), measured by a highly sensitive and specific radioimmunoassay established in this study, was found to reach a peak 6 h after the first injection of cerulein and then to remain elevated. On the other hand, the serum amylase and the histological alterations (i.e., interstitial edema, vacuolization, and inflammatory infiltration) were maximal 9 h after the first injection and returned to nearly normal after 24 h. These observations suggest that the BK generation is indicative of the participation of the kallikrein-kinin system in the pathophysiological change and that the plasma BK-LI level is a good marker of cellular damage and inflammation within the pancreas during the course of acute pancreatitis. (キーワード) Acute Disease / Amylases / Animals / Bradykinin / Caerulein / Immune Sera / Male / Pancreatitis / Radioimmunoassay / Rats / Rats, Wistar / Sensitivity and Specificity (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 7681581 ● Search Scopus @ Elsevier (PMID): 7681581 (PubMed: 7681581)
80.	Ichiro Shimizu, Satoshi Wada, Harunobu Fujikawa, Minoru Horikita, Shingo Hibino, Toshiya Okahisa, Seisuke Okamura, Hiroshige Hayashi, Hirohito Honda, Tetsuya Saijo, Mikio Yano, Joji Syundo, Susumu Ito and Yoshiaki Sano : A case of melanosis duodeni in which pigmentation disappeared after the discontinuation of hydralazine administration., Digestive Endoscopy, Vol.3, No.4, 574-580, 1991.
81.	Susumu Ito, Tomoharu Maeda, Akiharu Iwasaki, Harunobu Fujikawa, Toshiya Okahisa, Tetsuya Saijyou, Kunio Ii, Nobuya Sano, Yoshiko Matsuda and Hitoshi Endo : HISTOCHEMICAL AND BIOCHEMICAL STUDIES ON GUANASE IN THE HUMAN AND RAT KIDNEY, Acta Histochemica et Cytochemica, Vol.24, No.6, 591-596, 1991.

学術論文(紀要・その他):

1.	T Goji, Seisuke Okamura, H Takeuchi, Tetsuo Kimura, Shinji Kitamura, Katsuyoshi Tamaki, Koichi Okamoto, Masako Kaji, Naoki Muguruma, Toshiya Okahisa, J Shunto and Tetsuji Takayama : Migrated Endoclip and Stone Formation after Cholecystectomy: A Case Treated by Endoscopic Sphincterotomy, Internal Medicine, Vol.48, No.23, 2015-2017, 2009. (要約) Endoclip migration into the common bile duct following laparoscopic cholecystectomy (LC) is an extremely rare complication. Migrated endoclip into the common bile duct can cause obstruction, serve as a nidus for stone formation, and cause cholangitis. We report a case of cholangitis due to a migrated endoclip and consequent choledocholithiasis 6 years after LC, which was successfully treated by endoscopic extraction. (キーワード) Aged / Cholecystectomy / Common Bile Duct / Foreign-Body Migration / Gallstones / Humans / Male / Postoperative Complications / Sphincterotomy, Endoscopic / Surgical Instruments (出版サイトへのリンク) ● Publication site (DOI): 10.2169/internalmedicine.48.2634 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19952484 ● Search Scopus @ Elsevier (PMID): 19952484 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.48.2634 (DOI: 10.2169/internalmedicine.48.2634, PubMed: 19952484)
2.	宮本弘志, 岡久稔也, 居和城宏, 村田昌彦, 伊東進, 大西芳明, 大藤純, 大田宗幸, 安部正, 黒田泰弘 : 包括評価制度導入後の潰瘍性大腸炎に対する白血球除去療法, ICUとCCU, Vol.28, No.2, 215-217, 2004年. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1523669555147628416 (CiNii: 1523669555147628416)
3.	岡久稔也, 宮本弘志, 居和城宏, 伊東進, 大西芳明, 大藤純, 黒田泰弘 : 包括評価制度導入後の急性血液浄化療法, ICUとCCU, Vol.28, No.2, 7-10, 2004年. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1524232505373333376 (CiNii: 1524232505373333376)
4.	清水一郎, 六車直樹, 岡村誠介, 林重仁, 横井孝文, 安田貢, 岡久稔也, 柴田啓志, 伊東進, 佐野暢哉, 日比野真吾, 和田哲, 林秀樹 : 内視鏡的粘膜切除を施行した十二指腸腺腫の1例, 消化管の臨床, Vol.2, 67-71, 1996年.
5.	清水一郎, 柴田啓志, 横井孝文, 六車直樹, 梯泰昌, 松永裕子, 福田保, 林重仁, 安田貢, 堀江貴浩, 岡久稔也, 岡村誠介, 西條哲也, 伊東進 : 岡山医誌, Vol.108, No.3-6, 197-198, 1996年.
6.	清水一郎, 六車直樹, 岡村誠介, 岡久稔也, 梯泰昌, 林重仁, 横井孝文, 安田貢, 柴田啓志, 伊東進, 松森保道, 梶川愛一郎, 広瀬隆則, 林秀樹 : 大量下血をきたした空腸平滑筋腫の1例, 消化管の臨床, Vol.1, 99-103, 1995年.
7.	清水一郎, 柴田啓志, 六車直樹, 横井孝文, 堀江千昌, 堀北実, 安田貢, 梯泰昌, 林重仁, 岡久稔也, 岡村誠介, 伊東進, 矢野勇人, 佐野暢哉 : 各種画像診断にて肝癌と鑑別困難であった肝内多発結節性病変の1例, Liver Cancer, Vol.1, No.1, 43-50, 1995年.
8.	清水一郎, 柴田啓志, 矢野充保, 六車直樹, 本田浩仁, 岡村誠介, 岡久稔也, 西條哲也 : UDCA就寝前1回投与による胆石溶解について, 消化器科, Vol.18, No.4, 407-412, 1994年.
9.	清水一郎, 伊東進, 藤川晴信, 西條哲也, 岡久稔也, 日比野真吾, 岡村誠介, 柴田啓志, 本田浩仁, 矢野充保, 伊井邦雄 : 十二指腸液逆流にもとづく実験的逆流性食道炎の実験モデル作成法, 日本臨床生理学会雑誌, Vol.23, No.3, 309-311, 1993年.
10.	清水一郎, 西條哲也, 藤川晴信, 堀北実, 日比野真吾, 岡久稔也, 岡村誠介, 林広茂, 本田浩仁, 和田哲, 矢野充保, 伊東進, 後藤義明 : ラット実験的逆流性食道炎モデルの成因について, Ther Res, Vol.13, No.1, 25-26, 1992年.
11.	清水一郎, 柴昌子, 六車直樹, 岡村誠介, 岡久稔也, 矢野充保, 和田哲, 春藤譲治進, 伊東進 : 食道静脈瘤硬化療法が有効であった巨木型食道静脈瘤(pipeline varix)の1例, 臨床と研究, Vol.69, No.3, 827-830, 1992年.

総説・解説:

1.	宮本弘志, 三好人正, 竹中英喬, 木村哲夫, 竹内尚, 岡久稔也, 佐藤康史, 加藤淳二, 高山哲治 : 【StageIV胃癌治療への挑戦】StageIV胃癌に対するDCS療法の意義, 消化器外科, Vol.34, No.5, 575-581, 2011年5月. (キーワード) Cisplatin(治療的利用,毒性・副作用) 胃腫瘍(薬物療法) 腫瘍多剤併用療法生存分析第I相試験第II相試験治療成績 Docetaxel(治療的利用,毒性・副作用) TS-1(治療的利用,毒性・副作用) ヒト
2.	上野淳二, 髙尾正一郎, 岡久稔也, 久保満, 仁木登 : stool tagging法を用いたCT colonography, Early Colorectal Cancer, Vol.12, No.2, 155-159, 2008年3月.
3.	井上和俊, 芥川正武, 長篠博文, 木内陽介, 岡久稔也 : 血圧情報を統合したCRIT-LINE情報システムの開発, ICUとCCU, Vol.27, S89-S90, 2003年3月.
4.	清水一郎, 糸永美奈, Guangming Lu, Xuezhi Cui, 豊田敬生, 久保謙一郎, 四宮寛彦, 筒井朱美, 岡久稔也, 柴田啓志, 本田浩仁, 伊東進 : C型肝炎ウイルス持続感染患者の肝線維化における女性ホルモンの役割, 四国医学雑誌, Vol.58, No.1-2, 22-34, 2002年4月. (徳島大学機関リポジトリ) ● Metadata: 110522 (徳島大学機関リポジトリ: 110522)

国際会議:

1.	Yoshifumi Kida, Toshiya Okahisa, Yasushi Sato, Masahiro Bando, shota fujimoto, Tadahiko Nakagawa, Tomoyuki Kawaguchi, Fumika Nakamura, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Koichi Tsuneyama and Tetsuji Takayama : Thepapeutic strategy of Ulcerative Colitis targeting Urokinase-type Plasminogen Activator., DDW2023, May 2023.
2.	Tetsuji Takayama, Yoshifumi Kida, Toshiya Okahisa, Yasushi Sato, Masahiro Bando, shota Fujimoto, Tomoyuki Kawaguchi, Fumika Nakamura, Koichi Okamoto, Hiroshi Miyamoto, Koichi Tsuneyama and Masahiro Sogabe : The relevance of urokinase-type plasminogen activator in pathogenesis of ulcerative colitis., WCOG2022 (World Congress of Gastroenterology), Dubai, Dec. 2022.
3.	Toshiya Okahisa, Masahiro Sogabe, Ryosuke Ogata, Takatoshi Komatsu, Yoshiaki Ohnishi, Hiroyuki Ueda, Tomoyuki Kawaguchi, Akira Fukuya, Yoshifumi Kida, Tetsu Tomonari, Hiroshi Miyamoto and Tetsuji Takayama : Concentration Ratio Self-regulation Function of Ascites Filtration and Concentration Equipment for Cell-free and Concentrated Ascites Reinfusion Therapy, ASAIO 67th Annual Conference, Chicago, Jun. 2022.
4.	Oyama Eiji, Akihiro Shirai, Tadahiko Nakagawa, Masahiro Sogabe, Toshiya Okahisa and Kenji Teranishi : Effects of Physiological Saline Solution Treated by Ar Dielectric Barrier Discharge on Proliferation of Jurkat Cell, 74th Annual Gaseous Electronics Conference, Online, Oct. 2021.
5.	Sakamaki Sho, Tateishi Yoshinori, Kenji Teranishi, Naoyuki Shimomura and Toshiya Okahisa : Dielectric barrier discharge plasma treatment of porcine whole blood, The Joint Conference of XXXIV International Conference on Phenomena in Ionized Gases and the 10th International Conference on Reactive Plasmas, Jul. 2019.
6.	Naoki Igata, J nishioka, T Komatsu, S Kobayashi, Y Ohnishi, M Fukuhara, Hironori Tanaka, Tetsu Tomonari, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : Drainage with Normal Saline in Two Directions for Washing of the Clogging Filter During Cell-free and Concentrated Ascites Reinfusion Therapy., The 65th Annual Conference of American Society for Artificial Internal Organs (ASAIO), San Francisco, Jun. 2019.
7.	junji nishioka, T Komatsu, S Kobayashi, Y Ohnishi, M Fukuhara, Hironori Tanaka, Tetsu Tomonari, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : Development of Multiple Point Bowel-sound Analysis System (MPBAS) for the Optimization of the Bowel Sound Measurement Position., The 65th Annual Conference of American Society for Artificial Internal Organs (ASAIO), San Francisco, Jun. 2019.
8.	Toshiya Okahisa, Masahiro Sogabe, Mayu Uyama, Tadahiko Nakagawa, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Tetsuji Takayama, Takaaki Shimohata, Takashi Uebanso, Kazuaki Mawatari, Akira Takahashi, Takahiro Emoto, Masatake Akutagawa, M Yamada and M Fukuhara : Development Of A Multi-Ring Type Roller Pump Unit Equipped To A Compact And Convenient Ascites Purification Machine For Cell-Free And Concentrated Ascites Reinfusion Therapy (CART)., ASAIO 64th Annual Conference, Washington, D.C., Jun. 2018.
9.	Kaizo Kagemoto, Koichi Okamoto, Tohshi Takaoka, Yasuyuki Okada, Kumiko Tanaka, Akihiro Hirao, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa, Koichi Tsuneyama and Tetsuji Takayama : Detection of Aberrant Crypt Foci Using Image-Enhanced Endoscopy., Digestive Disease Week2017, Chicago, May 2017.
10.	Masahiro Sogabe, Toshiya Okahisa, Tadahiko Nakagawa, Noriaki Murayama, Masanori Takehara, Kaizo Kagemoto, Yoshifumi Takaoka, Tetsu Tomonari, Tatsuya Taniguchi, Tetsuo Kimura, Naoki Muguruma and Tetsuji Takayama : Influence of Lifestyle and Lifestyle-Related Disease on Nonalcoholic Fatty Liver Disease in Japanese With Metabolic Syndrome, Digestive Disease Week2016, San Diego, May 2016.
11.	Yoshihiko Miyamoto, Naoki Muguruma, Shota Fujimoto, Tadahiko Nakagawa, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Toshiya Okahisa and Tetsuji Takayama : Molecular Imaging Targeting Epidermal Growth Factor Receptor in Detection and Evaluation of Therapeutic Efficacy for Colorectal Cancer, Digestive Disease Week2016, San Diego, May 2016.
12.	Tadahiko Nakagawa, Yoshifumi Takaoka, Hironori Tanaka, Kumiko Tanaka, Tetsuji Takayama, Takaaki Shimohata, Takashi Uebanso, Kazuaki Mawatari, Akira Takahashi, Masatake Akutagawa, Takahiro Emoto, Yohsuke Kinouchi, Toru Murashima, Satoru Yamaji, Zenji Tanaka, Masahiro Sogabe and Toshiya Okahisa : Roller Pump Circulation System For Preventing Filter Clogging During Cell-free and Concentrated Ascites Reinfusion Therapy (cart)., The 61th Annual Conference of American Society for Artificial Internal Organs(ASAIO), Chicago, Jun. 2015.
13.	Tatsuya Taniguchi, Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Kazuhiro Kishi, Hiroshi Miyamoto, Naoki Muguruma, Masahiro Sogabe, Toshiya Okahisa, Tadahiko Nakagawa and Tetsuji Takayama : Des-G-Carboxy Prothrombin (DCP) Is Induced by PARP-1 in Hepatocellular Carcinoma, Digestive Disease Week 2015, Washington, D.C., May 2015.
14.	Kaizo Kagemoto, Atsushi Inoue, Koichi Okamoto, Yasuyuki Okada, Jun Okazaki, Yoshifumi Takaoka, Yoshihiko Miyamoto, Yasuhiro Mitsui, Jinsei Miyoshi, Kumiko Tanaka, Yasuteru Fujino, Shinji Kitamura, Tetsuo Kimura, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : Proximal Aberrant Crypt Foci As Precursor Lesions of SSA/P-Cancer Sequence., Digestive Disease Week 2015, Washington, D.C., May 2015.
15.	Kagawa Miwako, Toshiya Okahisa, Takaoka yoshifumi, Yasuteru Fujino, Jinsei Miyoshi, Takaoka Toshi, Tetsu Tomonari, Shinji Kitamura, Okada Yasuyuki, Kagemoto Kaizo, Takehara Masanori, Kumiko Tanaka, Matsumoto Sayo, Teramae Tomofumi, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama and Takaoka Toshi : Angiogenesis-Related Factors At the Residual Inflammation in Patients With Ulcerative Colitis in Clinical Remission Stage, Digestive Disease Week2014, Chicago, May 2014.
16.	Akina Nakanishi, Toshiya Okahisa, Emi Umezu, Tadahiko Nakagawa, Miwako Kagawa, Toshi Takaoka, Takahiro Goji, Hiromi Yano, Shinji Kitamura, Takahiro Goji, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Expression of Thymidline EMT via ERK 1/2 Signal Patway in Ulcerative Colitis, DDW2013,Orland, Orange County Convention Center, Orlando, May 2013.
17.	Yasuteru Fujino, Koichi Okamoto, Naoki Muguruma, Jun Okazaki, Yasuyuki Okada, Hironori Tanaka, Jinsei Miyoshi, Toshi Takaoka, Shinji Kitamura, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : Usefulness of a new sphincterotome for the endoscopic submucosal dissection of colorectal neoplasms, DDW2013, Orlando, May 2013.
18.	Koichi Shono, Takahiro Emoto, Toshiya Okahisa, Udantha R. Abeyratne, Hiromi Yano, Masatake Akutagawa, Shinsuke Konaka and Yohsuke Kinouchi : Automatic Evaluation of Gastrointestinal Motor Activity through the Analysis of Bowel Sounds, Proceedings of the 10th IASTED International Conference on biomedical engineering(biomed 2013), 136-140, Austria, Feb. 2013. (要約) この論文では， ARMAに基づく自動腸音検出法を提案する．コンピュータシミュレーションにより，提案法の性能が調査される．さらに，腸運動性と腸音発生間隔との関係が調査される．
19.	Atsushi Inoue, Koichi Okamoto, Yasuteru Fujino, Jinsei Miyoshi, Takahiro Tanaka, Tetsuo Kimura, Masako Kaji, Hiroshi Miyamoto, Toshiya Okahisa, Seisuke Okamura and Tetsuji Takayama : Aberrant Crypt Foci in Patients With Sessile Serrated Adenomas, Digestive Disease Week2011, Chicago, May 2011.
20.	Hidetaka Takenaka, Katsuyoshi Tamaki, Tatsuya Taniguchi, Tetsu Tomonari, Rie Harada, Katsutaka Sannomiya, Momoko Sato, Toshiya Okahisa, Seisuke Okamura and Tetsuji Takayama : Radiofrequency ablation using a balloon catheter for hepatocellular carcinoma adjacent to the gastrointestinal tract:Experimental and Clinical Study, Digestive Disease Week 2011, Chicago, Chicago, May 2011.
21.	Masako Kaji, Tetsu Tomonari, Kagawa Miwako, Saito Azusa, Tsuda Miho, Harada Rie, Tetsuo Kimura, Shinji Kitamura, Hiromi Yano, Koichi Okamoto, Niki Miyako, Toshiya Okahisa, Seisuke Okamura and Tetsuji Takayama : Usefulness of electrocolonography for evaluation of colonic motility, Digestive Disease Week 2010, New Orleans, May 2010.
22.	Toshiya Okahisa, Tsuda Miho, Tetsu Tomonari, Inoue Atsushi, Tetsuo Kimura, Shinji Kitamura, Hiromi Yano, Takeuchi Hisashi, Koichi Okamoto, Niki Miyako, Masako Kaji, Seisuke Okamura, Kanno Ryota, Shinsuke Konaka, Takahiro Emoto, Masatake Akutagawa and Tetsuji Takayama : Vascular patterns assessed by vascular analysis software are predictive of relapse in patients with inactive ulcerative colitis, Digestive Disease Week 2010, New Orleans, May 2010.
23.	Yoshinori Nitta, Masatake Akutagawa, Takahiro Emoto, Toshiya Okahisa, Hiroshi Miyamoto, Yoshiaki Ohnishi, Shunya Nakane, Ryuji Kaji, Masaji Nishimura and Yohsuke Kinouchi : The possibility of the classification about Ht values using the AR model, Proceedings of 2009 World Congress on Medical Physics and Biomedical Engineering, Vol.25, No.7, 525-528, Munich, Sep. 2009.
24.	Yoshinori Nitta, Masatake Akutagawa, Takahiro Emoto, Toshiya Okahisa, Hiroshi Miyamoto, Yoshiaki Ohnishi, Masaji Nishimura, Shunya Nakane, Ryuji Kaji and Yohsuke Kinouchi : Investigation of a Classification about Time Series Signal Using SOM, The 13th International Conference on Biomedical Engineering, 598-601, Singapore, Dec. 2008.
25.	Yoshinori Nitta, Masatake Akutagawa, Toshiya Okahisa, Hiroshi Miyamoto, Yoshiaki Ohnishi, Shunya Nakane, Ryuji Kaji, Abhijit S. Pandya and Yohsuke Kinouchi : Analysis of hematocrit value during the plasma exchange, Proceedings of the Intenational Symposium on Biological and Physiological Engineering /The 22nd SICE Symposium on Biological and Physiological Engineering, 278-279, Harbin, Jan. 2008.
26.	Igo Stephen, Sugita Yoichi, Motomura Tadashi, Toshiya Okahisa, Glueck Julia and Nosé Yukihiko : Long-Term Endurance and Performance Tests of Gyro Centrifugal Blood Pump, ASAIO J., Vol.55, No.2, 47A, Chicago, Jun. 2007.
27.	Sugita Yoichi, Motomura Tadashi, Toshiya Okahisa, Igo Steve, Glueck Julia and Nosé Yukihiko : Ion-Beam Surface Modification for Implantable Biomaterial, ASAIO J., Vol.55, No.2, 9A, Chicago, Jun. 2007.
28.	Won Y Chung, Toshiya Okahisa, Sugita Yoichi, Motomura Tadashi, Igo Steve, Glueck Julia and Nosé Yukihiko : Particle size changes in plasma due to temperature conrol., ASAIO J., Vol.55, No.2, 63A, Chicago, Jun. 2007.
29.	Toshiya Okahisa, Sugita Yoichi, Yuji Matsuda, Won Y Chung, Motomura1 Tadashi, Igo Steve, Glueck Julia, Teruya Jun, Torre-Amione Guillermo and Nosé Yukihiko : Pressure and temperature controlled apheresis therapy (pat cat) system, ASAIO J., Vol.55, No.2, 64A, Chicago, Jun. 2007.
30.	Toshiya Okahisa, Sugita Yoichi, Won Y Chung, Yuji Matsuda, Motomura Tadashi, Igo Stephan, Glueck Julia, Teruya Jun, G Torre-Amione and Nosé Yukihiko : Pressure and temperature controlled apheresis therapy system for the therapy of dilated cardiomyopathy., Ther Apher Dial., Vol.11, No.4, A60, Yokohama, Mar. 2007.
31.	Yoshinori Nitta, Masatake Akutagawa, Hiroshi Miyamoto, Toshiya Okahisa, Yoshiaki Ohnishi, Masaji Nishimura, Shunya Nakane, Ryuji Kaji and Yohsuke Kinouchi : Possibility of predicting Ht values during a plasma exchange therapy using back propagation neural network, Proceedings of 2006 World Congress on Medical Physics and Biomedical Engineering, Seoul, Korea, August 27-September 1, 2006, Vol.1, 1041-1044, Seoul, Aug. 2006. (キーワード) Guillain-Barre Syndrome / plasma exchange / hematocrit / Crit-Line Monitor / ニューラルネットワーク (neural network)
32.	Hansen Erlemd, Igo Stephan, Toshiya Okahisa, Yuji Matsuda, Motomura Tadashi, Glueck Julia and Nosé Yukihiko : In vitro endurance and performance verification of the gyro centrifugal blood pump system., UMEÅ, Vol.Sweden, Sweden, Jun. 2006.
33.	Okita Yoshio, Toshiya Okahisa, Sogabe Masahiro, Suzuki Masaharu, Hiroshi Miyamoto, Iwaki Hiroshi, Murata Masahiro and Susumu Ito : Trypsin removal by continuous hemodiafiltration., ASAIO J., Vol.52, No.2, 77A, Chicago, Jun. 2006.
34.	Igo Stephan, Motomura Tadashi, Toshiya Okahisa, Yuji Matsuda, Hansen Erlemd, Glueck Julia and Nosé Yukihiko : Long-term endurance of gyro centrifugal blood pump system., ASAIO J., Vol.52, No.2, 59A, Chicago, Jun. 2006.
35.	Hansen Erlemd, Motomura Tadashi, Toshiya Okahisa, Yuji Matsuda, Igo Stephan, Glueck Julia and Nosé Yukihiko : Miniaturized all-in-one rpm-controllable actuator for gyro centrifugal blood pump., ASAIO J., Vol.52, No.2, 37A, Chicago, Jun. 2006.
36.	Yuji Matsuda, Motomura Tadashi, Toshiya Okahisa, Igo Stephan, Hansen Erlemd, Glueck Julia and Nosé Yukihiko : In vivo evaluation of the fixed rpm flow control with the implantable centrifugal blood pump., ASAIO J., Vol.52, No.2, 45A, Chicago, Jun. 2006.
37.	Yuji Matsuda, Motomura Tadashi Tadashi, Toshiya Okahisa, Igo Stephan, Hansen Erlemd, Glueck Julia and Nosé Yukihiko : Over three-month in vivo ventricular assist Device study with the implantable centrifugal Blood Pump., ASAIO J., Vol.52, No.2, 40A, Chicago, Jun. 2006.
38.	Toshiya Okahisa, Yuji Matsuda, Hansen Erlemd, Motomura Tadashi, Glueck Julia and Nosé Yukihiko : Safety system using a new attachment to ensure proper mixing of double-bag bicarbonate replacement fluid sets., ASAIO J., Vol.52, No.2, 75A, Chicago, Jun. 2006.
39.	Toshiya Okahisa, Yuji Matsuda, Hansen Erlemd, Motomura Tadashi, Glueck Julia and Nosé Yukihiko : Is it possible to use the plasma separator as a cryofilter?, ASAIO J., Vol.52, No.2, 75A, Chicago, Jun. 2006.
40.	Igo Stephan, Motomura Tadashi, Oda Takeshi, Toshiya Okahisa and Nosé Yukihiko : Endurance testing of Gyro centrifugal blood pump., Artificial Organs., Vol.30, No.2, A22, Tokyo, Sep. 2005.
41.	Toshiya Okahisa, Hansen Erlemd, Oda Takeshi, Motomura Tadashi, Igo Stephan, Glueck Julia and Nosé Yukihiko : Is it possible to monitor the stenosis by analyzing the flow waveform using Fast Fourier Transform?, Artificial Organs., Vol.30, No.2, A21, Tokyo, Sep. 2005.
42.	Motomura Tadashi, Oda Takeshi, Yuriko Kose, Toshiya Okahisa, Igo Stephan, Glueck Julia and Nosé Yukihiko : Centrifugal pump hemolysis and clinical requirement., Artificial Organs., Vol.30, No.2, A18, Tokyo, Sep. 2005.
43.	Hansen Erlemd, Toshiya Okahisa, Oda Takeshi, Motomura Tadashi, Igo Stephan, Glueck Julia and Nosé Yukihiko : Is it possible to detect the difference of VAD inlet or outlet stenosis by analyzing the pressure waveform?, Artificial Organs., Vol.30, No.2, A17, Tokyo, Sep. 2005.
44.	Oda Takeshi, Motomura Tadashi, Toshiya Okahisa, Igo Stephan, Glueck Julia and Nosé Yukihiko : SELCAB (Self-Lung Cardiac Bypass) procedure with Gyro centrifugal blood pump., Artificial Organs., Vol.30, No.2, A16, Tokyo, Sep. 2005.
45.	Motomura Tadashi, Oda Takeshi, Toshiya Okahisa, Igo Stephan, A Brewer, P Ralston, J Meserko, Glueck Julia and Nosé Yukihiko : Centrifugal BVAD for functional total artificial heart application., Artificial Organs., Vol.30, No.2, A12, Tokyo, Sep. 2005.
46.	Yoshinori Nitta, Masatake Akutagawa, Toshiya Okahisa, Hiroshi Miyamoto, Yoshiaki Onishi, Kazuo Yoshizaki, Masaji Nishimura and Yohsuke Kinouchi : Short term prediction of Ht value using BPNN during LCAP, Proceedings of the 27th Annual Conference of the IEEE-EMBS, Vol.7, 4560-4563, Shanghai, Sep. 2005. (文献検索サイトへのリンク) ● Summary page in Scopus @ Elsevier: 2-s2.0-33846897208 (Elsevier: Scopus)
47.	Ogawa Daisuke, Yoshizawa Makoto, Tanaka Akira, Abe Ken-ichi, Motomura Tadashi, Okubo Hisashi, Oda Takeshi, Toshiya Okahisa and Nosé Yukihiko : Long term evaluation of flow rate estimation in NEDO PI centrifugal pump., Control and Information Technology, Okayama, Aug. 2005.
48.	Masahiro Sogabe, Toshiya Okahisa, Koji Tsujigami, Yoshio Okita, Hirokazu Hayashi, Toshikatsu Taniki, Hiroshi Hukuno, Masahiko Nakasono, Naoki Muguruma, Seisuke Okamura and Susumu Ito : Ultrasonographic assessment of gastric motility in diabetic gastroparesis before and after attaining glycemic control., Journal of Gastroenterology, Vol.40, No.6, 583-590, Jul. 2005. (要約) Glycemic control is important for maintaining gastric motility in diabetic patients, but gastric motility has not yet been studied ultrasonographically in relation to glycemic control. We made such observations before and after establishing glycemic control in diabetic patients with gastroparesis. We studied 30 diabetic patients with upper abdominal digestive symptoms who were hospitalized for correction of poor blood sugar control and who underwent upper digestive tract endoscopy to rule out structural causes such as gastric/duodenal lesions. Gastric motility was evaluated by transabdominal ultrasonography, using a test meal, before and after attainment of glycemic control (within 3 days after admission and 3 days before discharge). Also, upper abdominal digestive symptoms present on admission and at discharge were compared. After glycemic control was established, contractions of the antral region were more frequent than before the attainment of control (8.93 +/- 1.17/3 min vs 7.63 +/- 2.22/3 min, respectively; P < 0.001). Glycemic control also significantly improved gastric emptying (before glycemic control, 49.2 +/- 14.8%; after, 67.1 +/- 11.5%; P < 0.001). This was also true for the motility index, concerning antral gastric contractility (before control, 2.97 +/- 1.57; after, 3.75 +/- 1.09; P < 0.05). Upper abdominal symptom scores were also significantly lower after attainment of control than before (0.47 +/- 0.78 vs 3.17 +/- 2.00, respectively; P < 0.001). These findings suggest that attaining glycemic control improves gastric motility and attainments upper abdominal symptoms in diabetic patients with gastroparesis. (キーワード) Adult / Aged / Aged, 80 and over / Blood Glucose / Diabetes Mellitus, Type 1 / Diabetes Mellitus, Type 2 / Female / Follow-Up Studies / Gastric Emptying / Gastroparesis / Humans / Male / Middle Aged / Severity of Illness Index (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s00535-005-1592-1 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16007392 ● Search Scopus @ Elsevier (PMID): 16007392 ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-005-1592-1 (DOI: 10.1007/s00535-005-1592-1, PubMed: 16007392)
49.	Motomura Tadashi, Okubo Hisashi, Oda Takeshi, Ogawa Daisuke, Toshiya Okahisa, T Stephan Igohinohara Stephan, T Ishizuka, E Okamoto and Nosé Yukihiko : Ten-year NEDO BVAD development program: Moving forward to the clinical arena., ASAIO J., Vol.51, No.2, 33A, Washington, D.C., Jun. 2005.
50.	Oda Takeshi, Toshiya Okahisa, Motomura Tadashi, Okubo Hisashi, Ogawa Daisuke, Igo Stephan, Glueck Julia and Nosé Yukihiko : An evaluation of the flow balance between LVAD and RVAD., ASAIO J., Vol.51, No.2, 31A, Washington, D.C., Jun. 2005.
51.	Yamagishi Hiroto, Toshiya Okahisa, Ogawa Daisuke, Oda Takeshi, Okubo Hisashi, Motomura Tadashi, Igo Stephan, Glueck Julia, Sankai Yoshiyuki and Nosé Yukihiko : Monitoring of the inlet stenosis of the nonpulsatile ventricular assist pump by analyzing the pressure waveform using fast fourier transform., ASAIO J., Vol.51, No.2, 29A, Washington, D.C., Jun. 2005.
52.	Okubo Hisashi, Toshiya Okahisa, Oda Takeshi, Motomura Tadashi and Nosé Yukihiko : Could cryofiltration be applicable to the treatment of dilated cardiomyopathy (DCM)?, ASAIO J., Vol.51, No.2, 58A, Washington, D.C., Jun. 2005.
53.	Toshiya Okahisa, Okubo Hisashi, Oda Takeshi, Motomura Tadashi and Nosé Yukihiko : Is leukocytapheresis therapy applicable for the treatment of dilated cardiomyopathy (DCM)?, ASAIO J., Vol.51, No.2, 61A, Washington, D.C., Jun. 2005.
54.	Toshiya Okahisa, Hiroshi Miyamoto, Susumu Ito, Yoshiaki Ohnishi and Tamura Masahiro : Development of new double-bag type bicarbonate substitution fluid set to prevent the non mixture use., ASAIO J., Vol.51, No.2, 61A, Washington, D.C., Jun. 2005.
55.	Toshiya Okahisa, Okubo Hisashi, Ogawa Daisuke, Oda Takeshi, Motomura Tadashi, Glueck Julia and Nosé Yukihiko : Fast fourier transform used to analyze clogging in hemofilters: an in vitro study on pressure and flow waveforms., ASAIO J., Vol.51, No.2, 60A, Washington, D.C., Jun. 2005.
56.	Toshiya Okahisa, Okubo Hisashi, Oda Takeshi, Motomura Tadashi, Igo Stephan, Teruya Jun and Nosé Yukihiko : Could the combination therapy of cryofiltration and ventricular assistance be applicable for the treatment of dilated cardiomyopathy?, Ther Apher Dial., Vol.9, A10, Warnemuende, May 2005.
57.	Toshiya Okahisa, Okubo Hisashi, Oda Takeshi, Motomura Tadashi, Glueck Julia, Nosé Yukihiko, Hiroshi Miyamoto, Susumu Ito, Yoshiaki Ohnishi and Tamura Masahiro : New double-bag type bicarbonate substitution fluid set resolve the problem of non mixture use., Ther Apher Dial., Vol.9, No.A11, A11, Warnemuende, May 2005.
58.	Toshiya Okahisa, Hiroshi Iwaki, Hiroshi Miyamoto, Susumu Ito, Yoshiaki Ohnishi and Masahiro Tamura : A double-bag system filled with pre-measured bicarbonate substitution fluid reduces preparation time regardless of experience., Blood Purif., Vol.24, 266, California, Mar. 2005.
59.	Ogawa Daisuke, Yoshizawa Makoto, Tanaka Akira, Abe Ken-ichi, Olegario Paul, Motomura Tadashi, Okubo Hisashi, Oda Takeshi, Toshiya Okahisa and Yukihiko Nose' : Evaluation of flow rate estimation method for rotary blood pump with chronic animal experiment., Conf Proc IEEE Eng Med Biol Soc., No.7, 7616-7619, 2005. (文献検索サイトへのリンク) ● Summary page in Scopus @ Elsevier: 2-s2.0-33846917742 (Elsevier: Scopus)
60.	Yoshinori Nitta, Toshiya Okahisa, Masatake Akutagawa, Hiroshi Miyamoto, Ohnishi Yoshiaki, Yohsuke Kinouchi, Masaji Nishimura and Susumu Ito : Application of BPNN to prediction of hematocrit values during LCAP, Proceedings of Biomedical Engineering Conference, 125-129, Hong Kong, Sep. 2004.
61.	Yoshinori Nitta, Yohsuke Kinouchi, Masatake Akutagawa, Toshiya Okahisa, Hiroshi Miyamoto, Hiroshi Iwaki, Susumu Ito, Yoshiaki Ohnishi, Jun Oto, Yasuhiro Kuroda and Shuzo Oshita : Prediction of the hematocrit value using an artificial neural network during leukocytapheresis therapy, Proceedings of 4th World Congress of the International Society for Apheresis, A10, Nashville, TN, USA, Oct. 2003.
62.	Toshiya Okahisa, Hiroshi Iwaki, Hiroshi Miyamoto, Masahiro Sogabe, Susumu Ito, Yoshiaki Ohnishi, Jun Oto, Yasuhiro Kuroda, Shuzo Oshita, Yoshinori Nitta, Yohsuke Kinouchi and Masatake Akutagawa : Monitoring filter clogging by analyzing the conductive condition of the roller pump flow pressure wave, Proceedings of 4th World Congress of the International Society for Apheresis, A9, Nashville, TN, USA, Oct. 2003.
63.	Hiroshi Miyamoto, Toshiya Okahisa, Hiroshi Iwaki, Masaharu Suzuki, Susumu Ito, Yoshiaki Ohnishi, Jun Oto, Yasuhiro Kuroda, Shuzo Oshita, Yoshinori Nitta, Yohsuke Kinouchi and Masatake Akutagawa : Variation of the hematocrit value during leukocytapheresis therapy, Proceedings of 4th World Congress of the International Society for Apheresis, A5, Nashville, TN, USA, Oct. 2003.
64.	Hitoshi Miyajima, Masahiro Nomura, Tomomi Nada, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu, Susumu Ito and Yutaka Nakaya : Abnormal gastric motility in liver cirrhosis: Effect of autonomic nervous function and volume of portal blood flow, The 7th United European Gastroenterology Week, Roma,Italy, 1999.

国内講演発表:

1.	岡久稔也, 曽我部正弘, 高山哲治 : <シンポジウム>医工連携による胸腹水濾過濃縮専用装置開発の経緯と課題:医師であり医療機器開発者である立場から., 第62回日本人工臓器学会大会, 2024年11月.
2.	米山世那, 鈴木想生, 末内辰尚, 香川美和子, 曽我部正弘, 中川忠彦, 大野将樹, 獅々堀正幹, 樫原孝典, 岡久稔也 : <萌芽研究ポスターセッション>腸音解析による過敏性腸症候群診断のための音楽ストレス負荷試験の最適化., 第62回日本人工臓器学会大会, 2024年11月.
3.	中嶋健悟, 阿部愛美, 末内辰尚, 香川美和子, 曽我部正弘, 中川忠彦, 大野将樹, 獅々堀正幹, 樫原孝典, 岡久稔也 : <萌芽研究ポスターセッション>睡眠中腸音解析システムを用いた過敏性腸症候群患者の病態評価., 第62回日本人工臓器学会大会, 2024年11月.
4.	松永貴裕, 香川美和子, 曽我部正弘, 大野将樹, 獅々堀正幹, 泓田正雄, 寺田賢治, 岡久玲子, 樫原孝典, 岡久稔也 : <萌芽研究ポスターセッション>個人の特性を活かした行動変容促進システムの開発., 第62回日本人工臓器学会大会, 2024年11月.
5.	岡部一郎, 緒方良輔, 曽我部正弘, 中川忠彦, 川口智之, 上田浩之, 高山哲治, 樫原孝典, 岡久稔也 : <萌芽研究ポスターセッション>腹水濾過濃縮再静注法(CART)の腹水処理速度の最適化., 第62回日本人工臓器学会大会, 2024年11月.
6.	末内辰尚, 岡久稔也, 樫原孝典, 藤本将太, 横山怜子, 上田浩之, 喜田慶史, 香川美和子, 曽我部正弘, 高山哲治 : <パネルディスカッション>音楽ストレス負荷時の腸蠕動音測定による過敏性腸症候群の診断., 第110回日本消化器病学会総会, 2024年5月.
7.	喜田慶史, 岡久稔也, 佐藤康史, 藤本将太, 川口智之, 中村文香, 岡本耕一, 宮本弘志, 曽我部正弘, 高山哲治 : <シンポジウム>潰瘍性大腸炎におけるウロキナーゼ型プラスミノーゲンアクチベーター(uPA)の発現解析と治療標的としての意義., 第110回日本消化器病学会総会, 2024年5月.
8.	曽我部正弘, 香川美和子, 上田浩之, 田中宏典, 友成哲, 岡本耕一, 河野豊, 宮本弘志, 佐藤康史, 岡久稔也, 高山哲治 : MAFLDと逆流性食道炎発症との関係, 第110回日本消化器病学会総会, 2024年5月.
9.	近清唯人, 中川忠彦, 白井昭博, 曽我部正弘, 岡久稔也, 寺西研二 : 誘電体バリア放電を生理食塩水に照射した際に生成される活性酸素・窒素種の生成特性, 令和6年電気学会全国大会講演論文集, 100, 2024年3月.
10.	緒方良輔, 曽我部正弘, 中川忠彦, 岡久稔也 : M-CARTの現状と課題., 第61回日本人工臓器学会大会, 2023年11月.
11.	大野将樹, 藤本直希, 獅々堀正幹, 岡久稔也 : 教師なし学習に基づく腸蠕動音の自動検出システムの開発, 人工臓器, 2023年11月.
12.	阿部愛美, 瀬分宏美, 末内辰尚, 曽我部正弘, 大野将樹, 獅々堀正幹, 泓田正雄, 寺田賢治, 上田浩之, 岡久稔也 : 健診受診者を対象とした睡眠中の腸蠕動音解析システムの開発., 第61回日本人工臓器学会大会, 2023年11月.
13.	鈴木想生, 今村美和子, 末内辰尚, 曽我部正弘, 大野将樹, 獅々堀正幹, 泓田正雄, 寺田賢治, 上田浩之, 岡久稔也 : 音楽聴収ストレス負荷試験による腸蠕動音と自律神経の変化., 第61回日本人工臓器学会大会, 2023年11月.
14.	大野将樹, 森内飛希, 獅々堀正幹, 泓田正雄, 寺田賢治, 岡久稔也 : One-class SVMに基づく腸蠕動音の自動検出, 第60回日本人工臓器学会大会, 2022年11月.
15.	林開稀, 獅々堀正幹, 大野将樹, 泓田正雄, 寺田賢治, 緒方良輔, 岡久稔也 : 胸腹水濾過濃縮時の人工知能を用いた濾過器圧力推移の予測, 第60回日本人工臓器学会大会, 2022年11月.
16.	緒方良輔, 岡久稔也, 上田浩之, 小松崇俊, 大西芳明, 中川忠彦, 曽我部正弘, 高山哲治 : CART専用装置の開発とCARTの安全基準に関する実験的・臨床的検討., 第60回日本人工臓器学会大会, 2022年11月.
17.	川島武朗, 片岡俊人, 大工廻亮, 鈴木英夫, 緒方良輔, 友成哲, 高山哲治, 曽我部正弘, 上田浩之, 岡久稔也 : 胸腹水濾過濃縮時の濃縮圧の自動制御に関する実験的検討., 第60回日本人工臓器学会大会, 2022年11月.
18.	大野将樹, 森内翔希, 獅々堀正幹, 岡久稔也 : One-class SVMに基づく教師なし腸蠕動音検出, 令和4年度電気・電子・情報関係学会四国支部連合大会, 2022年9月.
19.	獅々堀正幹, 大野将樹, 泓田正雄, 寺田賢治, 緒方良輔, 岡久稔也 : 胸腹水濾過濃縮専用装置M-CARTへの人工知能応用の可能性, 第59回日本人工臓器学会大会, 2021年11月.
20.	曽我部正弘, 岡久稔也, 高山哲治 : 上部消化管内視鏡検査受診者の受容性向上への取り組み(循環動態・自律神経機能の評価から), JDDW2021(第29回日本消化器医関連学会週間), 2021年11月.
21.	岡久稔也, 緒方良輔, 福家慧, 曽我部正弘, 高山哲治 : CART専用装置を用いた胸腹水の濾過濃縮., 第42回日本アフェレシス学会学術大会, 2021年10月.
22.	大山永治, 立石義憲, 中川忠彦, 白井昭博, 曽我部正弘, 岡久稔也, 寺西研二 : アルゴン誘電体バリア放電を照射した生理食塩水に曝露した Jurkat 細胞の生存率, 令和3年電気学会基礎・材料・共通部門大会, 2021年9月.
23.	井形直紀, 緒方良輔, 佐藤翔平, 坂東直紀, 小松崇俊, 小林誠司, 大西芳明, 田中克哉, 福原正史, 中川忠彦, 田中久美子, 友成哲, 高山哲治, 曽我部正弘, 岡久稔也 : 腹水濾過濃縮再静注法施行時の濃縮器の目詰まり対策., 第58回日本人工臓器学会大会, 2020年11月.
24.	中川忠彦, 竹内彩郁薫, 山田青季, 井形直紀, 板東直紀, 緒方良輔, 佐藤翔平, 友成哲, 宮本弘志, 六車直樹, 高山哲治, 曽我部正弘, 岡久稔也 : 胸腹水の循環式濾過濃縮処理時の物理刺激によるサイトカイン濃度の上昇., 第58回日本人工臓器学会大会, 2020年11月.
25.	曽我部正弘, 岡久稔也, 高山哲治 : 腹水濾過濃縮再静注法の展開., 第58回日本人工臓器学会大会, 2020年11月.
26.	岡久稔也, 曽我部正弘, 高山哲治 : 胸腹水の安全な自動処理を目指した胸腹水濾過濃縮専用装置(M-CART)の開発., 第58回日本人工臓器学会大会, 2020年11月.
27.	多田理香, 竹内彩郁薫, 山田青季, 井形直紀, 大野将樹, 獅々堀正幹, 泓田正雄, 寺田賢治, 喜田慶史, 川口智之, 三井康裕, 末内辰尚, 六車直樹, 高山哲治, 曽我部正弘, 岡久稔也 : 睡眠中の腸蠕動音の解析に適した腸音図システムの試作開発., 第58回日本人工臓器学会大会, 2020年11月.
28.	竹内彩郁薫, 山田青季, 多田理香, 井形直紀, 佐藤翔平, 緒方良輔, 坂東直紀, 大西芳明, 大野将樹, 獅々堀正幹, 泓田正雄, 寺田賢治, 北村晋志, 宮本弘志, 高山哲治, 曽我部正弘, 岡久稔也 : 腹水濾過器洗浄液量の最適化を行うための模擬腹水を用いた評価系の構築., 第58回日本人工臓器学会大会, 2020年11月.
29.	山田青季, 井形直紀, 竹内彩郁薫, 多田理香, 緒方良輔, 佐藤翔平, 坂東直紀, 大西芳明, 大野将樹, 獅々堀正幹, 泓田正雄, 寺田賢治, 田中久美子, 友成哲, 谷口達哉, 高山哲治, 曽我部正弘, 岡久稔也 : 腹水濾過濃縮再静注法の圧力シート., 第58回日本人工臓器学会大会, 2020年11月.
30.	立石義憲, 大山永治, 酒巻奨, 白井昭博, 中川忠彦, 曽我部正弘, 岡久稔也, 寺西研二 : 放電プラズマを照射した生理食塩水がJurkat細胞に及ぼす影響, 第58回日本人工臓器学会大会, 2020年11月.
31.	大山永治, 立石義憲, 酒巻奨, 白井昭博, 中川忠彦, 曽我部正弘, 岡久稔也, 寺西研二 : 放電プラズマを照射した生理食塩水が血液の溶血と凝固に及ぼす影響, 第58回日本人工臓器学会大会, 2020年11月.
32.	佐藤翔平, 緒方良輔, 坂東直紀, 小松崇俊, 小林誠司, 大西芳明, 田中克哉, 福原正史, 中川忠彦, 井形直紀, 田中久美子, 友成哲, 高山哲治, 曽我部正弘, 岡久稔也 : 胸腹水濾過濃縮時のM-CARTによる濃縮倍率の自動調整., 第41回日本アフェレシス学会学術大会, 2020年10月.
33.	横山怜子, 中村文香, 佐藤康史, 岸和弘, 和田浩典, 友成哲, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 : 胃癌におけるICI治療の効果予測因子としてのirAEの意義とその後治療への影響., 第58回日本癌治療学会学術集会, 2020年10月.
34.	原口雅宣, 北田貴弘, 永瀬雅夫, 安井武史, 木内陽介, 宮脇克行, 髙橋章, 岡久稔也 : 2019年度におけるLEDライフイノベーション総合プラットフォーム推進事業の取り組み, LED総合フォーラム2020in徳島, 75-76, 2020年2月. (キーワード) LEDライフイノベーション / LED / テラヘルツ
35.	岡久稔也, 曽我部正弘, 高山哲治 : 腹水濾過濃縮再静注法(CART)に関する全国アンケート調査, 第39回日本アフェレシス学会学術大会, 2019年10月.
36.	立石義憲, 酒巻奨, 大山永治, 寺西研二, 下村直行, 岡久稔也 : 豚の血漿への誘電体バリア放電照射実験, 令和元年度電気関係学会四国支部連合大会講演論文集, 42, 2019年9月.
37.	末内辰尚, 岡久稔也, 高山哲治 : 過敏性腸症候群患者に対するアロマ療法施行時の腸蠕動音解析., 第105回日本消化器病学会総会, 2019年5月.
38.	坂東紀子, 近藤真代, 河野弘, 藤野泰輝, 岡久稔也, 豊田優子, 軒原浩, 吾妻雅彦, 後東久嗣, 高山哲治, 西岡安彦 : 潰瘍性大腸炎加療中に発症し，治療に難渋したニューモシスチス肺炎の一例, 第60回日本呼吸器学会中国・四国地方会, 2018年12月.
39.	水谷太郎, 西岡潤司, 井形直紀, 岩佐一秀, 本多哲也, 川口智之, 三井康裕, 三好人正, 末内辰尚, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治, 曽我部正弘, 岡久稔也 : 携帯型小型腸音図システムの試作による腸蠕動音測定時間の最適化., 第56回日本人工臓器学会大会, 2018年11月.
40.	本多哲也, 岩佐一秀, 井形直紀, 水谷太郎, 西岡潤司, 野田和克, 宮城愛, 山本加奈子, 新居徹, 津保友香, 福家慧, 武原正典, 寺前智史, 藤野泰輝, 宮本弘志, 六車直樹, 高山哲治, 曽我部正弘, 岡久稔也 : 潰瘍性大腸炎における内視鏡画像解析による腫瘍の診断., 第56回日本人工臓器学会大会, 2018年11月.
41.	岩佐一秀, 井形直紀, 本多哲也, 水谷太郎, 西岡潤司, 曽我部正弘, 岡久稔也, 大櫛聖子, 高岡慶史, 岡田泰行, 宮本佳彦, 田中久美子, 中村文香, 宮城愛, 香川美和子, 北村晋志, 北村晋志, 岡本耕一, 高山哲治 : 潰瘍性大腸炎での内視鏡画像解析による大腸粘膜の炎症評価., 第56回日本人工臓器学会大会, 2018年11月.
42.	井形直紀, 岩佐一秀, 西岡潤司, 本多哲也, 野田和克, 高岡慶史, 末内辰尚, 香川美和子, 友成哲, 北村晋志, 六車直樹, 高山哲治, 曽我部正弘, 岡久稔也 : 腹水濾過濃縮再静注法(CART)の濾過濃縮処理による腹水中物質の濃度変化., 第56回日本人工臓器学会大会, 2018年11月.
43.	西岡潤司, 水谷太郎, 井形直紀, 岩佐一秀, 本多哲也, 野田和克, 高岡慶史, 末内辰尚, 香川美和子, 友成哲, 北村晋志, 六車直樹, 高山哲治, 曽我部正弘, 岡久稔也 : Multiple Point Bowel-sound Analysis System(MPBAS)の試作による腸蠕動音測定部位の最適化, 第56回日本人工臓器学会大会, 2018年11月.
44.	岡久稔也, 曽我部正弘, 高山哲治 : 腹水濾過濃縮再静注法(CART)に関する全国アンケート調査., 第39回日本アフェレシス学会学術大会, 2018年10月.
45.	大井文香, 原口雅宣, 木内陽介, 中川忠彦, 玉井瑠人, 岡本耕一, 高山哲治, 曽我部正弘, 岡久稔也, 芥川正武, 榎本崇宏 : 小動物体外循環血液光照射実験法の作成と照射影響の探索, 生体医工学, Vol.annual 56, 171, 2018年6月. (要約) <p>徳島大学ライフオプティクス研究プロジェクトでは学内外の研究者の様々なアプローチによる光と生命に関する研究を進めている．著者らは治療抵抗性のT細胞リンパ種の患者の血液に光照射を行う治療法に着目し機器の小型化，光照射による血液への影響のメカニズムの解明，等に繋がることを目指しラットに対し体外循環血液に光を照射した際の影響を調べる研究を行った．実験ではSDラットに対し麻酔下で血液を体外に導出し返還する循環回路に波長の異なるLight Emitting Diode (LED)光を照射する実験システムを作りその影響を追跡した．LED素子は365nm(UVA光)，465nm(青色光)，525nm(青緑色光)のピーク波長をもつ3種を用いた．対照実験として無照射状態で血液の体外循環実験を行う群を設け365nm，465nm，525 nm の各波長毎に照射群を設定した．影響の指標として各実験の体外循環・光照射実験前後の血液検査値，白血球分画，各実験群間の実験後の生存率を比較した．今回は無照射群7例，465nm (電流量40mAでの照射群9例と 400mAでの照射群11例)，365nm (400mA)の照射群3例，525nm (400mA)2例の実験結果を得た．統計的解析ではRによるWilcoxonのT検定(P<0.05の時有意差有)を行った．各群の体外循環・光照射実験の前後の値を比較したところ，いずれの群にも有意差は見られなかった．また各群間の血液検査値の増減率に注目したところ照射波長に特有な影響があることが推測された．</p> (キーワード) 体外循環血液 / T細胞リンパ種 / LED / UVA光 / 青色光 / 青緑色光 (出版サイトへのリンク) ● Publication site (DOI): 10.11239/jsmbe.Annual56.S171 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390001288070721536 ● Search Scopus @ Elsevier (DOI): 10.11239/jsmbe.Annual56.S171 (DOI: 10.11239/jsmbe.Annual56.S171, CiNii: 1390001288070721536)
46.	末内辰尚, 岡久稔也, 高山哲治 : 健診時の腸蠕動音解析による過敏性腸症候群の診断., 第104回日本消化器病学会総会, 2018年4月.
47.	藤野泰輝, 野田和克, 村山典聡, 田中久美子, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 六車直樹, 岡久稔也, 高山哲治, 久保宜明, 坂東良美, 岡村誠介 : 胃巨大ポリープから出血をきたしたCowden病の一例., 第4回消化管ポリポーシス研究会(日本消化器病学会関連研究会), 2018年1月.
48.	岡田泰行, 福家慧, 郷司敬洋, 岡本耕一, 宮本弘志, 六車直樹, 岡久稔也, 辻靖, 高山哲治 : 大腸癌における抗 EGFR 抗体薬による EGFR の lysosome への誘導と治療効果との関連について., 第15回日本臨床腫瘍学会学術集会, 2017年7月.
49.	石村明美, 石村ゆかり, 濱田信一, 増矢幸子, 谷洋江, 岡久玲子, 曽我部正弘, 岡久稔也 : 人間ドック受診者のもつストレングスと主観的健康管理能力，生活習慣との関連, 日本医療マネジメント学会雑誌, Vol.18, 291, 2017年7月.
50.	末内辰尚, 岡久稔也, 高山哲治 : ストレス負荷時の腸蠕動音解析による過敏性腸症候群の診断, 第103回日本消化器病学会総会, 2017年4月.
51.	宇山真由, 曽我部正弘, 平田光里, 中川忠彦, 福家慧, 寺前智史, 藤本大策, 田中宏典, 三井康裕, 北村晋志, 岡本耕一, 高山哲治, 下畑隆明, 上番増喬, 馬渡一諭, 髙橋章, 榎本崇宏, 芥川正武, 片島るみ, 岡久稔也 : 模擬腹水による胸腹水濾過濃縮再静注法の教育体制の構築, 第37回日本アフェレシス学会学術大会, 2016年11月.
52.	宇山真由, 曽我部正弘, 岡久稔也, 平田光里, 中川忠彦, 村山典聡, 武原正典, 松本友里, 岡崎潤, 高岡慶史, 藤野泰輝, 香川美和子, 田中貴大, 友成哲, 谷口達哉, 郷司敬洋, 木村哲夫, 宮本弘志, 六車直樹, 高山哲治 : 胸腹水濾過濃縮再静注法の施行状況と今後の課題, 第37会日本アフェレシス学会学術大会, 2016年11月.
53.	玉井瑠人, 笠井嘉人, 田中大基, 谷直也, 平田光里, 中川忠彦, 友成哲, 谷口達哉, 岡本耕一, 宮本弘志, 高山哲治, 榎本崇宏, 芥川正武, 下畑隆明, 上番増喬, 馬渡一諭, 髙橋章, 宇山真由, 曽我部正弘, 岡久稔也 : 胸腹水濾過濃縮再静注法のクロスフロー方式の腹水濾過時の物理的刺激が腹水に及ぼす影響に関する実験的検討., 第54回日本人工臓器学会大会, 2016年11月.
54.	笠井嘉人, 玉井瑠人, 谷直也, 田中大基, 末内辰尚, 高岡慶史, 香川美和子, 中川忠彦, 北村晋志, 木村哲夫, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治, 宇山真由, 曽我部正弘, 岡久稔也 : 携帯型腸蠕動音収集解析システムの試作開発., 第54回日本人工臓器学会大会, 2016年11月.
55.	松本早代, 岡本耕一, 六車直樹, 中川忠彦, 関崚太, 武原正典, 影本開三, 高岡慶史, 岡崎潤, 藤本大策, 木村哲夫, 北村晋志, 宮本弘志, 岡久稔也, 高山哲治 : 10mm以下の直腸カルチノイド(NET-G1)に対する内視鏡的治療の有用性の検討., 第54回日本癌治療学会学術集会, 2016年10月.
56.	中川忠彦, 木村哲夫, 岡本耕一, 曽我部正弘, 宮本弘志, 坂東良美, 六車直樹, 岡久稔也, 高山哲治 : ヒストン脱メチル化酵素JMJD2Aは切除不能進行胃癌における新しい治療効果予測因子である., 第75回日本癌学会学術総会, 2016年10月.
57.	宇山真由, 曽我部正弘, 平田光里, 中川忠彦, 高岡慶史, 谷口達哉, 高山哲治, 榎本崇宏, 芥川正武, 下畑隆明, 上番増喬, 馬渡一諭, 髙橋章, 岡久稔也 : 胸腹水濾過濃縮再静注法の手技習得のための輸液製剤を用いた模擬腹水の作成, 第43回日本血液浄化技術学会学術大会, 2016年5月. (キーワード) 胸腹水濾過濃縮再静注法
58.	松岡史倫, 榎本崇宏, Abeyratne R. Udantha, 岡久稔也, 曽我部正弘, 芥川正武, 小中信典, 木内陽介 : Estimating the bowel sound source from bowel sounds acquired by the electronic stethoscopes, 第55回日本生体医工学会大会 2016, 2016年4月.
59.	合嶋裕樹, 榎本崇宏, 岡久稔也, Abeyratne R. Udantha, 曽我部正弘, 芥川正武, 小中信典, 木内陽介 : 腹鳴による過敏性腸症候群の腸活動評価, 第55回日本生体医工学会大会 2016, 2016年4月.
60.	原田路可, 森玲子, 鈴木察子, 久米博子, 木田菊恵, 宇山真由, 曽我部正弘, 岡久稔也 : 療養環境改善を目指したベッドサイド用伸縮椅子型ベッドの試作開発, 第18回日本医療マネジメント学会学術総会, 2016年4月.
61.	宇山真由, 曽我部正弘, 岡久稔也 : 徳島県における胸腹水濾過濃縮再静注法(CART)の普及に向けた取り組み, 第18回日本医療マネジメント学会学術総会, 2016年4月. (キーワード) 胸腹水濾過濃縮再静注法
62.	香川美和子, 岡久稔也, 高山哲治 : 潰瘍性大腸炎におけるThymidine Phosphorylase発現とその特異的阻害剤による抗炎症発癌予防効果, 第102回日本消化器病学会総会, 2016年4月.
63.	末内辰尚, 岡久稔也, 高山哲治 : 腸蠕動音解析による過敏性腸症候群の診断と病態評価, 第102回日本消化器病学会総会, 2016年4月.
64.	末内辰尚, 曽我部正弘, 岡久稔也, 榎本崇宏, 高山哲治 : 計算ストレス負荷試験時の腸蠕動音解析による過敏性腸症候群の診断, 第12回日本消化管学会総会学術集会, 2016年2月.
65.	松本早代, 岡本耕一, 六車直樹, 野口拓樹, 中川忠彦, 武原正典, 影本開三, 宮本佳彦, 高岡慶史, 岡崎潤, 岡田泰行, 藤野泰輝, 田中久美子, 香川美和子, 木村哲夫, 北村晋志, 宮本弘志, 岡久稔也, 高山哲治 : 10mm以下の直腸カルチノイド(NET-G1)に対する内視鏡的治療の有用性の検討, 第12回日本消化管学会総会学術集会, 2016年2月.
66.	谷直也, 田中大基, 末内辰尚, 高岡慶史, 中川忠彦, 高山哲治, 河野正樹, 榎本崇宏, 芥川正武, 木内陽介, 下畑隆明, 上番増喬, 馬渡一諭, 髙橋章, 宇山真由, 曽我部正弘, 岡久稔也 : イノベーション対話ツールを活用した腸蠕動音収集解析システムの開発, 第53回日本人工臓器学会大会, 2015年11月.
67.	田中大基, 谷直也, 武原正典, 田中宏典, 田中貴大, 友成哲, 谷口達哉, 中川忠彦, 高山哲治, 河野正樹, 榎本崇宏, 芥川正武, 木内陽介, 下畑隆明, 上番増喬, 馬渡一諭, 髙橋章, 宇山真由, 曽我部正弘, 岡久稔也 : 模擬腹水を用いた胸腹水濾過濃縮装置の評価・教育システムの構築, 第53回日本人工臓器学会大会, 2015年11月.
68.	武原正典, 宮本弘志, 岡田泰行, 三井康裕, 藤野泰輝, 田中久美子, 木村哲夫, 北村晋志, 岡本耕一, 仁木美也子, 木村雅子, 六車直樹, 岡久稔也, 坂東良美, 高山哲治 : 化学療法により長期生存が得られた脾臓原発血管肉腫の一例, 第53回日本癌治療学会学術集会, 2015年10月.
69.	中川忠彦, 曽我部正弘, 岡崎潤, 松本早代, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治, 榎本崇宏, 芥川正武, 岡久稔也 : 腹水濾過濃縮再静注法の濾過工程の物理刺激が腹水中サイトカイン濃度に及ぼす影響第2報:培養癌細胞を用いた検討, 第36回日本アフェレシス学会学術総会, 2015年10月.
70.	河野正樹, 榎本崇宏, 芥川正武, 宇山真由, 曽我部正弘, 中川忠彦, 高山哲治, 下畑隆明, 上番増喬, 馬渡一諭, 髙橋章, 村島徹, 出口喜宏, 荒巻広至, 岡久稔也 : 腹水濾過濃縮法(CART)用装置の現状と今後, 第36回日本アフェレシス学会学術総会, 2015年10月.
71.	駒井啓子, 曽我部正弘, 宇山真由, 岡田泰行, 宮本佳彦, 田中宏典, 田中久美子, 中川忠彦, 高山哲治, 立木弥生, 田中善二, 山路諭, 福光秀之, 岡久稔也 : 腹水濾過濃縮再静注法(CART)についての文献報告の推移, 第36回日本アフェレシス学会学術大会, 2015年10月.
72.	宇山真由, 曽我部正弘, 岡久稔也, 中川忠彦, 武原正典, 高岡慶史, 香川美和子, 田中貴大, 友成哲, 谷口達哉, 木村哲夫, 高山哲治 : 徳島県における胸腹水濾過濃縮療法(CART)の現状と課題, 第36回日本アフェレシス学会学術大会, 2015年10月.
73.	中川忠彦, 北村晋志, 岡田泰行, 谷口達哉, 田中貴大, 木村哲夫, 岡本耕一, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 : ヒストン脱メチル化酵素 JMJD2A は切除不能胃癌に対する化学療法の新しい治療効果予測因子である, 第74回日本癌学会学術総会, 2015年10月.
74.	田中久美子, 六車直樹, 岡崎潤, 岡田泰行, 高岡慶史, 田中宏典, 宮本佳彦, 松本早代, 田中貴大, 藤野泰輝, 香川美和子, 友成哲, 谷口達哉, 北村晋志, 木村哲夫, 岡本耕一, 宮本弘志, 岡久稔也, 石川秀樹, 高山哲治 : 家族性大腸腺腫症における小腸病変の検討 -形態学的，病理組織学的解析を含めて-, 第23回消化器関連学会週間(第57回日本消化器病学会大会), 2015年10月.
75.	岡本耕一, 藤野泰輝, 中川忠彦, 井上篤, 松本早代, 田中久美子, 三宮勝隆, 北村晋志, 六車直樹, 岡久稔也, 高山哲治 : SSA/P-cancer sequenceにおけるACFの前癌病変としての意義―右側大腸癌のバイオマーカーとしてのACF―, がん予防学術大会2015さいたま, 2015年6月.
76.	岡崎潤, 福家慧, 影本開三, 高岡慶史, 宮本佳彦, 岡田泰行, 松本早代, 三井康裕, 末内辰尚, 田中久美子, 藤野泰輝, 高岡遠, 北村晋志, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 : EUS-FNAで確定診断し得た小型退形成性膵管癌の1例., 第89回日本消化器内視鏡学会総会, 2015年5月.
77.	友成哲, 谷口達哉, 曽我部正弘, 影本開三, 岡田泰行, 田中宏典, 田中貴大, 岡久稔也, 高山哲治 : 肝細胞癌に対する球状塞栓物質を用いた肝動脈化学塞栓療法の有用性., 第51回日本肝臓学会総会, 2015年5月.
78.	高岡慶史, 岡久稔也, 岡崎潤, 岡田泰行, 松本早代, 末内辰尚, 三井康裕, 藤野泰輝, 田中久美子, 藤本大策, 木村哲夫, 北村晋志, 宮本弘志, 六車直樹, 河野正樹, 難波和樹, 赤田茂甫規, 榎本崇宏, 高山哲治 : 過敏性腸症候群の客観的診断と病態評価のための腸音図システムの開発, 第101回日本消化器病学会総会, 2015年4月.
79.	藤野泰輝, 松本早代, 佐藤勝哉, 藤本大策, 田中久美子, 末内辰尚, 三井康裕, 木村哲夫, 北村晋志, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 : Serrated polyposis syndromeの前癌病変としての意義―病理所見，発癌，遺伝子異常の解析―, 第101回日本消化器病学会総会, 2015年4月.
80.	藤本大策, 佐藤勝哉, 松本早代, 藤野泰輝, 末内辰尚, 三井康裕, 岡田泰行, 岡崎潤, 宮本佳彦, 高岡慶史, 田中宏典, 北村晋志, 木村哲夫, 宮本弘志, 岡久稔也, 武石俊作, 六車直樹, 高山哲治 : Serrated polyposisの前癌病変としての意義, 第11回日本消化管学会総会学術集会, 2015年2月.
81.	曽我部正弘, 岡久稔也, 高山哲治 : 高齢者メタボリック症候群のNAFLDに対する生活習慣の影響, 第18回日本肝臓学会大会, 2014年10月.
82.	中川忠彦, 片山雅仁, 曽我部正弘, 榎本崇宏, 芥川正武, 木内陽介, 田中久美子, 髙岡遠, 谷口達哉, 高山哲治, 荒巻広至, 山路諭, 田中善二, 岡久稔也 : 腹水濾過濃縮再静注法のローラーポンプとフィルターによる物理的刺激が腹水中サイトカインと補体に及ぼす影響, 第52回日本人工臓器学会大会, 2014年10月.
83.	中川忠彦, 田中宏典, 岡崎潤, 田中久美子, 田中貴大, 髙岡遠, 友成哲, 谷口達哉, 宮本弘志, 高山哲治, 曽我部正弘, 榎本崇宏, 芥川正武, 柴田啓志, 矢野充保, 岸史子, 大喜田義雄, 山路諭, 田中善二, 岡久稔也 : 腹水濾過濃縮再静注法の濾過工程の物理刺激が腹水中サイトカイン濃度に及ぼす影響, 第35回日本アフェレシス学会学術大会, 2014年9月.
84.	河野正樹, 榎本崇宏, 岡久稔也, 曽我部正弘, 芥川正武, 小中信典, 木内陽介 : S状結腸の電気的活動シミュレーション, 電気関係学会四国支部連合大会講演論文集, No.14-3, 231, 2014年9月.
85.	北村晋志, 六車直樹, 松本友里, 松本早代, 岡崎潤, 髙岡遠, 村山典聡, 香川美和子, 藤野泰輝, 三好人正, 中村文香, 大塚加奈子, 宮本弘志, 岡久稔也, 高山哲治 : 内視鏡切除された直腸カルチノイド(NET-G1)の臨床経過に関する検討, 第87回日本消化器内視鏡学会総会, 2014年5月.
86.	宮本佳彦, 六車直樹, 北村晋志, 松本友里, 松本早代, 中村文香, 髙岡遠, 藤野泰輝, 三好人正, 田中久美子, 郷司敬洋, 矢野弘美, 香川美和子, 宮本弘志, 岡久稔也, 高山哲治 : 大腸癌に対する内視鏡分子イメージング技術の開発, 第87回日本消化器内視鏡学会総会, 2014年5月.
87.	北村晋志, 六車直樹, 松本友里, 松本早代, 岡崎潤, 髙岡遠, 香川美和子, 藤野泰輝, 三好人正, 中村文香, 田中久美子, 宮本弘志, 岡久稔也, 高山哲治 : バレット食道癌における欧米と日本のマネジメントの相違に関する検討, 第87回日本消化器内視鏡学会総会, 2014年5月.
88.	田中宏典, 谷口達哉, 高山哲治, 田中貴大, 友成哲, 原田利枝, 佐藤桃子, 三宮勝隆, 宮本弘志, 六車直樹, 岡久稔也 : 高度進行肝細胞癌に対するミリプラチンを用いた放射線併用動注化学療法の有用性, 第100回日本消化器病学会総会, 2014年4月.
89.	藤野泰輝, 大塚加奈子, 田中久美子, 中村文香, 三好人正, 香川美和子, 郷司敬洋, 髙岡遠, 矢野弘美, 北村晋志, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 : Sessile serrated adenoma/polyp(SSA/P)の前病変としてのAberrant crypt foci(ACF)の解析, 第10回日本消化管学会総会学術集会, 2014年2月.
90.	大塚加奈子, 岡久稔也, 高山哲治, 香川美和子, 榎本崇宏 : 腸蠕動音解析による非侵襲的腸運動機能評価に基づく過敏性腸症候群の診断と治療, 第10回日本消化管学会学術集会, 2014年2月.
91.	松本早代, 六車直樹, 松本友里, 岡崎潤, 田中久美子, 中村文香, 藤野泰輝, 三好人正, 香川美和子, 郷司敬洋, 髙岡遠, 村山典聡, 矢野弘美, 北村晋志, 宮本弘志, 岡久稔也, 高山哲治 : 内視鏡治療された直腸カルチノイド(NET-G1)の臨床経過に関する検討, 第80回大腸癌研究会, 2014年1月.
92.	高岡遠, 藤野泰輝, 平尾章博, 宮本佳彦, 岡田泰行, 三井康裕, 田中貴大, 高場梓, 香川美和子, 友成哲, 津田美穂, 谷口達哉, 郷司敬洋, 矢野弘美, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 : SSA/PのLASSEREO Blue LASER Imaging併用拡大内視鏡診断, 第21回日本消化器関連学会週間JDDW2013,第86回日本消化器内視鏡学会総会, 2013年10月.
93.	六車直樹, 宮本佳彦, 藤野泰輝, 高岡遠, 北村晋志, 岡本耕一, 宮本弘志, 岡久稔也, 高山哲治 : 大腸癌における分子イメージング, 第21回日本消化器関連学会週間JDDW2013,第86回日本消化器内視鏡学会総会, 2013年10月.
94.	香川美和子, 岡久稔也, 中川忠彦, 高場梓, 郷司敬洋, 矢野弘美, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 : Thymidine Phosphorylaseを標的とした潰瘍性大腸炎治療薬の開発, 第21回日本消化器関連学会週間JDDW2013,第55回消化器病学会大会, 2013年10月.
95.	赤田茂甫規, 榎本崇宏, 岡久稔也, Abeyratne R. Udantha, 芥川正武, 小中信典, 木内陽介 : ストレス負荷試験時における腸音解析の基礎検討, 電気関係学会四国支部連合大会講演論文集, 244, 2013年9月.
96.	難波和樹, 榎本崇宏, 岡久稔也, Abeyratne R. Udantha, 芥川正武, 小中信典, 木内陽介 : 薬剤投与下における腸音解析の基礎的検討, 電気関係学会四国支部連合大会講演論文集, 248, 2013年9月.
97.	藤野泰輝, 六車直樹, 岡本耕一, 北村晋志, 矢野弘美, 高岡遠, 岡崎潤, 郷司敬洋, 宮本弘志, 岡久稔也, 島田光生, 高山哲治 : 多発性小腸重積を生じたPeutz-Jeghers syndromeの1例, 第19回日本家族性腫瘍学会学術集会, 2013年7月.
98.	三好人正, 宮本弘志, 三井康裕, 郷司敬洋, 矢野弘美, 北村晋志, 岡本耕一, 六車直樹, 岡久稔也, 高山哲治 : DAO活性による抗癌剤投与時の消化管粘膜障害と栄養の関連, 第110回日本内科学会総会・講演会, 2013年4月.
99.	高岡遠, 岡久稔也, 香川美和子, 岡田泰行, 宮本佳彦, 田中貴大, 津田美穂, 友成哲, 郷司敬洋, 矢野弘美, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治, 榎本崇宏 : 腸蠕動音測定による簡便かつ非侵襲的腸運動機能評価法の確立, 第9回日本消化管学会総会学術集会, 2013年1月.
100.	矢野弘美, 岡久稔也, 高山哲治 : 腸電図を用いた非侵襲的大腸運動機能評価法の確立, 第20回日本消化器関連学会週間, 2012年10月.
101.	庄野弘一, 榎本崇宏, 岡久稔也, Abeyratne R. Udantha, 芥川正武, 小中信典, 木内陽介 : フォルマント周波数に基づく腸蠕動音抽出, 電気関係学会四国支部連合大会講演論文集, 264, 2012年9月.
102.	津田美穂, 岡本耕一, 高岡遠, 北村晋志, 三宮勝隆, 青柳えりこ, 梶本真弓美, 六車直樹, 岡久稔也, 高山哲治 : RAS阻害剤における大腸発癌予防効果の検討, 第71回日本癌学会学術総会, 2012年9月.
103.	三井康裕, 藤野泰輝, 三好人正, 郷司敬洋, 竹中英喬, 北村晋志, 木村哲夫, 矢野弘美, 木村雅子, 仁木美也子, 宮本弘志, 岡久稔也, 高山哲治 : Docetaxe投与により過敏反応を呈した切除不能進行胃癌4症例の検討, 第10回臨床腫瘍学会学術集会,大阪,2012.7.26-28, 2012年7月.
104.	北村晋志, 岡村誠介, 木村哲夫, 木村哲夫, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 : シュミレーターを用いたESDトレーニングシステムの試み, 第8回日本消化管学会総会学術集会, 2012年2月.
105.	三好人正, 宮本弘志, 松本早代, 藤野泰輝, 郷司敬洋, 矢野弘美, 北村晋志, 木村哲夫, 岡本耕一, 六車直樹, 岡久稔也, 岡村誠介, 山口想太郎, 中屋豊, 高山哲治 : 消化管癌化学療法における血清Diamine Oxidase(DAO)活性と栄養障害に関する検討, 第8回日本消化管学会総会学術集会, 2012年2月.
106.	郷司敬洋, 木村哲夫, 松本早代, 藤野泰輝, 三好人正, 北村晋志, 矢野弘美, 岡本耕一, 宮本弘志, 仁木美也子, 六車直樹, 岡久稔也, 岡村誠介, 高山哲治 : CPT11+CDDP療法を施行した胃原発神経内分泌癌(NEC)の4例, 第49回日本癌治療学会学術集会, 2011年10月.
107.	北村晋志, 青柳えり子, 郷司敬洋, 木村哲夫, 矢野弘美, 宮本弘志, 六車直樹, 岡久稔也, 岡村誠介, 高山哲治 : DNAマイクロアレイを用いたdocetaxel+cisplatin+S-1併用化学療法の治療効果予測, 第49回日本癌治療学会学術集会, 2011年10月.
108.	小中信典, 神野遼太, 岡久稔也, 芥川正武, 榎本崇宏 : 大腸内視鏡血管画像抽出法の改良, 第34回日本生体医工学会中国四国支部大会講演抄録, Vol.V (24), 50, 2011年10月.
109.	楠本悟史, 榎本崇宏, 岡久稔也, 庄野弘一, Abeyratne R. Udantha, 芥川正武, 小中信典, 木内陽介 : 腸蠕動音解析による薬剤服用前後の腸活動の評価, 電気関係学会四国支部連合大会講演論文集, No.14-12, 241, 2011年9月.
110.	庄野弘一, 榎本崇宏, 岡久稔也, Abeyratne R. Udantha, 楠本悟史, 芥川正武, 小中信典, 木内陽介 : ARMA モデルを活用した腸蠕動音自動抽出, 電気関係学会四国支部連合大会講演論文集, No.14-11, 240, 2011年9月.
111.	小林遼平, 小中信典, 岡久稔也, 木内陽介, 芥川正武, 榎本崇宏 : エッジ抽出と方向性膨張処理による血管抽出の検討, 電気関係学会四国支部連合大会講演論文集, No.13-3, 204, 2011年9月.
112.	近藤将次, 小中信典, 岡久稔也, 木内陽介, 芥川正武, 榎本崇宏 : Laplacian filterを用いたNBI画像からの血管抽出の検討, 電気関係学会四国支部連合大会講演論文集, No.13-2, 203, 2011年9月.
113.	北村晋志, 青柳えりこ, 木村哲夫, 岡本耕一, 木村雅子, 矢野弘美, 宮本弘志, 六車直樹, 岡久稔也, 仁木美也子, 高山哲治 : 進行胃癌に対するdocetaxel+cisplatin+S-1併用化学療法の効果予測因子の開発, 第9回日本臨床腫瘍学会学術集会, 2011年7月.
114.	岡久稔也 : 内視鏡血管画像解析による炎症性腸疾患の最適治療, 第97回日本消化器病学会総会, 2011年5月.
115.	岡久稔也, 梶雅子, 岡本耕一, 岡村誠介, 高山哲治 : 腸電位測定による簡便かつ非侵襲的大腸運動機能評価法の確立, 第7回日本消化管学会総会学術集会,京都, 2011年2月.
116.	曽我部正弘, 山ノ井昭, 岡久稔也 : 内臓脂肪からみたメタボリック症候群該当者の特徴について(肝機能を中心に), 第94回日本消化器病学会,四国支部例会, 2010年12月.
117.	岡久稔也, 木村哲夫, 岡本耕一, 宮本弘志, 岡村誠介, 高山哲治, 神野涼太, 芥川正武, 榎本崇宏, 小中信典 : 炎症性腸疾患に対するアフェレシスを支える次世代内視鏡画像解析システムの開発, 第31回アフェレシス学会学術大会, 2010年11月.
118.	竹内尚, 岡久稔也, 梶雅子, 玉木克佳, 井上篤, 北村晋志, 木村哲夫, 岡本耕一, 岡村誠介, 仁木美也子, 高山哲治 : 放射線性直腸炎の発生機序の解析, 第48回日本癌治療学会学術集会,京都, 2010年10月.
119.	津田美穂, 岡久稔也, 原田利枝, 友成哲, 井上篤, 谷口達哉, 竹中英喬, 仁木美也子, 北村晋志, 木村哲夫, 矢野弘美, 佐藤桃子, 竹内尚, 岡本耕一, 梶雅子 : 潰瘍性大腸炎の寛解期残存炎症に対する血管新生因子の関与-抗体アレイを用いた解析-, 第52回日本消化器病学会大会,横浜, 2010年10月.
120.	近藤将次, 小中信典, 岡久稔也 : Laplacian Filterを用いたNBI画像からの血管抽出法の検討, 電気関係学会四国支部連合大会講演論文集, 152, 2010年9月.
121.	楠本悟史, 榎本崇宏, Abeyratne R. Udantha, 庄野弘一, 芥川正武, 岡久稔也, 木内陽介 : 腸音解析による腸の活動評価, 電気関係学会四国支部連合大会講演論文集, 204, 2010年9月.
122.	神野遼太, 小中信典, 岡久稔也, 芥川正武, 榎本崇宏 : 大腸内視鏡画像における血管抽出ガウス曲線テンプレートの改善, 電気関係学会四国支部連合大会講演論文集, 196, 2010年9月.
123.	Yoshinori Nitta, Masatake Akutagawa, Takahiro Emoto, Toshiya Okahisa, Hiroshi Miyamoto, Shinsuke Konaka, Yoshiaki Ohnishi and Yohsuke Kinouchi : Modeling and simulation about Ht value during LCAP, 第49回日本生体医工学会大会抄録集, No.48, 288, Jun. 2010.
124.	神野遼太, 小中信典, 岡久稔也, 榎本崇宏, 芥川正武 : 潰瘍性大腸炎内視鏡画像からの血管本数抽出の検討, 電子情報通信学会総合大会講演論文集, No.D-7-9, 2010年3月.
125.	新田佳伯, 芥川正武, 榎本崇宏, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 木内陽介 : LCAP施行中における現在と1分後のHt値の解析, 医療の質·安全学会誌, Vol.9, 163, 2009年11月.
126.	神野遼太, 小中信典, 岡久稔也, 榎本崇宏, 芥川正武 : 大腸内視鏡画像のマッチングフィルタを用いた血管抽出方法の検討, 電気関係学会四国支部連合大会講演論文集, No.14-8, 224, 2009年9月.
127.	新田佳伯, 芥川正武, 榎本崇宏, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 木内陽介 : LCAP施行時におけるHt値の解析, 電気関係学会四国支部連合大会講演論文集, 222, 2009年9月.
128.	新田佳伯, 芥川正武, 榎本崇宏, 岡久稔也, 宮本弘志, 大西芳明, 中根俊也, 梶龍兒, 西村匡司, 木内陽介 : SOMを使用した血液浄化療法中における患者体内の水分移動の評価, 第31回日本生体医工学会中四国支部大会講演抄録, 32, 2008年10月.
129.	新田佳伯, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 中根俊成, 梶龍兒, 木内陽介 : 自己組織化を用いたHt 波形のパターン分類の検討, 電気関係学会四国支部連合大会講演論文集, 257, 2008年9月.
130.	嘉村友一, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 中根俊成, 梶龍兒, 木内陽介 : 血漿交換療法時におけるヘマトクリット値の固有値解析, 電気関係学会四国支部連合大会講演論文集, 256, 2008年9月.
131.	新田佳伯, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 中根俊成, 梶龍兒, 木内陽介 : ニューラルネットワークを用いたHt値の予測と信号解析, システム・情報部門学術講演会2007講演論文集, 141-146, 2007年11月.
132.	嘉村友一, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 中根俊成, 梶龍兒, 木内陽介 : 血漿交換療法時におけるヘマトクリット値の解析, 電気関係学会四国支部連合大会講演論文集, 226, 2007年9月.
133.	新田佳伯, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 中根俊成, 梶龍兒, 木内陽介 : 血液浄化療法時における1分後のHt値の解析, 電気関係学会四国支部連合大会講演論文集, 225, 2007年9月.
134.	新田佳伯, 芥川正武, 宮本弘志, 岡久稔也, 大西芳明, 大藤純, 伊東進, 西村匡司, 木内陽介 : 人工ニューラルネットワークを用いたCHF施行時におけるHt値の予測, 日本集中治療医学会雑誌, Vol.13, 306, 2006年3月.
135.	新田佳伯, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 木内陽介 : 移動平均型ニューラルネットワークを用いたCHF施行時におけるHt値の予測, 日本生体医工学会中四国支部大会, 2005年10月.
136.	新田佳伯, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 木内陽介 : 血液浄化時におけるHt値予測精度向上, --- BPNN構造の検討 ---, 電気関係学会四国支部連合大会講演論文集, 224, 2005年9月.
137.	村上昭継, 岡久稔也, 宮本弘志, 伊東進, 大西芳明, 大藤純, 西村匡司, 新田佳伯, 芥川正武, 木内陽介 : 高速フーリエ変換を用いた血液浄化フィルタの目詰まり評価システムの開発, 第32回日本集中治療医学会学術集会プログラム・抄録集, Vol.12, 312, 2005年2月.
138.	新田佳伯, 木内陽介, 芥川正武, 岡久稔也, 宮本弘志, 居和城宏, 大西芳明, 大藤純, 西村匡司 : 白血球除去療法施行中のヘマトクリット値の予測, --- 人工ニューラルネットワークの最適化と予測時点の延長 ---, 第32回日本集中治療医学会学術集会プログラム・抄録集, Vol.12, 309, 2005年2月.
139.	山本芳郎, 岡本英治, 牧野勤, 田中秀治, 野口千加哉, 篠原聡之, 佐藤耕司郎, 小川大祐, 山本丈人, 田中明, Stephen R. Igo, 尾田毅, 岡久稔也, 大久保尚, 本村禎, Yukihiko Nosé : 臨床応用に向けた体内埋め込み型人工心臓システムの開発∼経皮的エネルギー伝送システムの開発状況∼, 人工心臓と補助循環懇話会, 2005年1月.
140.	松村晃子, 橋本理恵, 宇野和美, 佐賀啓子, 国清紀子, 山田静恵, 高橋保子, 岡久稔也, 吉本勝彦, 中屋豊 : (シンポジウム) NST導入により何がかわったか: NSTによる頭頸部悪性腫瘍患者の栄養管理, 第7回日本病態栄養学会年次学術集会, 2004年1月.
141.	井上和俊, 芥川正武, 長篠博文, 木内陽介, 居和城宏, 岡久稔也, 村田昌彦, 大西芳明, 黒田泰弘, 阿部正, 大下修造 : 血圧情報を統合したCRIT-LINE(TM)情報システムの開発, ICUとCCU, Vol.27, No.Suppl., S89-S90, 2003年3月.
142.	井上和俊, 芥川正武, 長篠博文, 木内陽介, 居和城宏, 岡久稔也, 村田昌彦, 大西芳明, 阿部正, 黒田泰弘, 大下修造 : 血圧情報を統合したCRIT-LINE(TM)モニタリングシステムの開発, 電気関係学会四国支部連合大会講演論文集, 257, 2002年10月.
143.	井上和俊, 芥川正武, 長篠博文, 木内陽介, 居和城宏, 岡久稔也, 大西芳明, 黒田泰弘, 阿部正, 大下修造 : 連続的ヘマトクリットモニタ情報システムの開発, 日本集中治療医学会雑誌, Vol.9, No.Suppl., 220, 2002年1月.
144.	清水一郎, 野村昌弘, 岡久稔也 : 高齢者消化器がん検診時の循環動態モニタリングの重要性，(パネルディスカッション), 第64回日本消化器内視鏡学会総会, 2002年.
145.	井上和俊, 芥川正武, 長篠博文, 木内陽介, 居和城宏, 岡久稔也, 大西芳明, 阿部正, 黒田泰弘, 大下修造 : 急性血液浄化における連続的ヘマトクリットモニタ情報の表示システム, 電気関係学会四国支部連合大会講演論文集, 269, 2001年9月.
146.	伊賀彰子, 野村昌弘, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進, 和田哲 : 21世紀の高齢化社会に対応する消化器病診断·治療手技，(合同シンポジウム)高齢者における消化器内視鏡検査時の循環動態の検討, 第76回日本消化器病学会四国支部例会, 2001年.

その他・研究会:

1.	原口雅宣, 永瀬雅夫, 安井武史, 木内陽介, 宮脇克行, 髙橋章, 岡久稔也 : 2021年度におけるLEDライフイノベーション総合プラットフォーム推進事業の取り組み, LED総合フォーラム2022 in 徳島, P-1, 2022年1月.
2.	原口雅宣, 北田貴弘, 永瀬雅夫, 安井武史, 木内陽介, 宮脇克行, 髙橋章, 岡久稔也 : 2020年度におけるLEDライフイノベーション総合プラットフォーム推進事業の取り組み, LED総合フォーラム2021 in 徳島, P-1, 2021年2月.
3.	木内陽介, 原口雅宣, 髙橋章, 岡久稔也 : 徳島大学ライフオプティクス研究プロジェクト, LED総合フォーラム2020in徳島, 73-74, 2020年2月. (キーワード) ライフオプティクス / LED / LEDバレイ徳島
4.	原口雅宣, 北田貴弘, 永瀬雅夫, 安井武史, 木内陽介, 宮脇克行, 髙橋章, 岡久稔也 : LEDライフイノベーション総合プラットフォーム推進事業の取り組み, LED総合フォーラム2019in徳島, P-2, 2019年2月.
5.	木内陽介, 原口雅宣, 髙橋章, 岡久稔也 : 徳島大学ライフオプティクス研究プロジェクトの進展, LED総合フォーラム2019in徳島, P-1, 2019年2月.
6.	原口雅宣, 北田貴弘, 永瀬雅夫, 安井武史, 木内陽介, 宮脇克行, 髙橋章, 岡久稔也 : LEDライフイノベーション総合プラットフォーム推進事業におけるテラヘルツLED応用基盤技術に関する取り組み, LED総合フォーラム2018in徳島, P-2, 2018年2月.
7.	大井文香, 中川忠彦, 岡本耕一, 高山哲治, 曽我部正弘, 岡久稔也, 芥川正武, 榎本崇宏, 木内陽介 : LED光を用いた体外循環照射モデルの構築, 電子情報通信学会技術研究報告(MEとバイオサイバネティックス), Vol.117, No.165, 17-20, 2017年7月. (キーワード) 発光ダイオード (LED) / 体外循環 / 動物実験 / ラット (rat) / 医工学
8.	原口雅宣, 木内陽介, 北田貴弘, 永瀬雅夫, 安井武史, 宮脇克行, 髙橋章, 岡久稔也 : LEDライフイノベーション総合プラットフォーム推進事業におけるテラヘルツLED応用基盤技術に関する取り組み, LED総合フォーラム2016in徳島論文集, 201-202, 2016年12月.
9.	楠本悟史, 榎本崇宏, 岡久稔也, 庄野弘一, Abeyratne R. Udantha, 芥川正武, 小中信典, 木内陽介 : 腸蠕動音解析による薬剤投与前後の腸活動評価, 電子情報通信学会技術研究報告，MEとバイオサイバネティックス研究会, Vol.111, No.121, 37-39, 2011年7月. (要約) 過敏性腸症候群(Irritable Bowel Syndrome : IBS)は腸の活動が活発になり下痢を引き起こすことが知られている．現在，確定診断のためには大腸内視鏡検査が必要であるが，患者にとっては苦痛を伴う．腸蠕動音(Bowel sound : BS)は腸活動の変化に応じて変化することが予想される．そこで，本研究では電子聴診器を用いて測定したBSから腸活動が評価できるかどうかを検討する．腸蠕動音促進剤服用前後において，BSの基本周波数と腸活動との関係が比較検討される． (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1520572357308622720 (CiNii: 1520572357308622720)
10.	神野遼太, 小中信典, 岡久稔也, 芥川正武, 榎本崇宏 : 大腸内視鏡画像からの血管パラメータ抽出, 電子情報通信学会技術研究報告，MEとバイオサイバネティックス研究会 MBE2010-17, Vol.110, No.120, 7-11, 2010年7月.
11.	神野遼太, 小中信典, 岡久稔也, 榎本崇宏, 芥川正武 : 大腸内視鏡画像からの血管抽出の一検討, 電子情報通信学会技術研究報告，MEとバイオサイバネティックス研究会 MBE2009-22, Vol.109, No.123, 17-20, 2009年7月.
12.	新田佳伯, 芥川正武, 岡久稔也, 宮本弘志, 大西芳明, 西村匡司, 木内陽介 : ニューラルネットワークを用いた変動するHt値の近未来予測, --- 1分後，3分後，5分後 ---, 電子情報通信学会技術研究報告, Vol.105, No.222, 41-44, 2005年7月.
13.	新田佳伯, 岡久稔也, 芥川正武, 宮本弘志, 大西芳明, 木内陽介, 西村匡司, 伊東進 : BPNNを用いた血液浄化施行時のヘマトクリット値の予測, 電子情報通信学会技術研究報告, Vol.104, No.179, 37-40, 2004年7月.
14.	Hiroshi Miyamoto, Toshiya Okahisa, Hiroshi Iwaki, Masaharu Suzuki, Susumu Ito, Yoshiaki Ohnishi, Jun Oto, Yasuhiro Kuroda, Shuzo Oshita, Yoshinori Nitta, Yohsuke Kinouchi and Masatake Akutagawa : Variation of the hematocrit value during leukocytapheresis therapy., Ther Apher&Dial(Therapeutic Apheresis and Dialysis), Vol.7, No.5, A5, Oct. 2003.
15.	Toshiya Okahisa, Hiroshi Iwaki, Hiroshi Miyamoto, Masahiro Sogabe, Susumu Ito, Yoshiaki Ohnishi, Jun Oto, Yasuhiro Kuroda, Shuzo Oshita, Yoshinori Nitta, Yohsuke Kinouchi and Masatake Akutagawa : Monitoring filter clogging by analyzing the conductive condition of the roller pump flow pressure wave., Ther Apher&Dial(Therapeutic Apheresis and Dialysis), Vol.7, No.5, A9, Oct. 2003.
16.	上村英子, 野村昌弘, 澤優子, 伊賀彰子, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進, 矢野充保 : 上部消化器内視鏡検査における循環動態への影響:脈波伝播速度との関連性, 第65回日本消化器内視鏡学会総会, 2003年5月. (要約) 上部消化器内視鏡検査中の循環動態とPWVとの関連性を検討し，年齢よりもPWVによる動脈硬化の診断が，検査中の循環動態の変動の予測因子である．
17.	上原康三, 野村昌弘, 上村英子, 澤優子, 伊賀彰子, 原田顕治, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 西角彰良, 清水一郎, 伊東進, 矢野充保 : 脈波伝播速度と上部内視鏡検査中の循環動態との関連性, 第5回日本高齢消化器医学会, 2003年1月. (要約) 上部消化器内視鏡検査中の循環動態とPWVとの関連性を検討し，年齢よりもPWVによる動脈硬化の診断が，検査中の循環動態の変動の予測因子である．
18.	井上和俊, 芥川正武, 長篠博文, 木内陽介, 村田昌彦, 居和城宏, 岡久稔也, 大西芳明, 阿部正, 黒田泰弘, 大下修造 : 連続的ヘマトクリットモニタ情報システムの開発, 第18回徳島急性血液浄化研究会, 2002年11月.
19.	伊賀彰子, 野村昌弘, 和田哲, 宮本弘志, 久次米佐映, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 : 消化器内視鏡下総胆管処置中の循環動態の検討, 第63回日本消化器内視鏡学会総会, 2002年4月. (要約) 内視鏡下総胆管処置中は自律神経活動のアンバランスとQT dispersionの増大がみられ，この自律神経活動が引き金となり偶発症へ進展する可能性が示唆された．
20.	野村昌弘, 伊賀彰子, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 清水一郎, 伊東進 : 亜硝酸薬投与による胃運動および自律神経活動の反応:胃電図および血圧·心拍変動スペクトル解析による検討, 日本消化器病学会大会, 2001年10月. (要約) 亜硝酸薬は，食後の胃運動機能の低下および副交感神経活動の低下および交感神経の増加をきたし，自律神経活動の点からも消化管運動を抑制する．
21.	野村昌弘, 森下智文, 名田智美, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 : エパルレスタットの糖尿病性胃運動機能障害への効果:胃電図および心拍変動解析による評価, 第87回日本消化器病学会総会, 2001年4月. (要約) エパルレスタットは糖尿病性胃麻痺への詳細な効果は報告されてない．本薬剤により胃電図の3cpm波の増大および自律神経の改善がみられた．
22.	野村昌弘, 名田智美, 加藤寛正, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進, 多田由恵, 矢野充保 : 上部消化管内視鏡検査により不整脈の発生素地は形成されるか?心電図QTc dispersionによる検討, 第42回日本消化器病学会大会, 2000年10月. (要約) 上部消化管内視鏡検査中の心電図QTc dispersionの変動を測定した．内視鏡中，特に十二指腸挿入中にその変動が大きく，不整脈の発生素地は形成される．
23.	加藤寛正, 野村昌弘, 名田智美, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 : 慢性消化性潰瘍におけるH. pylori除菌前後の自律神経機能の検討, 第42回日本消化器病学会大会, 2000年10月. (要約) 消化性潰瘍の発生にはH. pyloriが重要であるが，除菌後も交感·副交感神経亢進が残存しており，潰瘍形成には自律神経異常も関与している．
24.	野村昌弘, 宮島等, 名田智美, 森下智文, 木下桂午, 多田由恵, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進, 中屋豊 : 老年者における上部消化管内視鏡検査中の自律神経活動およびQTc dispersionの変動, 第25回老年消化器病研究討論会, 2000年6月. (要約) 老年者の上部消化管内視鏡検査中には副交感神経の抑制およびQTc dispersionの増大が壮年者より大きく老年者の検査中は循環動態に注意すべきである．
25.	宮島等, 野村昌弘, 名田智美, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 : 老年者における上部消化管内視鏡検査中の心電図QT dispersionの推移, 第42回日本老年医学会, 2000年6月. (要約) 老年者の上部消化管内視鏡検査中に12誘導心電図を連続記録してQT dispersionを検討した．12指腸検査中は，著明に延長して不整脈に注意すべきである．
26.	宮島等, 野村昌弘, 名田智美, 近藤幸, 多田由恵, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進, 原田雅史, 西谷弘, 中屋豊 : 肝硬変症における胃運動機能の検討:食道静脈瘤と門脈血流との関連性について, 第2回国際消化管運動研究会, 2000年4月. (要約) 肝硬変症では，摂食による門脈血流量の増加率の減少がみられ，摂食による胃運動機能低下の成因の一つとして門脈血流異常が考えられた．
27.	宮島等, 野村昌弘, 名田智美, 多田由恵, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 : 胃運動は食道静脈瘤の有無により影響をうけるのか?胃電図による検討, 第86回日本消化器病学会総会, 2000年4月. (要約) 食道静脈瘤のある肝硬変例では，門脈血流量が低下して，側副血行が増加しているため，胃電図で観察した胃運動の低下がみられた．
28.	宮島等, 野村昌弘, 近藤幸, 名田智美, 多田由恵, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進, 山口康男, 原田雅史 : 肝硬変症における胃運動機能の検討:自律神経機能および門脈血流量との関連性について, DDW-Japan 1999, 1999年10月. (要約) 門脈MRA，胃電図および心拍変動解析で検討した．肝硬変では，交感神経活動と門脈血流の低下による側副血流の増加により胃運動が低下すると思われた．
29.	川口律子, 野村昌弘, 宮島等, 名田智美, 多田由恵, 六車直樹, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 : 胃電図および心拍変動解析を用いた高齢者の食後低血圧の検討:若年者との比較, DDW-Japan 1999, 1999年10月. (要約) 食後低血圧の発生機序を胃電図により検討した．老年者では若年者よりも胃運動が低下していたが，自律神経の変動に対応できないため低血圧がおこる．
30.	多田由恵, 野村昌弘, 多田津昌也, 日下至弘, 大喜田義雄, 筒井朱美, 六車直樹, 岡久稔也, 岡村誠介, 齋藤憲, 伊東進 : 内視鏡的逆行性胆管膵管造影検査施行時における自律神経活動, 第57回日本消化器内視鏡学会総会, 1999年5月. (要約) 内視鏡的逆行性胆管膵管造影検査施行時において，胆道内圧の亢進による副交感神経の抑制がみられ，循環動態の変動がみられやすいと考えられた．
31.	名田智美, 近藤幸, 野村昌弘, 矢野充保, 由岐中道子, 多田由恵, 齋藤憲, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 : 慢性消化性潰瘍における心拍変動1/fゆらぎ解析:自律神経機能異常も潰瘍形成に必要か?, 第57回日本消化器内視鏡学会総会, 1999年5月. (要約) 消化性潰瘍では，1/fゆらぎ解析では1/f2ゆらぎとなり，自律神経異常がみられた．H. Pylori感染例でも潰瘍形成ない場合があり，自律神経異常も必要と思われた．
32.	由岐中道子, 野村昌弘, 近藤幸, 名田智美, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 : 肝硬変症における門脈血流波形および門脈血流量の検討:MR angiography (MRA)による検討, 第85回日本消化器病学会総会, 1999年4月. (要約) 肝硬変症における門脈血流波形および血流量をMRAにて測定した．門脈血流量は健常例に比して減少して，逆流波形もみられる症例があった．
33.	近藤幸, 野村昌弘, 由岐中道子, 名田智美, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 : 上部消化管内視鏡検査中における自律神経活動の検討-血圧変動スペクトル1/fゆらぎの変動, 第56回日本消化器内視鏡学会総会, 1998年11月. (要約) 上部消化管内視鏡検査中の自律神経活動を血圧変動スペクトル1/fゆらぎの変動で検討した．副交感神経の低下と1/f2ゆらぎがみられた．
34.	由岐中道子, 野村昌弘, 近藤幸, 名田智美, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 : 高血圧合併消化性潰瘍に自律神経機能異常は存在するのか?:Helicobacter pylori感染との関連性について, 第56回日本消化器内視鏡学会総会, 1998年11月. (要約) 高血圧症では潰瘍が少ないが，高血圧合併消化性潰瘍では，副交感神経が亢進してHelicobacter pylori感染と相まって，潰瘍形成すると思われた．
35.	近藤幸, 野村昌弘, 由岐中道子, 名田智美, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 : 肝硬変症において心臓交感神経機能異常の評価は可能か?, 第40回日本消化器病学会大会, 1998年10月. (要約) 肝硬変症ではNO産生の亢進により反射性のhyperdynamic状態が起こる．心拍変動解析とMIBG心臓シンチでは鋭敏に交感神経機能異常を捉えられた．
36.	由岐中道子, 野村昌弘, 近藤幸, 名田智美, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進 : インターフェロン療法における心筋障害は123I-BMIPP心筋シンチグラフィーで検出可能か?, 第40回日本消化器病学会大会, 1998年10月. (要約) C型慢性肝炎におけるインターフェロン療法における心筋障害は，心電図に先立って，123I-BMIPP心筋シンチグラフィーで検出可能であった．
37.	野村昌弘, 名田智美, 近藤幸, 由岐中道子, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 齋藤憲, 伊東進, 中屋豊 : 慢性消化性潰瘍形成において自律神経機能異常は必要条件か?心拍変動1/fゆらぎおよびHelicobactor pyroliとの関連性, 第15回四国消化性潰瘍研究会, 1998年5月. (要約) 慢性消化性潰瘍形成で自律神経異常は必要条件か検討した．潰瘍例で心拍変動1/fゆらぎは異常があり，pylori感染以外に自律神経異常が必要である．
38.	西條哲也, 野村昌弘, 齋藤憲, 岡久稔也, 岡村誠介, 本田浩仁, 清水一郎, 伊東進, 篠原尚典, 山本浩史, 折野俊介 : 心拍変動解析による大腸内視鏡検査時の自律神経機能の検討, 第31回日本臨床生理学会総会, 1994年11月. (要約) 心拍変動解析により大腸内視鏡検査時の自律神経機能を検討した．検査中，交感神経の指標LF/HF値が亢進しており，心事故との関連性が示唆された．
39.	西條哲也, 岡久稔也, 岡村誠介, 柴田啓志, 本田浩仁, 清水一郎, 折野俊介, 野村昌弘, 齋藤憲, 伊東進 : 高血圧合併消化性潰瘍の自律神経機能の検討, 第11回四国消化性潰瘍研究会, 1994年6月. (要約) 高血圧症では交感神経活動の亢進と副交感神経活動の低下がみられ消化性潰瘍は合併しにくいが，高血圧合併潰瘍例では，副交感神経活動の亢進がみられた．
40.	野村昌弘, 名田智美, 近藤幸, 由岐中道子, 多田由恵, 岡久稔也, 柴田啓志, 岡村誠介, 本田浩仁, 清水一郎, 伊東進, 中屋豊 : 64チャンネル超伝導量子干渉計による胃および小腸活動電流の検出, 第1回日本国際消化管運動研究会, 1994年4月. (要約) 胃および小腸磁界測定を測定した．この磁気信号はスペクトル解析すると小腸磁界と胃磁界を分離できて，それぞれ定量化して消化管運動を評価できた．

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

健康ビッグデータを活用したストレングス視点型保健指導システムの構築 (研究課題/領域番号: 24K14167 )
雑音環境における解釈可能な腸蠕動音自動検出システムの構築 (研究課題/領域番号: 23K11896 )
口腔内細菌叢・内臓脂肪解析による新しい観点からのバレット食道進展メカニズムの解明 (研究課題/領域番号: 23K10961 )
腹水濾過濃縮再静注法の発熱機序の解明と発熱予防法の確立 (研究課題/領域番号: 22K12766 )
炎症性腸疾患への治療応用の為のプラズマ照射溶液中の活性種とヒトT細胞への影響調査 (研究課題/領域番号: 21K04003 )
口腔内細菌と内臓脂肪評価による新しい観点からの逆流性食道炎発症メカニズムの解明 (研究課題/領域番号: 20K11511 )
腹部聴診音のコンピューター解析による過敏性腸症候群の病態評価システムの構築 (研究課題/領域番号: 19K12824 )
メタボリック症候群における新指標を用いた高リスク非アルコール性脂肪性肝疾患の抽出 (研究課題/領域番号: 16K09057 )
体外循環血への青色LED光照射による免疫制御システムの構築 (研究課題/領域番号: 15K12512 )
潰瘍性大腸炎合併腫瘍の発見および治療法選択を支援する内視鏡画像解析システムの構築 (研究課題/領域番号: 15K01333 )
過敏性腸症候群の診断と最適治療のための非侵襲的大腸小腸運動機能評価システムの開発 (研究課題/領域番号: 22659149 )
脳血流の自己調節機構(AR)を非侵襲的に評価できる数理モデルの開発 (研究課題/領域番号: 15659428 )
研究者番号（60304515）による検索

特任教授 : 岡久稔也

研究活動

個人のホームページ

専門分野

研究テーマ

著書・論文

著書:

学術論文(審査論文):

学術論文(紀要・その他):

総説・解説:

国際会議:

国内講演発表:

その他・研究会:

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

特任教授 : 岡久 稔也

研究活動

個人のホームページ

専門分野

研究テーマ

著書・論文

著書:

学術論文(審査論文):

学術論文(紀要・その他):

総説・解説:

国際会議:

国内講演発表:

その他・研究会:

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

特任教授 : 岡久稔也